[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fSFcH7TBFOdyfw-S3nfxJcr-j9w6KyafcQl7LX55ZlM4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":88,"rows":95},"University of California, Los Angeles",[4],1150,false,243,49,9288841,87,828,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Depression",56,{"name":18,"count":19},"Anxiety",30,{"name":21,"count":22},"HIV",26,{"name":24,"count":25},"HIV Infections",25,{"name":27,"count":28},"Major Depressive Disorder",23,{"name":30,"count":31},"Schizophrenia",22,{"name":33,"count":34},"Obesity",20,{"name":36,"count":37},"Alcohol Use Disorder",15,[39,44,49,54,59,64,69,74,79,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03266393","Envarsus XR® in Adolescent Renal Transplant Recipients","2023-03-31","Envarsus XR",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT01527591","Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)","2023-12-31","Pneumococcal Conjugate Vaccine 13",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03408080","Open Pilot Trial of BHV-4157","2024-12-15","BHV-4157",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05124457","DETERMINE: Detemir vs NPH","2025-06","Insulin Detemir",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05007470","Alcoholic Liver Disease and the Gut Microbiome","2025-06-30","VSL #3 112.5",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06915792","PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy","2025-07-31","Labetalol",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT04451863","Analgesic and Subjective Effects of Terpenes","2025-11-12","Low THC",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT05980117","Remimazolam for Cataract Surgery","2025-12","Remimazolam",{"nctId":80,"briefTitle":81,"date":77,"intervention":82},"NCT04592744","Angiotensin 2 for AKI After OLT","Angiotensin II",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT04859296","AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)","2025-12-04","Low CBG",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,164,206,256,298,321,339,364,382,400,423,441,459,477,495,522,562,594,628,678,696,722,778,861,895,920,938,966,984,1016,1042,1066,1092,1117,1140,1158,1184,1210,1233,1259,1285,1310,1335,1358,1382,1409,1427,1469,1503,1525,1543,1561,1579,1603,1632,1650,1668,1686,1708,1734,1752,1770,1788,1806,1831,1849,1867,1885,1903,1921,1943,1969,1996,2025,2048,2070,2095,2118,2168,2196,2218,2243,2265,2288,2314,2342,2368,2390,2461,2525,2575,2631,2685,2731,2767,2812,2855,2882,2919,2945,2978,3010,3038,3072,3095,3121,3145,3163,3188,3213,3231,3255,3273,3296,3319,3344,3369,3387,3414,3432,3450,3475,3493,3515,3540,3558,3580,3604,3622,3647,3665,3683,3713,3736,3754,3777,3795,3813,3839,3865,3887,3912,3930,3954,3976,4000,4018,4036,4054,4072,4090,4113,4135,4161,4189,4207,4232,4256,4281,4307,4325,4351,4374,4392,4420,4438,4461,4479,4497,4515,4539,4562,4580,4604,4628,4646,4694,4728,4763,4788,4812,4830,4848,4874,4900,4918,4936,4963,4991,5009,5035,5053,5076,5094,5118,5140,5168,5192,5210,5234,5259,5282,5309,5327,5353,5401,5448,5477,5512,5534,5566,5604,5626,5650,5676,5699,5721,5743,5761,5784,5802,5824,5842,5868,5892,5915,5941,5959,5983,6009,6027,6050,6072,6093,6118,6136,6154,6172,6190,6208,6231,6249,6267,6288,6310,6334,6352,6370,6395,6422,6440,6458,6482,6500,6522,6540,6566,6590,6613,6638,6661,6685,6707,6732,6755,6776,6828,6851,6869,6892,6910,6934,6952,6976,7002,7026,7048,7074,7092,7110,7132,7150,7173,7196,7214,7232,7250,7268,7291,7312,7336,7360,7378,7401,7419,7451,7473,7491,7509,7527,7550,7573,7598,7621,7639,7662,7687,7710,7767,7810,7845,7884,7915,7956,7984,8015,8046,8068,8093,8111,8134,8157,8183,8208,8233,8257,8280,8298,8320,8343,8366,8384,8406,8429,8453,8477,8499,8517,8540,8558,8576,8594,8612,8630,8652,8674,8696,8717,8739,8760],{"intervention":97,"totalTrials":98,"cells":99},"Ropivacaine",4,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":117,"PHASE3":119,"PHASE4":121,"NA":162},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":22,"conditions":113,"interventions":116},"NCT03935815","Quadratus Lumborum Nerve Blocks for Myomectomies","TERMINATED",[90],"2020-06-06","2020-06-08","2019-05-01",[114,115],"Laparoscopic Myomectomy","Quadratus Lumborum Nerve Block",[97],{"trials":118,"activeCount":102},[],{"trials":120,"activeCount":102},[],{"trials":122,"activeCount":161,"soonestReadout":155},[123,137,151],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":136},"NCT03796572","Regional Blocks for Lateral Condyle Fractures","RECRUITING",[93],"2027-01-07","2027-03-07","2019-09-16",90,[133,134,135],"Fractures, Closed","Humeral Fractures","Pain",[97],{"nctId":138,"briefTitle":139,"status":140,"phases":141,"primaryCompletion":42,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":149},"NCT04074265","Peri-operative Use of a Pain Injection in Pediatric Patients With Cerebral Palsy","COMPLETED",[93],"2023-04-30","2019-12-01",34,[146,147,148],"Cerebral Palsy","Hip Dysplasia","Pain, Postoperative",[97,150],"normal saline",{"nctId":152,"briefTitle":153,"status":126,"phases":154,"primaryCompletion":155,"completion":156,"start":157,"enrollment":131,"conditions":158,"interventions":159},"NCT06189781","Pain Injection Versus Epidural Anesthesia for Hip Surgery in Pediatric Patients With Cerebral Palsy",[93],"2026-12-30","2027-06-30","2023-12-01",[146,147,148],[97,160],"Bupivacaine, lidocaine, ropivacaine",2,{"trials":163,"activeCount":102},[],{"intervention":165,"totalTrials":161,"cells":166},"Suzetrigine",{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":175,"NA":204},{"trials":168,"activeCount":102},[],{"trials":170,"activeCount":102},[],{"trials":172,"activeCount":102},[],{"trials":174,"activeCount":102},[],{"trials":176,"activeCount":161,"soonestReadout":182},[177,189],{"nctId":178,"briefTitle":179,"status":180,"phases":181,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},"NCT07355166","Suzetrigine Versus Usual-care Opioids for Postop Pain in Sports","NOT_YET_RECRUITING",[93],"2026-07","2026-02",140,[186],"Postoperative Pain Management",[165,188],"Multimodal Pain Regimen",{"nctId":190,"briefTitle":191,"status":180,"phases":192,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":201},"NCT07600697","Suzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery",[93],"2027-07-01","2028-07-01","2026-07-01",120,[198,199,200],"Pelvic Organ Prolapse (POP)","Stress Urinary Incontinence (SUI)","Postoperative Pain",[165,202,203],"Opioid Analgesics","Scheduled Acetaminophen and Ibuprofen",{"trials":205,"activeCount":102},[],{"intervention":207,"totalTrials":208,"cells":209},"Tacrolimus",3,{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":254},{"trials":211,"activeCount":102},[],{"trials":213,"activeCount":102},[],{"trials":215,"activeCount":102},[],{"trials":217,"activeCount":102},[],{"trials":219,"activeCount":253,"soonestReadout":42},[220,231,241],{"nctId":221,"briefTitle":222,"status":140,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":229},"NCT02866682","Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients",[93],"2021-06-11","2018-03-01",176,[228],"Renal Transplant Rejection",[230,207],"Prograf",{"nctId":40,"briefTitle":41,"status":232,"phases":233,"primaryCompletion":42,"completion":42,"start":234,"enrollment":235,"conditions":236,"interventions":240},"ACTIVE_NOT_RECRUITING",[93],"2019-01-15",28,[237,238,239],"Kidney Transplantation","Renal Transplantation","Grafting, Kidney",[43,207],{"nctId":242,"briefTitle":243,"status":140,"phases":244,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NCT02123108","Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation",[93],"2015-01","2011-01",59,[249],"Liver Transplantation",[251,207,207,252],"Basiliximab","Mycophenolic Acid",1,{"trials":255,"activeCount":102},[],{"intervention":82,"totalTrials":161,"cells":257},{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":280,"PHASE4":282,"NA":296},{"trials":259,"activeCount":102},[],{"trials":261,"activeCount":102},[],{"trials":263,"activeCount":102},[264],{"nctId":265,"briefTitle":266,"status":267,"phases":268,"primaryCompletion":269,"completion":270,"start":271,"enrollment":102,"conditions":272,"interventions":276},"NCT04048707","Angiotensin 2 for Hepatorenal Syndrome","WITHDRAWN",[91],"2023-06-30","2023-07-01","2021-07-01",[273,274,275],"Hepatorenal Syndrome","Cirrhosis","Kidney Failure, Acute",[82,277,278,279],"Midodrine","Octreotide","Albumin solution",{"trials":281,"activeCount":102},[],{"trials":283,"activeCount":253,"soonestReadout":77},[284],{"nctId":80,"briefTitle":81,"status":285,"phases":286,"primaryCompletion":77,"completion":287,"start":288,"enrollment":19,"conditions":289,"interventions":294},"ENROLLING_BY_INVITATION",[93],"2026-03","2022-04-08",[290,291,292,293],"Cirrhosis, Liver","End Stage Liver DIsease","Acute Kidney Injury","Liver Transplant; Complications",[82,295],"Norepinephrine",{"trials":297,"activeCount":102},[],{"intervention":78,"totalTrials":253,"cells":299},{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":306,"PHASE4":308,"NA":319},{"trials":301,"activeCount":102},[],{"trials":303,"activeCount":102},[],{"trials":305,"activeCount":102},[],{"trials":307,"activeCount":102},[],{"trials":309,"activeCount":253,"soonestReadout":77},[310],{"nctId":75,"briefTitle":76,"status":126,"phases":311,"primaryCompletion":77,"completion":312,"start":313,"enrollment":196,"conditions":314,"interventions":317},[93],"2026-01","2025-03-10",[315,316],"Cataract Surgery","Cognitive Impairment",[78,318],"Midazolam",{"trials":320,"activeCount":102},[],{"intervention":43,"totalTrials":253,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":337},{"trials":324,"activeCount":102},[],{"trials":326,"activeCount":102},[],{"trials":328,"activeCount":102},[],{"trials":330,"activeCount":102},[],{"trials":332,"activeCount":253,"soonestReadout":42},[333],{"nctId":40,"briefTitle":41,"status":232,"phases":334,"primaryCompletion":42,"completion":42,"start":234,"enrollment":235,"conditions":335,"interventions":336},[93],[237,238,239],[43,207],{"trials":338,"activeCount":102},[],{"intervention":340,"totalTrials":253,"cells":341},"Metformin Extended Release (ER) Oral",{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":348,"PHASE4":350,"NA":362},{"trials":343,"activeCount":102},[],{"trials":345,"activeCount":102},[],{"trials":347,"activeCount":102},[],{"trials":349,"activeCount":102},[],{"trials":351,"activeCount":253,"soonestReadout":356},[352],{"nctId":353,"briefTitle":354,"status":232,"phases":355,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":361},"NCT05949008","Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo",[93],"2027-07-30","2023-11-22",150,[360,33],"NIDDM",[340],{"trials":363,"activeCount":102},[],{"intervention":188,"totalTrials":253,"cells":365},{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":380},{"trials":367,"activeCount":102},[],{"trials":369,"activeCount":102},[],{"trials":371,"activeCount":102},[],{"trials":373,"activeCount":102},[],{"trials":375,"activeCount":253,"soonestReadout":182},[376],{"nctId":178,"briefTitle":179,"status":180,"phases":377,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":378,"interventions":379},[93],[186],[165,188],{"trials":381,"activeCount":102},[],{"intervention":295,"totalTrials":253,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":392,"NA":398},{"trials":385,"activeCount":102},[],{"trials":387,"activeCount":102},[],{"trials":389,"activeCount":102},[],{"trials":391,"activeCount":102},[],{"trials":393,"activeCount":253,"soonestReadout":77},[394],{"nctId":80,"briefTitle":81,"status":285,"phases":395,"primaryCompletion":77,"completion":287,"start":288,"enrollment":19,"conditions":396,"interventions":397},[93],[290,291,292,293],[82,295],{"trials":399,"activeCount":102},[],{"intervention":68,"totalTrials":253,"cells":401},{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":408,"PHASE4":410,"NA":421},{"trials":403,"activeCount":102},[],{"trials":405,"activeCount":102},[],{"trials":407,"activeCount":102},[],{"trials":409,"activeCount":102},[],{"trials":411,"activeCount":253,"soonestReadout":67},[412],{"nctId":65,"briefTitle":66,"status":180,"phases":413,"primaryCompletion":67,"completion":414,"start":415,"enrollment":416,"conditions":417,"interventions":419},[93],"2025-10-31","2025-04-01",110,[418],"Postpartum Hypertension (PPHT)",[68,420],"Nifedipine",{"trials":422,"activeCount":102},[],{"intervention":420,"totalTrials":253,"cells":424},{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":431,"PHASE4":433,"NA":439},{"trials":426,"activeCount":102},[],{"trials":428,"activeCount":102},[],{"trials":430,"activeCount":102},[],{"trials":432,"activeCount":102},[],{"trials":434,"activeCount":253,"soonestReadout":67},[435],{"nctId":65,"briefTitle":66,"status":180,"phases":436,"primaryCompletion":67,"completion":414,"start":415,"enrollment":416,"conditions":437,"interventions":438},[93],[418],[68,420],{"trials":440,"activeCount":102},[],{"intervention":202,"totalTrials":253,"cells":442},{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":449,"PHASE4":451,"NA":457},{"trials":444,"activeCount":102},[],{"trials":446,"activeCount":102},[],{"trials":448,"activeCount":102},[],{"trials":450,"activeCount":102},[],{"trials":452,"activeCount":253,"soonestReadout":193},[453],{"nctId":190,"briefTitle":191,"status":180,"phases":454,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":455,"interventions":456},[93],[198,199,200],[165,202,203],{"trials":458,"activeCount":102},[],{"intervention":203,"totalTrials":253,"cells":460},{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":467,"PHASE4":469,"NA":475},{"trials":462,"activeCount":102},[],{"trials":464,"activeCount":102},[],{"trials":466,"activeCount":102},[],{"trials":468,"activeCount":102},[],{"trials":470,"activeCount":253,"soonestReadout":193},[471],{"nctId":190,"briefTitle":191,"status":180,"phases":472,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":473,"interventions":474},[93],[198,199,200],[165,202,203],{"trials":476,"activeCount":102},[],{"intervention":160,"totalTrials":253,"cells":478},{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":483,"PHASE3":485,"PHASE4":487,"NA":493},{"trials":480,"activeCount":102},[],{"trials":482,"activeCount":102},[],{"trials":484,"activeCount":102},[],{"trials":486,"activeCount":102},[],{"trials":488,"activeCount":253,"soonestReadout":155},[489],{"nctId":152,"briefTitle":153,"status":126,"phases":490,"primaryCompletion":155,"completion":156,"start":157,"enrollment":131,"conditions":491,"interventions":492},[93],[146,147,148],[97,160],{"trials":494,"activeCount":102},[],{"intervention":496,"totalTrials":253,"cells":497},"Ibuprofen",{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":506,"NA":520},{"trials":499,"activeCount":102},[],{"trials":501,"activeCount":102},[],{"trials":503,"activeCount":102},[],{"trials":505,"activeCount":102},[],{"trials":507,"activeCount":253,"soonestReadout":512},[508],{"nctId":509,"briefTitle":510,"status":126,"phases":511,"primaryCompletion":512,"completion":513,"start":514,"enrollment":131,"conditions":515,"interventions":517},"NCT03759028","Supracondylar Post-Operative Pain Study",[93],"2027-12-01","2027-12-20","2019-02-26",[516],"Supracondylar Humerus Fracture",[496,518,519],"Oxycodone","Acetaminophen",{"trials":521,"activeCount":102},[],{"intervention":519,"totalTrials":208,"cells":523},{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":530,"PHASE4":532,"NA":548},{"trials":525,"activeCount":102},[],{"trials":527,"activeCount":102},[],{"trials":529,"activeCount":102},[],{"trials":531,"activeCount":102},[],{"trials":533,"activeCount":253,"soonestReadout":512},[534,544],{"nctId":535,"briefTitle":536,"status":108,"phases":537,"primaryCompletion":538,"completion":538,"start":539,"enrollment":540,"conditions":541,"interventions":543},"NCT01737593","Can Acetaminophen Given 1-2 Hours to Children Before Ear Tube Surgery Reduce Agitation After Anesthesia?",[93],"2014-04","2012-11",108,[542,135],"Emergence Agitation",[519],{"nctId":509,"briefTitle":510,"status":126,"phases":545,"primaryCompletion":512,"completion":513,"start":514,"enrollment":131,"conditions":546,"interventions":547},[93],[516],[496,518,519],{"trials":549,"activeCount":102},[550],{"nctId":551,"briefTitle":552,"status":553,"phases":554,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":560},"NCT03880981","NSAID Use and Healing After Tibia Fractures and Achilles Tendon Ruptures","UNKNOWN",[94],"2020-07-31","2019-08-01",456,[559],"Musculoskeletal Injury",[561,519],"Ibuprofen 600 mg",{"intervention":318,"totalTrials":161,"cells":563},{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":570,"PHASE4":572,"NA":578},{"trials":565,"activeCount":102},[],{"trials":567,"activeCount":102},[],{"trials":569,"activeCount":102},[],{"trials":571,"activeCount":102},[],{"trials":573,"activeCount":253,"soonestReadout":77},[574],{"nctId":75,"briefTitle":76,"status":126,"phases":575,"primaryCompletion":77,"completion":312,"start":313,"enrollment":196,"conditions":576,"interventions":577},[93],[315,316],[78,318],{"trials":579,"activeCount":102},[580],{"nctId":581,"briefTitle":582,"status":267,"phases":583,"primaryCompletion":584,"completion":584,"start":585,"enrollment":102,"conditions":586,"interventions":592},"NCT03490903","Coronary Angiography THerapeutic Virtual Reality",[94],"2018-06-30","2018-06-01",[587,588,589,18,590,591],"Virtual Reality","Atherosclerosis","Coronary Artery Disease","Pain, Acute","Vasospasm;Peripheral",[593,318],"Fentanyl",{"intervention":595,"totalTrials":161,"cells":596},"oxycodone",{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":603,"PHASE4":605,"NA":611},{"trials":598,"activeCount":102},[],{"trials":600,"activeCount":102},[],{"trials":602,"activeCount":102},[],{"trials":604,"activeCount":102},[],{"trials":606,"activeCount":253,"soonestReadout":512},[607],{"nctId":509,"briefTitle":510,"status":126,"phases":608,"primaryCompletion":512,"completion":513,"start":514,"enrollment":131,"conditions":609,"interventions":610},[93],[516],[496,518,519],{"trials":612,"activeCount":102},[613],{"nctId":614,"briefTitle":615,"status":553,"phases":616,"primaryCompletion":617,"completion":617,"start":538,"enrollment":618,"conditions":619,"interventions":621},"NCT02136784","Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals",[94],"2014-12",12,[620],"Analgesic Response",[622,623,624,595,625,626,627],"morphine sulfate","hydrocodone","hydromorphone HCI","buprenorphine","oral tablet placebo","sublingual tablet placebo",{"intervention":629,"totalTrials":208,"cells":630},"Saline",{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":649,"PHASE3":651,"PHASE4":664,"NA":676},{"trials":632,"activeCount":102},[],{"trials":634,"activeCount":102},[635],{"nctId":636,"briefTitle":637,"status":140,"phases":638,"primaryCompletion":639,"completion":639,"start":640,"enrollment":25,"conditions":641,"interventions":644},"NCT01257191","A Study to Compare the Effects of Different Sized Particles on Cells in the Nose",[90],"2012-01","2010-04",[642,643],"Hypersensitivity, Immediate","Atopic Hypersensitivity",[645,646,647,648,629],"Carbon Black","Diesel Exhaust Particles","Fine Concentrated Ambient Particles","Ultrafine Concentrated Ambient Particles",{"trials":650,"activeCount":102},[],{"trials":652,"activeCount":253,"soonestReadout":657},[653],{"nctId":654,"briefTitle":655,"status":126,"phases":656,"primaryCompletion":657,"completion":657,"start":658,"enrollment":659,"conditions":660,"interventions":662},"NCT06182319","Optimizing Treatment of Adhesive Small Bowel Obstruction",[92],"2025-12-15","2024-01-01",40,[661],"Adhesive Small Bowel Obstruction",[663,629],"Gastrografin",{"trials":665,"activeCount":102},[666],{"nctId":667,"briefTitle":668,"status":108,"phases":669,"primaryCompletion":670,"completion":670,"start":671,"enrollment":161,"conditions":672,"interventions":674},"NCT01738243","Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease",[93],"2021-09","2013-12",[673],"Thyroid Eye Disease",[675,629],"Hyaluronic Acid Gel",{"trials":677,"activeCount":102},[],{"intervention":663,"totalTrials":253,"cells":679},{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":692,"NA":694},{"trials":681,"activeCount":102},[],{"trials":683,"activeCount":102},[],{"trials":685,"activeCount":102},[],{"trials":687,"activeCount":253,"soonestReadout":657},[688],{"nctId":654,"briefTitle":655,"status":126,"phases":689,"primaryCompletion":657,"completion":657,"start":658,"enrollment":659,"conditions":690,"interventions":691},[92],[661],[663,629],{"trials":693,"activeCount":102},[],{"trials":695,"activeCount":102},[],{"intervention":53,"totalTrials":253,"cells":697},{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":718,"NA":720},{"trials":699,"activeCount":102},[],{"trials":701,"activeCount":102},[],{"trials":703,"activeCount":102},[],{"trials":705,"activeCount":253,"soonestReadout":52},[706],{"nctId":50,"briefTitle":51,"status":232,"phases":707,"primaryCompletion":52,"completion":52,"start":708,"enrollment":709,"conditions":710,"interventions":717},[92],"2017-12-15",24,[711,712,713,714,715,716],"Spinocerebellar Ataxias","Spinocerebellar Ataxia Type 1","Spinocerebellar Ataxia Type 2","Spinocerebellar Ataxia 3","Spinocerebellar Ataxia Type 6","MSA-C",[53],{"trials":719,"activeCount":102},[],{"trials":721,"activeCount":102},[],{"intervention":723,"totalTrials":98,"cells":724},"Psilocybin",{"EARLY_PHASE1":725,"PHASE1":739,"PHASE2":750,"PHASE3":772,"PHASE4":774,"NA":776},{"trials":726,"activeCount":102},[727],{"nctId":728,"briefTitle":729,"status":730,"phases":731,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":738},"NCT06102434","Safety Profile of Psilocybin for Cocaine Use Disorder","SUSPENDED",[89],"2029-05","2029-06","2029-02-01",10,[737],"Cocaine Use Disorder",[723],{"trials":740,"activeCount":102},[741],{"nctId":742,"briefTitle":743,"status":140,"phases":744,"primaryCompletion":745,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":749},"NCT05227612","Psilocybin-assisted CBT for Depression",[90],"2025-09-12","2023-06-27",16,[27],[723],{"trials":751,"activeCount":161,"soonestReadout":756},[752,762],{"nctId":753,"briefTitle":754,"status":126,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":761},"NCT07281352","RCT of Psilocybin-assisted CBT for Depression",[90,91],"2027-11-30","2026-01-05",50,[760],"Major Depressive Diorder",[723],{"nctId":763,"briefTitle":764,"status":180,"phases":765,"primaryCompletion":766,"completion":766,"start":767,"enrollment":19,"conditions":768,"interventions":771},"NCT07566104","Group PACBT for Depression",[91],"2028-12","2027-01",[769,723,770],"Depression - Major Depressive Disorder","Cognitive Behavioral Therapy",[723],{"trials":773,"activeCount":102},[],{"trials":775,"activeCount":102},[],{"trials":777,"activeCount":102},[],{"intervention":779,"totalTrials":780,"cells":781},"Endotoxin",7,{"EARLY_PHASE1":782,"PHASE1":810,"PHASE2":832,"PHASE3":855,"PHASE4":857,"NA":859},{"trials":783,"activeCount":102},[784,794,801],{"nctId":785,"briefTitle":786,"status":140,"phases":787,"primaryCompletion":788,"completion":788,"start":789,"enrollment":790,"conditions":791,"interventions":792},"NCT01671150","Inflammation-Induced Depressed Mood: The Role of Social Neurocognitive Mechanisms",[89],"2013-08","2011-03",100,[15],[793],"endotoxin",{"nctId":795,"briefTitle":796,"status":140,"phases":797,"start":798,"conditions":799,"interventions":800},"NCT00949845","Cytokine-Associated Depression and Social Pain",[89],"2007-01",[15],[779],{"nctId":802,"briefTitle":803,"status":140,"phases":804,"primaryCompletion":805,"completion":805,"start":806,"enrollment":807,"conditions":808,"interventions":809},"NCT02270619","Sleep Health, Inflammation, and Emotion Study",[89],"2021-01","2014-10",95,[15],[779],{"trials":811,"activeCount":102},[812,823],{"nctId":813,"briefTitle":814,"status":140,"phases":815,"primaryCompletion":816,"completion":816,"start":817,"enrollment":659,"conditions":818,"interventions":822},"NCT05363527","Aging and Reward System Response to Inflammation and Anxiety Study",[90],"2025-12-08","2023-03-29",[819,820,18,821,15],"Anhedonia","Inflammation","Aging",[779],{"nctId":824,"briefTitle":825,"status":140,"phases":826,"primaryCompletion":827,"completion":828,"start":829,"enrollment":659,"conditions":830,"interventions":831},"NCT03848715","Sleep and Healthy Aging Research on Depression for Younger Women",[90],"2022-07-22","2024-07-22","2019-10-02",[819,15],[779],{"trials":833,"activeCount":253,"soonestReadout":849},[834,845],{"nctId":835,"briefTitle":836,"status":140,"phases":837,"primaryCompletion":838,"completion":838,"start":839,"enrollment":34,"conditions":840,"interventions":844},"NCT04310423","An Inflammatory Challenge Using Endotoxin",[91],"2023-11-14","2021-10-19",[36,841,842,843],"Inflammatory Response","Craving","Depressed Mood",[779],{"nctId":846,"briefTitle":847,"status":180,"phases":848,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":853,"interventions":854},"NCT07452146","Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use",[91],"2028-06","2028-07","2026-06",64,[36,841,842],[779],{"trials":856,"activeCount":102},[],{"trials":858,"activeCount":102},[],{"trials":860,"activeCount":102},[],{"intervention":862,"totalTrials":161,"cells":863},"Sodium Lactate",{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":889,"PHASE4":891,"NA":893},{"trials":865,"activeCount":102},[],{"trials":867,"activeCount":102},[],{"trials":869,"activeCount":253,"soonestReadout":882},[870,878],{"nctId":871,"briefTitle":872,"status":267,"phases":873,"primaryCompletion":77,"completion":851,"start":874,"enrollment":102,"conditions":875,"interventions":877},"NCT02776488","Exogenous Sodium Lactate Infusion in Traumatic Brain Injury (ELI-TBI)",[91],"2020-09",[876],"Brain Injuries, Traumatic",[862],{"nctId":879,"briefTitle":880,"status":180,"phases":881,"primaryCompletion":882,"completion":883,"start":884,"enrollment":885,"conditions":886,"interventions":888},"NCT06701760","Sodium Lactate in Severe TBI",[91],"2035-12-30","2038-07-01","2028-01-10",264,[887],"Traumatic Brain Injury",[862],{"trials":890,"activeCount":102},[],{"trials":892,"activeCount":102},[],{"trials":894,"activeCount":102},[],{"intervention":896,"totalTrials":253,"cells":897},"Acetazolamide 500 MG QHS",{"EARLY_PHASE1":898,"PHASE1":900,"PHASE2":902,"PHASE3":914,"PHASE4":916,"NA":918},{"trials":899,"activeCount":102},[],{"trials":901,"activeCount":102},[],{"trials":903,"activeCount":253,"soonestReadout":908},[904],{"nctId":905,"briefTitle":906,"status":126,"phases":907,"primaryCompletion":908,"completion":908,"start":909,"enrollment":358,"conditions":910,"interventions":912},"NCT05953610","Endotypic Traits and Obstructive Sleep Apnea Surgery",[91],"2028-08-31","2024-01-07",[911],"Obstructive Sleep Apnea",[896,913],"Eszopiclone 3 mg QHS",{"trials":915,"activeCount":102},[],{"trials":917,"activeCount":102},[],{"trials":919,"activeCount":102},[],{"intervention":913,"totalTrials":253,"cells":921},{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":926,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":923,"activeCount":102},[],{"trials":925,"activeCount":102},[],{"trials":927,"activeCount":253,"soonestReadout":908},[928],{"nctId":905,"briefTitle":906,"status":126,"phases":929,"primaryCompletion":908,"completion":908,"start":909,"enrollment":358,"conditions":930,"interventions":931},[91],[911],[896,913],{"trials":933,"activeCount":102},[],{"trials":935,"activeCount":102},[],{"trials":937,"activeCount":102},[],{"intervention":939,"totalTrials":253,"cells":940},"Prednisolone",{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":960,"PHASE4":962,"NA":964},{"trials":942,"activeCount":102},[],{"trials":944,"activeCount":102},[],{"trials":946,"activeCount":253,"soonestReadout":951},[947],{"nctId":948,"briefTitle":949,"status":126,"phases":950,"primaryCompletion":951,"completion":952,"start":953,"enrollment":659,"conditions":954,"interventions":958},"NCT06819670","A Study to Prevent Infantile Spasms Relapse",[91],"2028-02-28","2028-06-30","2025-05-05",[955,956,957],"Infantile Spasms","Infantile Epileptic Spasms Syndrome","West Syndrome",[939,959],"Famotidine",{"trials":961,"activeCount":102},[],{"trials":963,"activeCount":102},[],{"trials":965,"activeCount":102},[],{"intervention":959,"totalTrials":253,"cells":967},{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":969,"activeCount":102},[],{"trials":971,"activeCount":102},[],{"trials":973,"activeCount":253,"soonestReadout":951},[974],{"nctId":948,"briefTitle":949,"status":126,"phases":975,"primaryCompletion":951,"completion":952,"start":953,"enrollment":659,"conditions":976,"interventions":977},[91],[955,956,957],[939,959],{"trials":979,"activeCount":102},[],{"trials":981,"activeCount":102},[],{"trials":983,"activeCount":102},[],{"intervention":985,"totalTrials":253,"cells":986},"Donor Hematopoietic Stem and Progenitor Cell",{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":1010,"PHASE4":1012,"NA":1014},{"trials":988,"activeCount":102},[],{"trials":990,"activeCount":102},[],{"trials":992,"activeCount":253,"soonestReadout":997},[993],{"nctId":994,"briefTitle":995,"status":126,"phases":996,"primaryCompletion":997,"completion":998,"start":999,"enrollment":618,"conditions":1000,"interventions":1009},"NCT07269041","Immune Tolerance Induction After Liver Transplantation",[90,91],"2029-01","2033-01","2026-02-20",[249,1001,1002,1003,1004,1005,1006,1007,1008],"Immune Tolerance","Immune Tolerance\u002FDrug Effects","Graft Survival","Hematopoietic Stem Cell","Chimerism","Immunosuppression After Liver Transplantation","Immunosuppression Disorders","End Stage Liver Disease",[985],{"trials":1011,"activeCount":102},[],{"trials":1013,"activeCount":102},[],{"trials":1015,"activeCount":102},[],{"intervention":1017,"totalTrials":253,"cells":1018},"CeFAZolin Injectable Solution",{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1023,"PHASE3":1036,"PHASE4":1038,"NA":1040},{"trials":1020,"activeCount":102},[],{"trials":1022,"activeCount":102},[],{"trials":1024,"activeCount":253,"soonestReadout":1029},[1025],{"nctId":1026,"briefTitle":1027,"status":126,"phases":1028,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":1032,"conditions":1033,"interventions":1035},"NCT06327113","Antibiotic Tumescent For Chronic Wounds",[91],"2027-05-25","2028-05-25","2024-05-17",60,[1034],"Non-healing Wound",[1017],{"trials":1037,"activeCount":102},[],{"trials":1039,"activeCount":102},[],{"trials":1041,"activeCount":102},[],{"intervention":1043,"totalTrials":253,"cells":1044},"Intravenous Alcohol",{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1049,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1046,"activeCount":102},[],{"trials":1048,"activeCount":102},[],{"trials":1050,"activeCount":253,"soonestReadout":1055},[1051],{"nctId":1052,"briefTitle":1053,"status":126,"phases":1054,"primaryCompletion":1055,"completion":156,"start":1056,"enrollment":1057,"conditions":1058,"interventions":1059},"NCT06494891","Motivation for IV Alcohol Self-Administration in Humans",[91],"2027-04-30","2024-01-16",210,[36],[1043],{"trials":1061,"activeCount":102},[],{"trials":1063,"activeCount":102},[],{"trials":1065,"activeCount":102},[],{"intervention":1067,"totalTrials":253,"cells":1068},"Benzathine penicillin 2.4 million units",{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1086,"PHASE4":1088,"NA":1090},{"trials":1070,"activeCount":102},[],{"trials":1072,"activeCount":102},[],{"trials":1074,"activeCount":253,"soonestReadout":1079},[1075],{"nctId":1076,"briefTitle":1077,"status":126,"phases":1078,"primaryCompletion":1079,"completion":1080,"start":1081,"enrollment":1082,"conditions":1083,"interventions":1085},"NCT07189208","Evaluation of Antimicrobial Prophylaxis to Prevent Syphilis in Pregnancy in Patients at Risk in Rio de Janeiro, Brazil",[91],"2029-12-01","2030-07-31","2025-09-24",500,[1084],"Congenital Syphilis",[1067],{"trials":1087,"activeCount":102},[],{"trials":1089,"activeCount":102},[],{"trials":1091,"activeCount":102},[],{"intervention":1093,"totalTrials":253,"cells":1094},"Brivaracetam",{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1096,"activeCount":102},[],{"trials":1098,"activeCount":102},[],{"trials":1100,"activeCount":253,"soonestReadout":1105},[1101],{"nctId":1102,"briefTitle":1103,"status":180,"phases":1104,"primaryCompletion":1105,"completion":1105,"start":1106,"enrollment":25,"conditions":1107,"interventions":1110},"NCT05899764","Epileptic Hippocampus in Alzheimer's Disease",[90,91],"2029-06-01","2026-01-01",[1108,1109],"Alzheimer Disease","Mild Cognitive Impairment",[1093],{"trials":1112,"activeCount":102},[],{"trials":1114,"activeCount":102},[],{"trials":1116,"activeCount":102},[],{"intervention":58,"totalTrials":253,"cells":1118},{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1134,"PHASE4":1136,"NA":1138},{"trials":1120,"activeCount":102},[],{"trials":1122,"activeCount":102},[],{"trials":1124,"activeCount":253,"soonestReadout":57},[1125],{"nctId":55,"briefTitle":56,"status":126,"phases":1126,"primaryCompletion":57,"completion":57,"start":1127,"enrollment":1128,"conditions":1129,"interventions":1132},[91],"2022-02-01",336,[1130,1131],"Gestational Diabetes","Diabetes Mellitus, Type 2",[58,1133],"Insulin NPH",{"trials":1135,"activeCount":102},[],{"trials":1137,"activeCount":102},[],{"trials":1139,"activeCount":102},[],{"intervention":1133,"totalTrials":253,"cells":1141},{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1152,"PHASE4":1154,"NA":1156},{"trials":1143,"activeCount":102},[],{"trials":1145,"activeCount":102},[],{"trials":1147,"activeCount":253,"soonestReadout":57},[1148],{"nctId":55,"briefTitle":56,"status":126,"phases":1149,"primaryCompletion":57,"completion":57,"start":1127,"enrollment":1128,"conditions":1150,"interventions":1151},[91],[1130,1131],[58,1133],{"trials":1153,"activeCount":102},[],{"trials":1155,"activeCount":102},[],{"trials":1157,"activeCount":102},[],{"intervention":1159,"totalTrials":253,"cells":1160},"Buspirone",{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1165,"PHASE3":1178,"PHASE4":1180,"NA":1182},{"trials":1162,"activeCount":102},[],{"trials":1164,"activeCount":102},[],{"trials":1166,"activeCount":253,"soonestReadout":1171},[1167],{"nctId":1168,"briefTitle":1169,"status":232,"phases":1170,"primaryCompletion":1171,"completion":155,"start":1172,"enrollment":618,"conditions":1173,"interventions":1177},"NCT02313194","Spinal Cord Neuromodulation for Spinal Cord Injury",[90,91],"2026-06-30","2013-07",[1174,1175,1176],"Cervical Spinal Cord Injury","Tetraparesis","Tetraplegia",[1159],{"trials":1179,"activeCount":102},[],{"trials":1181,"activeCount":102},[],{"trials":1183,"activeCount":102},[],{"intervention":1185,"totalTrials":253,"cells":1186},"Cannabidiol (CBD) 800 mg",{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1204,"PHASE4":1206,"NA":1208},{"trials":1188,"activeCount":102},[],{"trials":1190,"activeCount":102},[],{"trials":1192,"activeCount":253,"soonestReadout":1197},[1193],{"nctId":1194,"briefTitle":1195,"status":126,"phases":1196,"primaryCompletion":1197,"completion":1197,"start":1198,"enrollment":196,"conditions":1199,"interventions":1203},"NCT06218056","Cannabidiol for Reducing Cigarette Use",[91],"2026-12-31","2024-10-31",[1200,1201,1202],"Tobacco Use Disorder","Tobacco Smoking","Tobacco Dependence",[1185],{"trials":1205,"activeCount":102},[],{"trials":1207,"activeCount":102},[],{"trials":1209,"activeCount":102},[],{"intervention":1211,"totalTrials":253,"cells":1212},"Buprenorphine 0.15 MG [Belbuca]",{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1227,"PHASE4":1229,"NA":1231},{"trials":1214,"activeCount":102},[],{"trials":1216,"activeCount":102},[],{"trials":1218,"activeCount":253,"soonestReadout":1223},[1219],{"nctId":1220,"briefTitle":1221,"status":126,"phases":1222,"primaryCompletion":1223,"completion":1224,"start":1031,"enrollment":659,"conditions":1225,"interventions":1226},"NCT05778591","Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia",[91],"2026-12-01","2027-03-01",[30],[1211],{"trials":1228,"activeCount":102},[],{"trials":1230,"activeCount":102},[],{"trials":1232,"activeCount":102},[],{"intervention":1234,"totalTrials":253,"cells":1235},"Ferric Citrate",{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1240,"PHASE3":1253,"PHASE4":1255,"NA":1257},{"trials":1237,"activeCount":102},[],{"trials":1239,"activeCount":102},[],{"trials":1241,"activeCount":253,"soonestReadout":1246},[1242],{"nctId":1243,"briefTitle":1244,"status":126,"phases":1245,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":1249,"conditions":1250,"interventions":1252},"NCT04741646","Ferric Citrate and Chronic Kidney Disease in Children",[91],"2027-10","2028-11-30","2022-06-17",160,[1251],"Chronic Kidney Diseases",[1234],{"trials":1254,"activeCount":102},[],{"trials":1256,"activeCount":102},[],{"trials":1258,"activeCount":102},[],{"intervention":1260,"totalTrials":253,"cells":1261},"Testosterone Replacement Therapy",{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1279,"PHASE4":1281,"NA":1283},{"trials":1263,"activeCount":102},[],{"trials":1265,"activeCount":102},[],{"trials":1267,"activeCount":253,"soonestReadout":851},[1268],{"nctId":1269,"briefTitle":1270,"status":232,"phases":1271,"primaryCompletion":851,"completion":1272,"start":1273,"enrollment":758,"conditions":1274,"interventions":1278},"NCT07287800","TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation",[90,91],"2027-06","2025-07-01",[1275,1276,1277],"Hypogonadism, Male","End Stage Renal Disease (ESRD)","Kidney Transplant",[1260],{"trials":1280,"activeCount":102},[],{"trials":1282,"activeCount":102},[],{"trials":1284,"activeCount":102},[],{"intervention":1286,"totalTrials":253,"cells":1287},"Propofol sedation",{"EARLY_PHASE1":1288,"PHASE1":1290,"PHASE2":1292,"PHASE3":1304,"PHASE4":1306,"NA":1308},{"trials":1289,"activeCount":102},[],{"trials":1291,"activeCount":102},[],{"trials":1293,"activeCount":253,"soonestReadout":1298},[1294],{"nctId":1295,"briefTitle":1296,"status":126,"phases":1297,"primaryCompletion":1298,"completion":1298,"start":1299,"enrollment":1300,"conditions":1301,"interventions":1303},"NCT00695214","Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea",[91],"2030-06","2004-02",800,[1302],"Sleep Apnea, Obstructive",[1286],{"trials":1305,"activeCount":102},[],{"trials":1307,"activeCount":102},[],{"trials":1309,"activeCount":102},[],{"intervention":1311,"totalTrials":253,"cells":1312},"A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme",{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1329,"PHASE4":1331,"NA":1333},{"trials":1314,"activeCount":102},[],{"trials":1316,"activeCount":102},[],{"trials":1318,"activeCount":253,"soonestReadout":1323},[1319],{"nctId":1320,"briefTitle":1321,"status":126,"phases":1322,"primaryCompletion":1323,"completion":1324,"start":1325,"enrollment":34,"conditions":1326,"interventions":1328},"NCT05432310","Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector",[90,91],"2027-11-14","2027-12-31","2023-01-04",[1327],"Adenosine Deaminase Severe Combined Immune Deficiency",[1311],{"trials":1330,"activeCount":102},[],{"trials":1332,"activeCount":102},[],{"trials":1334,"activeCount":102},[],{"intervention":1336,"totalTrials":253,"cells":1337},"Fimepinostat",{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1352,"PHASE4":1354,"NA":1356},{"trials":1339,"activeCount":102},[],{"trials":1341,"activeCount":102},[],{"trials":1343,"activeCount":253,"soonestReadout":997},[1344],{"nctId":1345,"briefTitle":1346,"status":126,"phases":1347,"primaryCompletion":997,"completion":997,"start":1348,"enrollment":34,"conditions":1349,"interventions":1351},"NCT05971758","Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease",[91],"2025-01-16",[1350],"Cushing Disease",[1336],{"trials":1353,"activeCount":102},[],{"trials":1355,"activeCount":102},[],{"trials":1357,"activeCount":102},[],{"intervention":1359,"totalTrials":253,"cells":1360},"Cytisinicline",{"EARLY_PHASE1":1361,"PHASE1":1363,"PHASE2":1365,"PHASE3":1376,"PHASE4":1378,"NA":1380},{"trials":1362,"activeCount":102},[],{"trials":1364,"activeCount":102},[],{"trials":1366,"activeCount":253,"soonestReadout":1371},[1367],{"nctId":1368,"briefTitle":1369,"status":126,"phases":1370,"primaryCompletion":1371,"completion":1371,"start":1372,"enrollment":852,"conditions":1373,"interventions":1375},"NCT06617312","Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity",[91],"2026-12","2024-12-05",[1374,1200],"Smoking Cessation",[1359],{"trials":1377,"activeCount":102},[],{"trials":1379,"activeCount":102},[],{"trials":1381,"activeCount":102},[],{"intervention":1383,"totalTrials":253,"cells":1384},"Potassium Citrate",{"EARLY_PHASE1":1385,"PHASE1":1387,"PHASE2":1389,"PHASE3":1403,"PHASE4":1405,"NA":1407},{"trials":1386,"activeCount":102},[],{"trials":1388,"activeCount":102},[],{"trials":1390,"activeCount":253,"soonestReadout":1395},[1391],{"nctId":1392,"briefTitle":1393,"status":180,"phases":1394,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":19,"conditions":1398,"interventions":1401},"NCT07408076","Sodium Bicarbonate as an Alternative to Potassium Citrate for Kidney Stones",[90,91],"2026-08-01","2028-02-01","2026-02-01",[1399,1400],"Kidney Stones, Urolithiasis, Hypocitraturia","Nephrolithiasis",[1383,1402],"Sodium Bicarbonate",{"trials":1404,"activeCount":102},[],{"trials":1406,"activeCount":102},[],{"trials":1408,"activeCount":102},[],{"intervention":1402,"totalTrials":253,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1421,"PHASE4":1423,"NA":1425},{"trials":1412,"activeCount":102},[],{"trials":1414,"activeCount":102},[],{"trials":1416,"activeCount":253,"soonestReadout":1395},[1417],{"nctId":1392,"briefTitle":1393,"status":180,"phases":1418,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":19,"conditions":1419,"interventions":1420},[90,91],[1399,1400],[1383,1402],{"trials":1422,"activeCount":102},[],{"trials":1424,"activeCount":102},[],{"trials":1426,"activeCount":102},[],{"intervention":1428,"totalTrials":161,"cells":1429},"THC",{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1461,"PHASE3":1463,"PHASE4":1465,"NA":1467},{"trials":1431,"activeCount":102},[],{"trials":1433,"activeCount":161,"soonestReadout":1451},[1434,1447],{"nctId":1435,"briefTitle":1436,"status":126,"phases":1437,"primaryCompletion":1438,"completion":1439,"start":1440,"enrollment":19,"conditions":1441,"interventions":1443},"NCT06859710","THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy",[90],"2027-09-01","2028-09-01","2025-11-05",[1442,135],"Abuse, Drug",[1428,1444,1445,1446],"CBD 20 mg","CBD 40 mg","CBD 80 mg",{"nctId":1448,"briefTitle":1449,"status":180,"phases":1450,"primaryCompletion":1451,"completion":1452,"start":1453,"enrollment":31,"conditions":1454,"interventions":1458},"NCT05067387","Evaluation of Oral THC and CBD in Men and Women",[90],"2027-06-15","2028-06-15","2026-04-15",[1455,1456,1457],"Drug Abuse","Intoxication by Drug","Impairment",[1428,1459,1460],"CBD","THC + CBD",{"trials":1462,"activeCount":102},[],{"trials":1464,"activeCount":102},[],{"trials":1466,"activeCount":102},[],{"trials":1468,"activeCount":102},[],{"intervention":73,"totalTrials":161,"cells":1470},{"EARLY_PHASE1":1471,"PHASE1":1473,"PHASE2":1495,"PHASE3":1497,"PHASE4":1499,"NA":1501},{"trials":1472,"activeCount":102},[],{"trials":1474,"activeCount":161,"soonestReadout":72},[1475,1484],{"nctId":84,"briefTitle":85,"status":232,"phases":1476,"primaryCompletion":86,"completion":1477,"start":1478,"enrollment":34,"conditions":1479,"interventions":1481},[90],"2026-12-04","2023-02-15",[135,1480,1442],"Appetite Loss",[87,1482,73,1483],"High CBG","High THC",{"nctId":70,"briefTitle":71,"status":232,"phases":1485,"primaryCompletion":72,"completion":1486,"start":1487,"enrollment":1488,"conditions":1489,"interventions":1490},[90],"2026-07-30","2021-12-15",45,[135,1442],[73,1483,1491,1492,1493,1494],"Low Myrcene","High Myrcene","Low Beta-Caryophyllene","High Beta-Caryophyllene",{"trials":1496,"activeCount":102},[],{"trials":1498,"activeCount":102},[],{"trials":1500,"activeCount":102},[],{"trials":1502,"activeCount":102},[],{"intervention":1483,"totalTrials":161,"cells":1504},{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1523},{"trials":1506,"activeCount":102},[],{"trials":1508,"activeCount":161,"soonestReadout":72},[1509,1513],{"nctId":84,"briefTitle":85,"status":232,"phases":1510,"primaryCompletion":86,"completion":1477,"start":1478,"enrollment":34,"conditions":1511,"interventions":1512},[90],[135,1480,1442],[87,1482,73,1483],{"nctId":70,"briefTitle":71,"status":232,"phases":1514,"primaryCompletion":72,"completion":1486,"start":1487,"enrollment":1488,"conditions":1515,"interventions":1516},[90],[135,1442],[73,1483,1491,1492,1493,1494],{"trials":1518,"activeCount":102},[],{"trials":1520,"activeCount":102},[],{"trials":1522,"activeCount":102},[],{"trials":1524,"activeCount":102},[],{"intervention":1444,"totalTrials":253,"cells":1526},{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1535,"PHASE3":1537,"PHASE4":1539,"NA":1541},{"trials":1528,"activeCount":102},[],{"trials":1530,"activeCount":253,"soonestReadout":1438},[1531],{"nctId":1435,"briefTitle":1436,"status":126,"phases":1532,"primaryCompletion":1438,"completion":1439,"start":1440,"enrollment":19,"conditions":1533,"interventions":1534},[90],[1442,135],[1428,1444,1445,1446],{"trials":1536,"activeCount":102},[],{"trials":1538,"activeCount":102},[],{"trials":1540,"activeCount":102},[],{"trials":1542,"activeCount":102},[],{"intervention":1445,"totalTrials":253,"cells":1544},{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1553,"PHASE3":1555,"PHASE4":1557,"NA":1559},{"trials":1546,"activeCount":102},[],{"trials":1548,"activeCount":253,"soonestReadout":1438},[1549],{"nctId":1435,"briefTitle":1436,"status":126,"phases":1550,"primaryCompletion":1438,"completion":1439,"start":1440,"enrollment":19,"conditions":1551,"interventions":1552},[90],[1442,135],[1428,1444,1445,1446],{"trials":1554,"activeCount":102},[],{"trials":1556,"activeCount":102},[],{"trials":1558,"activeCount":102},[],{"trials":1560,"activeCount":102},[],{"intervention":1446,"totalTrials":253,"cells":1562},{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1571,"PHASE3":1573,"PHASE4":1575,"NA":1577},{"trials":1564,"activeCount":102},[],{"trials":1566,"activeCount":253,"soonestReadout":1438},[1567],{"nctId":1435,"briefTitle":1436,"status":126,"phases":1568,"primaryCompletion":1438,"completion":1439,"start":1440,"enrollment":19,"conditions":1569,"interventions":1570},[90],[1442,135],[1428,1444,1445,1446],{"trials":1572,"activeCount":102},[],{"trials":1574,"activeCount":102},[],{"trials":1576,"activeCount":102},[],{"trials":1578,"activeCount":102},[],{"intervention":1580,"totalTrials":253,"cells":1581},"cLSC",{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1595,"PHASE3":1597,"PHASE4":1599,"NA":1601},{"trials":1583,"activeCount":102},[],{"trials":1585,"activeCount":253,"soonestReadout":1590},[1586],{"nctId":1587,"briefTitle":1588,"status":232,"phases":1589,"primaryCompletion":1590,"completion":1055,"start":1591,"enrollment":34,"conditions":1592,"interventions":1594},"NCT03957954","Stem Cell Therapy for Limbal Stem Cell Deficiency",[90],"2027-02-04","2020-09-30",[1593],"Limbal Stem-cell Deficiency",[1580],{"trials":1596,"activeCount":102},[],{"trials":1598,"activeCount":102},[],{"trials":1600,"activeCount":102},[],{"trials":1602,"activeCount":102},[],{"intervention":1604,"totalTrials":253,"cells":1605},"Cannabis",{"EARLY_PHASE1":1606,"PHASE1":1608,"PHASE2":1624,"PHASE3":1626,"PHASE4":1628,"NA":1630},{"trials":1607,"activeCount":102},[],{"trials":1609,"activeCount":253,"soonestReadout":1614},[1610],{"nctId":1611,"briefTitle":1612,"status":126,"phases":1613,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":1618,"interventions":1620},"NCT05865470","Age-dependent Effects of Smoked and Oral Delta-9-THC",[90],"2028-10-15","2029-10-15","2025-04-30",103,[135,1442,1619],"Intoxication; Cannabinoids",[1604,1621,1622,1623],"Dronabinol","Smoked Placebo","Oral Placebo",{"trials":1625,"activeCount":102},[],{"trials":1627,"activeCount":102},[],{"trials":1629,"activeCount":102},[],{"trials":1631,"activeCount":102},[],{"intervention":1621,"totalTrials":253,"cells":1633},{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1642,"PHASE3":1644,"PHASE4":1646,"NA":1648},{"trials":1635,"activeCount":102},[],{"trials":1637,"activeCount":253,"soonestReadout":1614},[1638],{"nctId":1611,"briefTitle":1612,"status":126,"phases":1639,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":1640,"interventions":1641},[90],[135,1442,1619],[1604,1621,1622,1623],{"trials":1643,"activeCount":102},[],{"trials":1645,"activeCount":102},[],{"trials":1647,"activeCount":102},[],{"trials":1649,"activeCount":102},[],{"intervention":1622,"totalTrials":253,"cells":1651},{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1660,"PHASE3":1662,"PHASE4":1664,"NA":1666},{"trials":1653,"activeCount":102},[],{"trials":1655,"activeCount":253,"soonestReadout":1614},[1656],{"nctId":1611,"briefTitle":1612,"status":126,"phases":1657,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":1658,"interventions":1659},[90],[135,1442,1619],[1604,1621,1622,1623],{"trials":1661,"activeCount":102},[],{"trials":1663,"activeCount":102},[],{"trials":1665,"activeCount":102},[],{"trials":1667,"activeCount":102},[],{"intervention":1623,"totalTrials":253,"cells":1669},{"EARLY_PHASE1":1670,"PHASE1":1672,"PHASE2":1678,"PHASE3":1680,"PHASE4":1682,"NA":1684},{"trials":1671,"activeCount":102},[],{"trials":1673,"activeCount":253,"soonestReadout":1614},[1674],{"nctId":1611,"briefTitle":1612,"status":126,"phases":1675,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":1676,"interventions":1677},[90],[135,1442,1619],[1604,1621,1622,1623],{"trials":1679,"activeCount":102},[],{"trials":1681,"activeCount":102},[],{"trials":1683,"activeCount":102},[],{"trials":1685,"activeCount":102},[],{"intervention":1687,"totalTrials":253,"cells":1688},"Active Cannabis",{"EARLY_PHASE1":1689,"PHASE1":1691,"PHASE2":1700,"PHASE3":1702,"PHASE4":1704,"NA":1706},{"trials":1690,"activeCount":102},[],{"trials":1692,"activeCount":253,"soonestReadout":195},[1693],{"nctId":1694,"briefTitle":1695,"status":126,"phases":1696,"primaryCompletion":195,"completion":193,"start":1697,"enrollment":1249,"conditions":1698,"interventions":1699},"NCT04385082","Cannabis Effects as a Function of Sex",[90],"2021-07-08",[135,1442],[1687],{"trials":1701,"activeCount":102},[],{"trials":1703,"activeCount":102},[],{"trials":1705,"activeCount":102},[],{"trials":1707,"activeCount":102},[],{"intervention":1709,"totalTrials":253,"cells":1710},"Donor CD34+, CD3+. and belumosudil",{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1726,"PHASE3":1728,"PHASE4":1730,"NA":1732},{"trials":1712,"activeCount":102},[],{"trials":1714,"activeCount":253,"soonestReadout":1719},[1715],{"nctId":1716,"briefTitle":1717,"status":232,"phases":1718,"primaryCompletion":1719,"completion":1719,"start":1720,"enrollment":747,"conditions":1721,"interventions":1725},"NCT05806749","Immunological Tolerance in Patients With Mismatched Kidney Transplants",[90],"2028-08","2023-07-07",[1722,1723,1724,1251],"End Stage Kidney Disease","Immunological Tolerance","Kidney Transplant Failure and Rejection",[1709],{"trials":1727,"activeCount":102},[],{"trials":1729,"activeCount":102},[],{"trials":1731,"activeCount":102},[],{"trials":1733,"activeCount":102},[],{"intervention":1459,"totalTrials":253,"cells":1735},{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1744,"PHASE3":1746,"PHASE4":1748,"NA":1750},{"trials":1737,"activeCount":102},[],{"trials":1739,"activeCount":253,"soonestReadout":1451},[1740],{"nctId":1448,"briefTitle":1449,"status":180,"phases":1741,"primaryCompletion":1451,"completion":1452,"start":1453,"enrollment":31,"conditions":1742,"interventions":1743},[90],[1455,1456,1457],[1428,1459,1460],{"trials":1745,"activeCount":102},[],{"trials":1747,"activeCount":102},[],{"trials":1749,"activeCount":102},[],{"trials":1751,"activeCount":102},[],{"intervention":1460,"totalTrials":253,"cells":1753},{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1762,"PHASE3":1764,"PHASE4":1766,"NA":1768},{"trials":1755,"activeCount":102},[],{"trials":1757,"activeCount":253,"soonestReadout":1451},[1758],{"nctId":1448,"briefTitle":1449,"status":180,"phases":1759,"primaryCompletion":1451,"completion":1452,"start":1453,"enrollment":31,"conditions":1760,"interventions":1761},[90],[1455,1456,1457],[1428,1459,1460],{"trials":1763,"activeCount":102},[],{"trials":1765,"activeCount":102},[],{"trials":1767,"activeCount":102},[],{"trials":1769,"activeCount":102},[],{"intervention":87,"totalTrials":253,"cells":1771},{"EARLY_PHASE1":1772,"PHASE1":1774,"PHASE2":1780,"PHASE3":1782,"PHASE4":1784,"NA":1786},{"trials":1773,"activeCount":102},[],{"trials":1775,"activeCount":253,"soonestReadout":86},[1776],{"nctId":84,"briefTitle":85,"status":232,"phases":1777,"primaryCompletion":86,"completion":1477,"start":1478,"enrollment":34,"conditions":1778,"interventions":1779},[90],[135,1480,1442],[87,1482,73,1483],{"trials":1781,"activeCount":102},[],{"trials":1783,"activeCount":102},[],{"trials":1785,"activeCount":102},[],{"trials":1787,"activeCount":102},[],{"intervention":1482,"totalTrials":253,"cells":1789},{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1798,"PHASE3":1800,"PHASE4":1802,"NA":1804},{"trials":1791,"activeCount":102},[],{"trials":1793,"activeCount":253,"soonestReadout":86},[1794],{"nctId":84,"briefTitle":85,"status":232,"phases":1795,"primaryCompletion":86,"completion":1477,"start":1478,"enrollment":34,"conditions":1796,"interventions":1797},[90],[135,1480,1442],[87,1482,73,1483],{"trials":1799,"activeCount":102},[],{"trials":1801,"activeCount":102},[],{"trials":1803,"activeCount":102},[],{"trials":1805,"activeCount":102},[],{"intervention":1807,"totalTrials":253,"cells":1808},"Low dose THC",{"EARLY_PHASE1":1809,"PHASE1":1811,"PHASE2":1823,"PHASE3":1825,"PHASE4":1827,"NA":1829},{"trials":1810,"activeCount":102},[],{"trials":1812,"activeCount":253,"soonestReadout":193},[1813],{"nctId":1814,"briefTitle":1815,"status":126,"phases":1816,"primaryCompletion":193,"completion":194,"start":1817,"enrollment":19,"conditions":1818,"interventions":1821},"NCT06859723","High Potency Cannabis: Acute and Protracted Effects",[90],"2025-07-03",[1819,135,1820],"Abuse Cannabis","Pharmacokinetics",[1807,1822],"High dose THC",{"trials":1824,"activeCount":102},[],{"trials":1826,"activeCount":102},[],{"trials":1828,"activeCount":102},[],{"trials":1830,"activeCount":102},[],{"intervention":1822,"totalTrials":253,"cells":1832},{"EARLY_PHASE1":1833,"PHASE1":1835,"PHASE2":1841,"PHASE3":1843,"PHASE4":1845,"NA":1847},{"trials":1834,"activeCount":102},[],{"trials":1836,"activeCount":253,"soonestReadout":193},[1837],{"nctId":1814,"briefTitle":1815,"status":126,"phases":1838,"primaryCompletion":193,"completion":194,"start":1817,"enrollment":19,"conditions":1839,"interventions":1840},[90],[1819,135,1820],[1807,1822],{"trials":1842,"activeCount":102},[],{"trials":1844,"activeCount":102},[],{"trials":1846,"activeCount":102},[],{"trials":1848,"activeCount":102},[],{"intervention":1491,"totalTrials":253,"cells":1850},{"EARLY_PHASE1":1851,"PHASE1":1853,"PHASE2":1859,"PHASE3":1861,"PHASE4":1863,"NA":1865},{"trials":1852,"activeCount":102},[],{"trials":1854,"activeCount":253,"soonestReadout":72},[1855],{"nctId":70,"briefTitle":71,"status":232,"phases":1856,"primaryCompletion":72,"completion":1486,"start":1487,"enrollment":1488,"conditions":1857,"interventions":1858},[90],[135,1442],[73,1483,1491,1492,1493,1494],{"trials":1860,"activeCount":102},[],{"trials":1862,"activeCount":102},[],{"trials":1864,"activeCount":102},[],{"trials":1866,"activeCount":102},[],{"intervention":1492,"totalTrials":253,"cells":1868},{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1877,"PHASE3":1879,"PHASE4":1881,"NA":1883},{"trials":1870,"activeCount":102},[],{"trials":1872,"activeCount":253,"soonestReadout":72},[1873],{"nctId":70,"briefTitle":71,"status":232,"phases":1874,"primaryCompletion":72,"completion":1486,"start":1487,"enrollment":1488,"conditions":1875,"interventions":1876},[90],[135,1442],[73,1483,1491,1492,1493,1494],{"trials":1878,"activeCount":102},[],{"trials":1880,"activeCount":102},[],{"trials":1882,"activeCount":102},[],{"trials":1884,"activeCount":102},[],{"intervention":1493,"totalTrials":253,"cells":1886},{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1895,"PHASE3":1897,"PHASE4":1899,"NA":1901},{"trials":1888,"activeCount":102},[],{"trials":1890,"activeCount":253,"soonestReadout":72},[1891],{"nctId":70,"briefTitle":71,"status":232,"phases":1892,"primaryCompletion":72,"completion":1486,"start":1487,"enrollment":1488,"conditions":1893,"interventions":1894},[90],[135,1442],[73,1483,1491,1492,1493,1494],{"trials":1896,"activeCount":102},[],{"trials":1898,"activeCount":102},[],{"trials":1900,"activeCount":102},[],{"trials":1902,"activeCount":102},[],{"intervention":1494,"totalTrials":253,"cells":1904},{"EARLY_PHASE1":1905,"PHASE1":1907,"PHASE2":1913,"PHASE3":1915,"PHASE4":1917,"NA":1919},{"trials":1906,"activeCount":102},[],{"trials":1908,"activeCount":253,"soonestReadout":72},[1909],{"nctId":70,"briefTitle":71,"status":232,"phases":1910,"primaryCompletion":72,"completion":1486,"start":1487,"enrollment":1488,"conditions":1911,"interventions":1912},[90],[135,1442],[73,1483,1491,1492,1493,1494],{"trials":1914,"activeCount":102},[],{"trials":1916,"activeCount":102},[],{"trials":1918,"activeCount":102},[],{"trials":1920,"activeCount":102},[],{"intervention":1922,"totalTrials":253,"cells":1923},"Conditioning and Stem cell",{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1935,"PHASE3":1937,"PHASE4":1939,"NA":1941},{"trials":1925,"activeCount":102},[],{"trials":1927,"activeCount":253,"soonestReadout":1371},[1928],{"nctId":1929,"briefTitle":1930,"status":126,"phases":1931,"primaryCompletion":1371,"completion":1371,"start":1932,"enrollment":735,"conditions":1933,"interventions":1934},"NCT05525507","Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants",[90],"2022-12-21",[1722,1723,1724,1251],[1922],{"trials":1936,"activeCount":102},[],{"trials":1938,"activeCount":102},[],{"trials":1940,"activeCount":102},[],{"trials":1942,"activeCount":102},[],{"intervention":1944,"totalTrials":253,"cells":1945},"Thiamine",{"EARLY_PHASE1":1946,"PHASE1":1959,"PHASE2":1961,"PHASE3":1963,"PHASE4":1965,"NA":1967},{"trials":1947,"activeCount":253,"soonestReadout":1171},[1948],{"nctId":1949,"briefTitle":1950,"status":126,"phases":1951,"primaryCompletion":1171,"completion":1952,"start":1953,"enrollment":1954,"conditions":1955,"interventions":1958},"NCT06326996","Thiamine Intervention and Coronary Artery Bypass Grafting",[89],"2026-09-30","2024-10-10",52,[1956,1957],"Coronary Heart Disease","Coronary Artery Bypass Grafting",[1944],{"trials":1960,"activeCount":102},[],{"trials":1962,"activeCount":102},[],{"trials":1964,"activeCount":102},[],{"trials":1966,"activeCount":102},[],{"trials":1968,"activeCount":102},[],{"intervention":1970,"totalTrials":253,"cells":1971},"Bupivacaine",{"EARLY_PHASE1":1972,"PHASE1":1986,"PHASE2":1988,"PHASE3":1990,"PHASE4":1992,"NA":1994},{"trials":1973,"activeCount":253,"soonestReadout":1978},[1974],{"nctId":1975,"briefTitle":1976,"status":232,"phases":1977,"primaryCompletion":1978,"completion":1979,"start":1980,"enrollment":235,"conditions":1981,"interventions":1984},"NCT04126824","Effect of Addition of Steroids on Duration of Analgesia",[89],"2026-08-02","2027-08-02","2022-01-06",[1982,1983],"Uterine Fibroids","Adenomyosis",[1985,1970],"Triamcinolone",{"trials":1987,"activeCount":102},[],{"trials":1989,"activeCount":102},[],{"trials":1991,"activeCount":102},[],{"trials":1993,"activeCount":102},[],{"trials":1995,"activeCount":102},[],{"intervention":1997,"totalTrials":253,"cells":1998},"68Ga-FAPi-46",{"EARLY_PHASE1":1999,"PHASE1":2015,"PHASE2":2017,"PHASE3":2019,"PHASE4":2021,"NA":2023},{"trials":2000,"activeCount":253,"soonestReadout":1371},[2001],{"nctId":2002,"briefTitle":2003,"status":126,"phases":2004,"primaryCompletion":1371,"completion":1371,"start":2005,"enrollment":19,"conditions":2006,"interventions":2014},"NCT05365802","FAPI PET for Lung Fibrosis",[89],"2021-11-16",[2007,2008,2009,2010,2011,2012,2013],"Interstitial Lung Disease","Idiopathic Interstitial Pneumonias","Drug-Induced Pneumonitis","Hypersensitivity Pneumonitis","Radiation Pneumonitis","Pneumoconiosis","Pulmonary Fibrosis",[1997],{"trials":2016,"activeCount":102},[],{"trials":2018,"activeCount":102},[],{"trials":2020,"activeCount":102},[],{"trials":2022,"activeCount":102},[],{"trials":2024,"activeCount":102},[],{"intervention":2026,"totalTrials":253,"cells":2027},"Active Comparator",{"EARLY_PHASE1":2028,"PHASE1":2038,"PHASE2":2040,"PHASE3":2042,"PHASE4":2044,"NA":2046},{"trials":2029,"activeCount":253,"soonestReadout":1371},[2030],{"nctId":2031,"briefTitle":2032,"status":126,"phases":2033,"primaryCompletion":1371,"completion":767,"start":2034,"enrollment":2035,"conditions":2036,"interventions":2037},"NCT05247255","Quadratus Lumborum Block for Total Hip Arthroplasty",[89],"2022-03-29",80,[148],[2026],{"trials":2039,"activeCount":102},[],{"trials":2041,"activeCount":102},[],{"trials":2043,"activeCount":102},[],{"trials":2045,"activeCount":102},[],{"trials":2047,"activeCount":102},[],{"intervention":2049,"totalTrials":253,"cells":2050},"Adderall-XR",{"EARLY_PHASE1":2051,"PHASE1":2060,"PHASE2":2062,"PHASE3":2064,"PHASE4":2066,"NA":2068},{"trials":2052,"activeCount":253,"soonestReadout":512},[2053],{"nctId":2054,"briefTitle":2055,"status":285,"phases":2056,"primaryCompletion":512,"completion":512,"start":2057,"enrollment":19,"conditions":2058,"interventions":2059},"NCT04509102","Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder",[89],"2021-09-27",[27],[2049],{"trials":2061,"activeCount":102},[],{"trials":2063,"activeCount":102},[],{"trials":2065,"activeCount":102},[],{"trials":2067,"activeCount":102},[],{"trials":2069,"activeCount":102},[],{"intervention":2071,"totalTrials":253,"cells":2072},"Anakinra",{"EARLY_PHASE1":2073,"PHASE1":2085,"PHASE2":2087,"PHASE3":2089,"PHASE4":2091,"NA":2093},{"trials":2074,"activeCount":253,"soonestReadout":2079},[2075],{"nctId":2076,"briefTitle":2077,"status":126,"phases":2078,"primaryCompletion":2079,"completion":2079,"start":2080,"enrollment":2081,"conditions":2082,"interventions":2084},"NCT03968913","Biologic Therapy to Prevent Osteoarthritis After ACL Injury",[89],"2027-01-30","2021-09-15",32,[2083],"Anterior Cruciate Ligament Injuries",[2071],{"trials":2086,"activeCount":102},[],{"trials":2088,"activeCount":102},[],{"trials":2090,"activeCount":102},[],{"trials":2092,"activeCount":102},[],{"trials":2094,"activeCount":102},[],{"intervention":2096,"totalTrials":253,"cells":2097},"intravenous citalopram hydrochloride",{"EARLY_PHASE1":2098,"PHASE1":2108,"PHASE2":2110,"PHASE3":2112,"PHASE4":2114,"NA":2116},{"trials":2099,"activeCount":253,"soonestReadout":2104},[2100],{"nctId":2101,"briefTitle":2102,"status":232,"phases":2103,"primaryCompletion":2104,"completion":2104,"start":2105,"enrollment":19,"conditions":2106,"interventions":2107},"NCT04846829","Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)",[89],"2028-04-24","2017-04-24",[27],[2096],{"trials":2109,"activeCount":102},[],{"trials":2111,"activeCount":102},[],{"trials":2113,"activeCount":102},[],{"trials":2115,"activeCount":102},[],{"trials":2117,"activeCount":102},[],{"intervention":2119,"totalTrials":98,"cells":2120},"Naltrexone",{"EARLY_PHASE1":2121,"PHASE1":2132,"PHASE2":2134,"PHASE3":2153,"PHASE4":2155,"NA":2157},{"trials":2122,"activeCount":253,"soonestReadout":2127},[2123],{"nctId":2124,"briefTitle":2125,"status":285,"phases":2126,"primaryCompletion":2127,"completion":2127,"start":2128,"enrollment":1032,"conditions":2129,"interventions":2131},"NCT04166071","Opioids and Social Support Enhanced Extinction Effects",[89],"2026-09","2021-12-13",[2130],"Fear",[2119],{"trials":2133,"activeCount":102},[],{"trials":2135,"activeCount":102},[2136,2143],{"nctId":2137,"briefTitle":2138,"status":140,"phases":2139,"primaryCompletion":2140,"completion":2140,"start":671,"enrollment":11,"conditions":2141,"interventions":2142},"NCT02026011","Naltrexone for Individuals of East Asian Descent",[91],"2016-09",[36],[2119],{"nctId":2144,"briefTitle":2145,"status":140,"phases":2146,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":2149,"conditions":2150,"interventions":2151},"NCT04249882","A Novel Human Lab Model for Screening AUD Medications",[91],"2022-06-28","2020-01-28",53,[36],[2119,2152],"Varenicline",{"trials":2154,"activeCount":102},[],{"trials":2156,"activeCount":102},[],{"trials":2158,"activeCount":102},[2159],{"nctId":2160,"briefTitle":2161,"status":140,"phases":2162,"primaryCompletion":2163,"completion":2163,"start":2164,"enrollment":144,"conditions":2165,"interventions":2167},"NCT01672723","Neuropharmacological Basis of Social Connection: The Role of Opioids",[94],"2014-02","2012-10",[2166],"Psychology, Social",[2119],{"intervention":1985,"totalTrials":161,"cells":2169},{"EARLY_PHASE1":2170,"PHASE1":2176,"PHASE2":2178,"PHASE3":2180,"PHASE4":2182,"NA":2184},{"trials":2171,"activeCount":253,"soonestReadout":1978},[2172],{"nctId":1975,"briefTitle":1976,"status":232,"phases":2173,"primaryCompletion":1978,"completion":1979,"start":1980,"enrollment":235,"conditions":2174,"interventions":2175},[89],[1982,1983],[1985,1970],{"trials":2177,"activeCount":102},[],{"trials":2179,"activeCount":102},[],{"trials":2181,"activeCount":102},[],{"trials":2183,"activeCount":102},[],{"trials":2185,"activeCount":102},[2186],{"nctId":2187,"briefTitle":2188,"status":140,"phases":2189,"primaryCompletion":2190,"completion":2191,"start":2192,"enrollment":31,"conditions":2193,"interventions":2195},"NCT04841343","Triamcinolone Packing Following Endoscopic Sinus Surgery",[],"2021-09-30","2022-09-30","2021-01-29",[2194],"Sinusitis",[1985],{"intervention":2197,"totalTrials":253,"cells":2198},"Semaglutide Injectable Product",{"EARLY_PHASE1":2199,"PHASE1":2201,"PHASE2":2203,"PHASE3":2205,"PHASE4":2207,"NA":2209},{"trials":2200,"activeCount":102},[],{"trials":2202,"activeCount":102},[],{"trials":2204,"activeCount":102},[],{"trials":2206,"activeCount":102},[],{"trials":2208,"activeCount":102},[],{"trials":2210,"activeCount":253,"soonestReadout":1106},[2211],{"nctId":2212,"briefTitle":2213,"status":126,"phases":2214,"primaryCompletion":1106,"completion":1397,"start":2215,"enrollment":34,"conditions":2216,"interventions":2217},"NCT05419726","Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.",[],"2023-02-01",[33],[2197],{"intervention":2219,"totalTrials":253,"cells":2220},"Xiidra (Lifitegrast ophthalmic solution) 5%",{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2227,"PHASE4":2229,"NA":2231},{"trials":2222,"activeCount":102},[],{"trials":2224,"activeCount":102},[],{"trials":2226,"activeCount":102},[],{"trials":2228,"activeCount":102},[],{"trials":2230,"activeCount":102},[],{"trials":2232,"activeCount":253,"soonestReadout":1223},[2233],{"nctId":2234,"briefTitle":2235,"status":126,"phases":2236,"primaryCompletion":1223,"completion":1223,"start":2237,"enrollment":2238,"conditions":2239,"interventions":2242},"NCT04354545","Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications",[],"2021-04-01",75,[2240,2241],"Glaucoma","Ocular Surface Disease",[2219],{"intervention":63,"totalTrials":253,"cells":2244},{"EARLY_PHASE1":2245,"PHASE1":2247,"PHASE2":2249,"PHASE3":2251,"PHASE4":2253,"NA":2255},{"trials":2246,"activeCount":102},[],{"trials":2248,"activeCount":102},[],{"trials":2250,"activeCount":102},[],{"trials":2252,"activeCount":102},[],{"trials":2254,"activeCount":102},[],{"trials":2256,"activeCount":253,"soonestReadout":62},[2257],{"nctId":60,"briefTitle":61,"status":232,"phases":2258,"primaryCompletion":62,"completion":2259,"start":2260,"enrollment":2035,"conditions":2261,"interventions":2264},[94],"2025-09-01","2022-01-31",[36,2262,2263],"Alcoholic Liver Disease","Microbiome",[63],{"intervention":2266,"totalTrials":253,"cells":2267},"Lenacapavir",{"EARLY_PHASE1":2268,"PHASE1":2270,"PHASE2":2272,"PHASE3":2274,"PHASE4":2276,"NA":2278},{"trials":2269,"activeCount":102},[],{"trials":2271,"activeCount":102},[],{"trials":2273,"activeCount":102},[],{"trials":2275,"activeCount":102},[],{"trials":2277,"activeCount":102},[],{"trials":2279,"activeCount":253,"soonestReadout":1197},[2280],{"nctId":2281,"briefTitle":2282,"status":126,"phases":2283,"primaryCompletion":1197,"completion":1324,"start":2284,"enrollment":790,"conditions":2285,"interventions":2287},"NCT07467018","Mobile Vehicle-Based Delivery of Lenacapavir Pre-Exposure Prophylaxis in Los Angeles County",[],"2026-04-21",[2286],"HIV Prevention",[2266],{"intervention":2289,"totalTrials":253,"cells":2290},"Non-selective beta blockers",{"EARLY_PHASE1":2291,"PHASE1":2293,"PHASE2":2295,"PHASE3":2297,"PHASE4":2299,"NA":2301},{"trials":2292,"activeCount":102},[],{"trials":2294,"activeCount":102},[],{"trials":2296,"activeCount":102},[],{"trials":2298,"activeCount":102},[],{"trials":2300,"activeCount":102},[],{"trials":2302,"activeCount":253,"soonestReadout":2307},[2303],{"nctId":2304,"briefTitle":2305,"status":180,"phases":2306,"primaryCompletion":2307,"completion":2308,"start":2309,"enrollment":2310,"conditions":2311,"interventions":2313},"NCT07168395","Pre-emptive RTO for An Early Detected Gastric Varices in CT\u002FMR Angiogram Trial",[94],"2027-11","2028-11","2025-11",68,[2312],"Gastric Varices",[2289],{"intervention":2315,"totalTrials":253,"cells":2316},"Ivacaftor or elexacaftor\u002Ftezacaftor\u002Fivacaftor",{"EARLY_PHASE1":2317,"PHASE1":2319,"PHASE2":2321,"PHASE3":2323,"PHASE4":2325,"NA":2327},{"trials":2318,"activeCount":102},[],{"trials":2320,"activeCount":102},[],{"trials":2322,"activeCount":102},[],{"trials":2324,"activeCount":102},[],{"trials":2326,"activeCount":102},[],{"trials":2328,"activeCount":253,"soonestReadout":2333},[2329],{"nctId":2330,"briefTitle":2331,"status":126,"phases":2332,"primaryCompletion":2333,"completion":2333,"start":2334,"enrollment":2035,"conditions":2335,"interventions":2341},"NCT06191640","Sinus Disease in Young Children With Cystic Fibrosis",[],"2029-06-30","2023-04-12",[2336,2337,2338,2339,2340],"Cystic Fibrosis in Children","Cystic Fibrosis","Chronic Rhinosinusitis (Diagnosis)","Olfactory Disorder","Olfactory Impairment",[2315],{"intervention":2343,"totalTrials":253,"cells":2344},"autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase",{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2346,"activeCount":102},[],{"trials":2348,"activeCount":102},[],{"trials":2350,"activeCount":102},[],{"trials":2352,"activeCount":102},[],{"trials":2354,"activeCount":102},[],{"trials":2356,"activeCount":253,"soonestReadout":2361},[2357],{"nctId":2358,"briefTitle":2359,"status":285,"phases":2360,"primaryCompletion":2361,"completion":2361,"start":2362,"enrollment":2363,"conditions":2364,"interventions":2367},"NCT04049084","An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID",[],"2040-08","2019-09-26",70,[2365,2366],"Adenosine Deaminase Deficiency","Severe Combined Immunodeficiency (SCID)",[2343],{"intervention":48,"totalTrials":253,"cells":2369},{"EARLY_PHASE1":2370,"PHASE1":2372,"PHASE2":2374,"PHASE3":2376,"PHASE4":2378,"NA":2380},{"trials":2371,"activeCount":102},[],{"trials":2373,"activeCount":102},[],{"trials":2375,"activeCount":102},[],{"trials":2377,"activeCount":102},[],{"trials":2379,"activeCount":102},[],{"trials":2381,"activeCount":253,"soonestReadout":47},[2382],{"nctId":45,"briefTitle":46,"status":232,"phases":2383,"primaryCompletion":47,"completion":2384,"start":2385,"enrollment":2386,"conditions":2387,"interventions":2389},[94],"2025-12-30","2012-02-01",17,[2388],"Infection in Solid Organ Transplant Recipients",[48],{"intervention":2152,"totalTrials":2391,"cells":2392},6,{"EARLY_PHASE1":2393,"PHASE1":2395,"PHASE2":2409,"PHASE3":2444,"PHASE4":2446,"NA":2459},{"trials":2394,"activeCount":102},[],{"trials":2396,"activeCount":102},[2397],{"nctId":2398,"briefTitle":2399,"status":108,"phases":2400,"primaryCompletion":2401,"completion":2401,"start":2402,"enrollment":2403,"conditions":2404,"interventions":2408},"NCT03059563","Dopamine D2\u002FD3 Receptor Upregulation by Varenicline in Methamphetamine Users",[90],"2023-09-28","2018-01-11",62,[2405,2406,2407],"Dopamine D2\u002F3 Receptor Availability","Cognitive Function","Methamphetamine Abuse",[2152],{"trials":2410,"activeCount":102},[2411,2421,2429,2440],{"nctId":2412,"briefTitle":2413,"status":140,"phases":2414,"primaryCompletion":2415,"completion":2415,"start":2416,"enrollment":1954,"conditions":2417,"interventions":2420},"NCT01365819","Varenicline for Methamphetamine Dependence",[91],"2014-08","2012-02",[2418,2419,2407],"Methamphetamine Dependence","Substance Abuse",[2152],{"nctId":2422,"briefTitle":2423,"status":140,"phases":2424,"primaryCompletion":2425,"completion":2425,"start":2426,"enrollment":34,"conditions":2427,"interventions":2428},"NCT01011829","Varenicline vs Placebo for the Treatment of Methamphetamine Dependence",[91],"2010-05","2009-11",[2418,2419,2407],[2152],{"nctId":2430,"briefTitle":2431,"status":140,"phases":2432,"primaryCompletion":2433,"completion":2433,"start":2434,"enrollment":2435,"conditions":2436,"interventions":2438},"NCT02698215","Combining Varenicline and Naltrexone for Smoking Cessation",[91],"2019-12","2016-05",165,[2437,36],"Nicotine Dependence",[2152,2439],"Varenicline plus Naltrexone",{"nctId":2144,"briefTitle":2145,"status":140,"phases":2441,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":2149,"conditions":2442,"interventions":2443},[91],[36],[2119,2152],{"trials":2445,"activeCount":102},[],{"trials":2447,"activeCount":102},[2448],{"nctId":2449,"briefTitle":2450,"status":267,"phases":2451,"primaryCompletion":2452,"completion":2452,"start":2453,"enrollment":102,"conditions":2454,"interventions":2457},"NCT02488889","Effects of Varenicline in Heavy Drinking Smokers",[93],"2016-07-17","2015-08",[2455,2456],"Cigarette Smoking","Alcohol Consumption",[2152,2458],"Alcohol",{"trials":2460,"activeCount":102},[],{"intervention":2462,"totalTrials":2463,"cells":2464},"venlafaxine",5,{"EARLY_PHASE1":2465,"PHASE1":2467,"PHASE2":2469,"PHASE3":2471,"PHASE4":2473,"NA":2523},{"trials":2466,"activeCount":102},[],{"trials":2468,"activeCount":102},[],{"trials":2470,"activeCount":102},[],{"trials":2472,"activeCount":102},[],{"trials":2474,"activeCount":102},[2475,2485,2495,2505,2515],{"nctId":2476,"briefTitle":2477,"status":140,"phases":2478,"primaryCompletion":2479,"completion":2479,"start":2480,"enrollment":2481,"conditions":2482,"interventions":2483},"NCT00200902","Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression",[93],"2009-06","2005-08",88,[15],[2484],"Venlafaxine",{"nctId":2486,"briefTitle":2487,"status":140,"phases":2488,"primaryCompletion":2489,"completion":2490,"start":2491,"enrollment":2492,"conditions":2493,"interventions":2494},"NCT00759317","Physiologic Monitoring of Antidepressant Treatment Response",[93],"2002-08","2002-09","2001-06",37,[15],[2462],{"nctId":2496,"briefTitle":2497,"status":140,"phases":2498,"primaryCompletion":2499,"completion":2500,"start":2499,"enrollment":2501,"conditions":2502,"interventions":2504},"NCT00792168","Physiologic Monitoring of Antidepressant Response",[93],"1996-11","1998-12",38,[2503],"Major Depression",[2462],{"nctId":2506,"briefTitle":2507,"status":140,"phases":2508,"primaryCompletion":2509,"completion":2510,"start":2511,"enrollment":2512,"conditions":2513,"interventions":2514},"NCT00759122","Electroencephalography (EEG) Biomarkers of Response in Depression",[93],"2005-11","2005-12","2002-11",44,[27],[2462],{"nctId":2516,"briefTitle":2517,"status":140,"phases":2518,"primaryCompletion":2519,"completion":2519,"start":2520,"enrollment":2391,"conditions":2521,"interventions":2522},"NCT00634283","Study of the Effects of an Antidepressant Medication and Placebo on the Brain Functioning of Normal Subjects",[93],"2009-02","2008-02",[15],[2462],{"trials":2524,"activeCount":102},[],{"intervention":2526,"totalTrials":98,"cells":2527},"Fluoxetine",{"EARLY_PHASE1":2528,"PHASE1":2539,"PHASE2":2541,"PHASE3":2554,"PHASE4":2556,"NA":2573},{"trials":2529,"activeCount":102},[2530],{"nctId":2531,"briefTitle":2532,"status":267,"phases":2533,"primaryCompletion":2534,"completion":2534,"start":2535,"enrollment":102,"conditions":2536,"interventions":2538},"NCT01615055","Fluoxetine Prevention Trial",[89],"2020-10","2018-06",[2537],"Cognitive Dysfunction",[2526],{"trials":2540,"activeCount":102},[],{"trials":2542,"activeCount":102},[2543],{"nctId":2544,"briefTitle":2545,"status":140,"phases":2546,"primaryCompletion":2547,"completion":2547,"start":2548,"enrollment":144,"conditions":2549,"interventions":2551},"NCT01714310","Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation",[91],"2016-06","2013-01",[2550],"Severe Mood Dysregulation",[2552,2553],"lisdexamfetamine","fluoxetine",{"trials":2555,"activeCount":102},[],{"trials":2557,"activeCount":102},[2558,2565],{"nctId":2559,"briefTitle":2560,"status":140,"phases":2561,"primaryCompletion":2562,"start":640,"enrollment":22,"conditions":2563,"interventions":2564},"NCT01185977","Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)",[93],"2011-10",[27],[2526],{"nctId":2566,"briefTitle":2567,"status":140,"phases":2568,"primaryCompletion":2569,"completion":2569,"start":2570,"enrollment":709,"conditions":2571,"interventions":2572},"NCT01360190","Neurophysiologic Monitoring of Antidepressant Treatment",[93],"1996-08","1994-08",[27],[2553],{"trials":2574,"activeCount":102},[],{"intervention":2576,"totalTrials":98,"cells":2577},"Risperidone",{"EARLY_PHASE1":2578,"PHASE1":2580,"PHASE2":2582,"PHASE3":2594,"PHASE4":2596,"NA":2629},{"trials":2579,"activeCount":102},[],{"trials":2581,"activeCount":102},[],{"trials":2583,"activeCount":102},[2584],{"nctId":2585,"briefTitle":2586,"status":140,"phases":2587,"primaryCompletion":2140,"completion":2588,"start":2589,"enrollment":2590,"conditions":2591,"interventions":2593},"NCT01171937","Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior",[91],"2016-12","2008-09",41,[2592],"Autism",[2576],{"trials":2595,"activeCount":102},[],{"trials":2597,"activeCount":102},[2598,2609,2621],{"nctId":2599,"briefTitle":2600,"status":140,"phases":2601,"primaryCompletion":2602,"completion":2603,"start":2604,"enrollment":2605,"conditions":2606,"interventions":2607},"NCT00183625","Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients",[93],"2005-06","2006-09","2000-06",107,[30],[2608,2576],"Olanzapine",{"nctId":2610,"briefTitle":2611,"status":140,"phases":2612,"primaryCompletion":2613,"completion":2614,"start":2562,"enrollment":2615,"conditions":2616,"interventions":2618},"NCT01451736","Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia",[93],"2021-12-01","2021-12-31",146,[2617],"Schizophrenia (Recent-onset)",[2619,2620],"paliperidone palmitate","risperidone",{"nctId":2622,"briefTitle":2623,"status":108,"phases":2624,"completion":2625,"start":2626,"enrollment":1488,"conditions":2627,"interventions":2628},"NCT00203723","Use of Risperidone in ECT for Treatment Resistant Depression",[93],"2006-05","2005-03",[2503],[2576],{"trials":2630,"activeCount":102},[],{"intervention":2632,"totalTrials":98,"cells":2633},"Escitalopram",{"EARLY_PHASE1":2634,"PHASE1":2636,"PHASE2":2638,"PHASE3":2640,"PHASE4":2642,"NA":2683},{"trials":2635,"activeCount":102},[],{"trials":2637,"activeCount":102},[],{"trials":2639,"activeCount":102},[],{"trials":2641,"activeCount":102},[],{"trials":2643,"activeCount":102},[2644,2654,2661,2672],{"nctId":2645,"briefTitle":2646,"status":140,"phases":2647,"primaryCompletion":2648,"completion":2648,"start":2649,"enrollment":2650,"conditions":2651,"interventions":2652},"NCT00917059","Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)",[93],"2012-05","2009-05",172,[15],[2632,2653],"Bupropion XL",{"nctId":2655,"briefTitle":2656,"status":140,"phases":2657,"primaryCompletion":2164,"completion":2164,"start":2658,"enrollment":2035,"conditions":2659,"interventions":2660},"NCT01082237","Biomarkers for Outcomes In Late-life Depression (BOLD)",[93],"2009-10",[27],[2632],{"nctId":2662,"briefTitle":2663,"status":140,"phases":2664,"primaryCompletion":2665,"completion":2665,"start":2666,"enrollment":2667,"conditions":2668,"interventions":2670},"NCT01902004","Brain Aging and Treatment Response in Geriatric Depression",[93],"2019-01-23","2013-10",115,[2669,15],"Mild Cognitive Impairment (MCI)",[2632,2671],"Memantine",{"nctId":2673,"briefTitle":2674,"status":553,"phases":2675,"primaryCompletion":2426,"completion":2676,"start":2677,"enrollment":1032,"conditions":2678,"interventions":2680},"NCT00628914","Brain Mechanisms and Targeting Insomnia in Major Depression",[93],"2010-02","2008-05",[27,2679],"Insomnia",[2681,2682,2632],"escitalopram and eszopiclone","Escitalopram, eszopiclone, and placebo",{"trials":2684,"activeCount":102},[],{"intervention":2686,"totalTrials":208,"cells":2687},"Placebos",{"EARLY_PHASE1":2688,"PHASE1":2701,"PHASE2":2703,"PHASE3":2714,"PHASE4":2716,"NA":2729},{"trials":2689,"activeCount":102},[2690],{"nctId":2691,"briefTitle":2692,"status":140,"phases":2693,"primaryCompletion":2694,"completion":2695,"start":2696,"enrollment":2697,"conditions":2698,"interventions":2699},"NCT03771612","Inflammation and Daily Life Study",[89],"2023-11-09","2024-06-21","2022-02-09",144,[820],[2700,2686],"Naproxen",{"trials":2702,"activeCount":102},[],{"trials":2704,"activeCount":102},[2705],{"nctId":2706,"briefTitle":2707,"status":267,"phases":2708,"primaryCompletion":269,"completion":658,"start":2709,"enrollment":102,"conditions":2710,"interventions":2712},"NCT03000127","Testosterone for Fatigue in Men With MS",[91],"2018-07-01",[2711],"Multiple Sclerosis",[2713,2686],"AndroGel 1 % Topical Gel",{"trials":2715,"activeCount":102},[],{"trials":2717,"activeCount":102},[2718],{"nctId":2719,"briefTitle":2720,"status":140,"phases":2721,"primaryCompletion":2722,"completion":2722,"start":2723,"enrollment":2724,"conditions":2725,"interventions":2727},"NCT00423943","Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia",[93],"2012-12","2005-09",33,[30,2726],"Schizoaffective Disorder",[2728,2686],"modafinil",{"trials":2730,"activeCount":102},[],{"intervention":2728,"totalTrials":208,"cells":2732},{"EARLY_PHASE1":2733,"PHASE1":2735,"PHASE2":2737,"PHASE3":2749,"PHASE4":2751,"NA":2765},{"trials":2734,"activeCount":102},[],{"trials":2736,"activeCount":102},[],{"trials":2738,"activeCount":102},[2739],{"nctId":2740,"briefTitle":2741,"status":140,"phases":2742,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":2745,"conditions":2746,"interventions":2747},"NCT00469508","Modafinil vs Placebo for the Treatment of Methamphetamine Dependence",[91],"2009-01","2007-04",71,[2418],[2748],"Modafinil",{"trials":2750,"activeCount":102},[],{"trials":2752,"activeCount":102},[2753,2757],{"nctId":2719,"briefTitle":2720,"status":140,"phases":2754,"primaryCompletion":2722,"completion":2722,"start":2723,"enrollment":2724,"conditions":2755,"interventions":2756},[93],[30,2726],[2728,2686],{"nctId":2758,"briefTitle":2759,"status":140,"phases":2760,"primaryCompletion":2761,"completion":2761,"start":2677,"enrollment":2762,"conditions":2763,"interventions":2764},"NCT00711464","Modafinil Effects on Cognition in Schizophrenia Patients",[93],"2012-07",29,[30],[2728],{"trials":2766,"activeCount":102},[],{"intervention":2768,"totalTrials":208,"cells":2769},"Buprenorphine\u002Fnaloxone",{"EARLY_PHASE1":2770,"PHASE1":2772,"PHASE2":2774,"PHASE3":2776,"PHASE4":2797,"NA":2810},{"trials":2771,"activeCount":102},[],{"trials":2773,"activeCount":102},[],{"trials":2775,"activeCount":102},[],{"trials":2777,"activeCount":102},[2778,2789],{"nctId":2779,"briefTitle":2780,"status":140,"phases":2781,"primaryCompletion":2489,"completion":2489,"start":2782,"enrollment":2783,"conditions":2784,"interventions":2788},"NCT00032968","Buprenorphine\u002FNaloxone Versus Clonidine for Outpatient Opiate Detoxification - 1",[92],"2001-01",341,[2785,2786,2787],"Heroin Dependence","Morphine Dependence","Substance Withdrawal Syndrome",[2768],{"nctId":2790,"briefTitle":2791,"status":140,"phases":2792,"primaryCompletion":2489,"completion":2489,"start":2793,"enrollment":2794,"conditions":2795,"interventions":2796},"NCT00032955","Buprenorphine\u002FNaloxone Versus Clonidine for Inpatient Opiate Detoxification - 1",[92],"2001-02",163,[2785,2786,2787],[2768],{"trials":2798,"activeCount":102},[2799],{"nctId":2800,"briefTitle":2801,"status":140,"phases":2802,"primaryCompletion":2803,"completion":2803,"start":2804,"enrollment":2805,"conditions":2806,"interventions":2808},"NCT00315341","Starting Treatment With Agonist Replacement Therapies (START)",[93],"2010-08","2006-04",1269,[2807],"Opiate-related Disorders",[2768,2809],"Methadone",{"trials":2811,"activeCount":102},[],{"intervention":2813,"totalTrials":208,"cells":2814},"Methylphenidate",{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2819,"PHASE3":2830,"PHASE4":2832,"NA":2853},{"trials":2816,"activeCount":102},[],{"trials":2818,"activeCount":102},[],{"trials":2820,"activeCount":102},[2821],{"nctId":2822,"briefTitle":2823,"status":553,"phases":2824,"primaryCompletion":2825,"completion":2825,"start":2826,"enrollment":131,"conditions":2827,"interventions":2828},"NCT01044238","Methylphenidate to Treat Methamphetamine Dependence",[91],"2014-07","2010-10",[2418],[2829,2813],"methylphenidate",{"trials":2831,"activeCount":102},[],{"trials":2833,"activeCount":102},[2834,2843],{"nctId":2835,"briefTitle":2836,"status":140,"phases":2837,"primaryCompletion":2548,"completion":2838,"start":2520,"enrollment":2839,"conditions":2840,"interventions":2841},"NCT00602290","Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression",[93],"2013-02",181,[15],[2842,2813],"Citalopram",{"nctId":2844,"briefTitle":2845,"status":140,"phases":2846,"primaryCompletion":2847,"completion":2847,"start":798,"enrollment":2848,"conditions":2849,"interventions":2851},"NCT00429273","Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder",[93],"2011-07",212,[2850],"Attention Deficit Disorder With Hyperactivity",[2852,2813],"Guanfacine",{"trials":2854,"activeCount":102},[],{"intervention":2458,"totalTrials":161,"cells":2856},{"EARLY_PHASE1":2857,"PHASE1":2859,"PHASE2":2861,"PHASE3":2872,"PHASE4":2874,"NA":2880},{"trials":2858,"activeCount":102},[],{"trials":2860,"activeCount":102},[],{"trials":2862,"activeCount":102},[2863],{"nctId":2864,"briefTitle":2865,"status":140,"phases":2866,"primaryCompletion":2867,"completion":2867,"start":2163,"enrollment":2868,"conditions":2869,"interventions":2870},"NCT02046200","Development of Ivermectin for Alcohol Use Disorders",[90,91],"2015-03",11,[36],[2871,2458],"Ivermectin",{"trials":2873,"activeCount":102},[],{"trials":2875,"activeCount":102},[2876],{"nctId":2449,"briefTitle":2450,"status":267,"phases":2877,"primaryCompletion":2452,"completion":2452,"start":2453,"enrollment":102,"conditions":2878,"interventions":2879},[93],[2455,2456],[2152,2458],{"trials":2881,"activeCount":102},[],{"intervention":2883,"totalTrials":161,"cells":2884},"Propofol",{"EARLY_PHASE1":2885,"PHASE1":2887,"PHASE2":2889,"PHASE3":2891,"PHASE4":2893,"NA":2917},{"trials":2886,"activeCount":102},[],{"trials":2888,"activeCount":102},[],{"trials":2890,"activeCount":102},[],{"trials":2892,"activeCount":102},[],{"trials":2894,"activeCount":102},[2895,2907],{"nctId":2896,"briefTitle":2897,"status":108,"phases":2898,"primaryCompletion":2899,"completion":671,"start":2648,"enrollment":2900,"conditions":2901,"interventions":2903},"NCT02664922","Anesthetic Techniques in EP Patients",[93],"2013-09",35,[2902],"Cardiac Disease",[2883,2904,2905,2906],"Ketamine","Remifentanil","Sevoflurane",{"nctId":2908,"briefTitle":2909,"status":267,"phases":2910,"primaryCompletion":2911,"completion":2911,"start":2911,"enrollment":102,"conditions":2912,"interventions":2915},"NCT02119806","Decreasing the Incidence of Delirium After Cardiac Surgery",[93],"2017-08",[2913,2914],"C.Surgical Procedure; Cardiac","Delirium",[2916,593,2883],"Benzodiazepine",{"trials":2918,"activeCount":102},[],{"intervention":2904,"totalTrials":161,"cells":2920},{"EARLY_PHASE1":2921,"PHASE1":2923,"PHASE2":2933,"PHASE3":2935,"PHASE4":2937,"NA":2943},{"trials":2922,"activeCount":102},[],{"trials":2924,"activeCount":102},[2925],{"nctId":2926,"briefTitle":2927,"status":140,"phases":2928,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":1032,"conditions":2931,"interventions":2932},"NCT02165449","Biomarkers of Fast Acting Therapies in Major Depression",[90],"2019-08","2014-06",[27],[2904],{"trials":2934,"activeCount":102},[],{"trials":2936,"activeCount":102},[],{"trials":2938,"activeCount":102},[2939],{"nctId":2896,"briefTitle":2897,"status":108,"phases":2940,"primaryCompletion":2899,"completion":671,"start":2648,"enrollment":2900,"conditions":2941,"interventions":2942},[93],[2902],[2883,2904,2905,2906],{"trials":2944,"activeCount":102},[],{"intervention":2946,"totalTrials":161,"cells":2947},"Oral Risperidone",{"EARLY_PHASE1":2948,"PHASE1":2950,"PHASE2":2952,"PHASE3":2954,"PHASE4":2956,"NA":2976},{"trials":2949,"activeCount":102},[],{"trials":2951,"activeCount":102},[],{"trials":2953,"activeCount":102},[],{"trials":2955,"activeCount":102},[],{"trials":2957,"activeCount":102},[2958,2967],{"nctId":2959,"briefTitle":2960,"status":140,"phases":2961,"primaryCompletion":539,"completion":539,"start":2962,"enrollment":2963,"conditions":2964,"interventions":2965},"NCT00330551","Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia",[93],"2006-03",126,[30],[2946,2966],"Risperidone in Long-Acting Injectable Form",{"nctId":2968,"briefTitle":2969,"status":140,"phases":2970,"primaryCompletion":2971,"completion":2971,"start":2972,"enrollment":11,"conditions":2973,"interventions":2974},"NCT00203788","Improving Work Outcome in People With Recent-onset Schizophrenia",[93],"2006-12","1999-05",[30],[2975],"Oral risperidone",{"trials":2977,"activeCount":102},[],{"intervention":2979,"totalTrials":161,"cells":2980},"atorvastatin",{"EARLY_PHASE1":2981,"PHASE1":2983,"PHASE2":2985,"PHASE3":2987,"PHASE4":2989,"NA":3008},{"trials":2982,"activeCount":102},[],{"trials":2984,"activeCount":102},[],{"trials":2986,"activeCount":102},[],{"trials":2988,"activeCount":102},[],{"trials":2990,"activeCount":102},[2991,2999],{"nctId":2992,"briefTitle":2993,"status":140,"phases":2994,"primaryCompletion":2519,"completion":2519,"start":2480,"enrollment":2995,"conditions":2996,"interventions":2998},"NCT00233480","Statin Therapy in Heart Failure: Potential Mechanisms of Benefit",[93],27,[2997],"Heart Failure, Congestive",[2979],{"nctId":3000,"briefTitle":3001,"status":140,"phases":3002,"primaryCompletion":2723,"completion":2723,"start":3003,"enrollment":34,"conditions":3004,"interventions":3006},"NCT00356473","Effects of Atorvastatin on Disease Activity and HDL Cholesterol Function in Patients With Rheumatoid Arthritis",[93],"2003-03",[3005],"Rheumatoid Arthritis",[3007],"Atorvastatin",{"trials":3009,"activeCount":102},[],{"intervention":2671,"totalTrials":161,"cells":3011},{"EARLY_PHASE1":3012,"PHASE1":3014,"PHASE2":3016,"PHASE3":3018,"PHASE4":3030,"NA":3036},{"trials":3013,"activeCount":102},[],{"trials":3015,"activeCount":102},[],{"trials":3017,"activeCount":102},[],{"trials":3019,"activeCount":102},[3020],{"nctId":3021,"briefTitle":3022,"status":140,"phases":3023,"primaryCompletion":3024,"completion":3024,"start":3025,"enrollment":2386,"conditions":3026,"interventions":3029},"NCT00674219","Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder",[92],"2008-01","2005-05",[3027,3028],"Obsessive-Compulsive Disorder","Generalized Anxiety Disorder",[2671],{"trials":3031,"activeCount":102},[3032],{"nctId":2662,"briefTitle":2663,"status":140,"phases":3033,"primaryCompletion":2665,"completion":2665,"start":2666,"enrollment":2667,"conditions":3034,"interventions":3035},[93],[2669,15],[2632,2671],{"trials":3037,"activeCount":102},[],{"intervention":3039,"totalTrials":161,"cells":3040},"macitentan",{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3045,"PHASE3":3047,"PHASE4":3049,"NA":3070},{"trials":3042,"activeCount":102},[],{"trials":3044,"activeCount":102},[],{"trials":3046,"activeCount":102},[],{"trials":3048,"activeCount":102},[],{"trials":3050,"activeCount":102},[3051,3059],{"nctId":3052,"briefTitle":3053,"status":267,"phases":3054,"primaryCompletion":3055,"completion":3055,"start":2140,"enrollment":102,"conditions":3056,"interventions":3058},"NCT02893176","Macitentan in the Treatment of Organ Rejection After Lung Transplantation",[93],"2019-09-19",[3057],"Lung Transplant Rejection",[3039],{"nctId":3060,"briefTitle":3061,"status":140,"phases":3062,"primaryCompletion":3063,"completion":3063,"start":3064,"enrollment":3065,"conditions":3066,"interventions":3068},"NCT05373108","Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)",[93],"2023-02-14","2022-05-19",19,[3067],"Cardiac Allograft Vasculopathy",[3069],"Macitentan",{"trials":3071,"activeCount":102},[],{"intervention":3073,"totalTrials":253,"cells":3074},"glaucoma medications",{"EARLY_PHASE1":3075,"PHASE1":3077,"PHASE2":3079,"PHASE3":3081,"PHASE4":3083,"NA":3093},{"trials":3076,"activeCount":102},[],{"trials":3078,"activeCount":102},[],{"trials":3080,"activeCount":102},[],{"trials":3082,"activeCount":102},[],{"trials":3084,"activeCount":102},[3085],{"nctId":3086,"briefTitle":3087,"status":140,"phases":3088,"primaryCompletion":3089,"completion":3089,"start":3090,"enrollment":1954,"conditions":3091,"interventions":3092},"NCT00869141","Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma",[93],"2013-03","2009-03",[2240],[3073],{"trials":3094,"activeCount":102},[],{"intervention":3096,"totalTrials":253,"cells":3097},"Estrogen",{"EARLY_PHASE1":3098,"PHASE1":3100,"PHASE2":3102,"PHASE3":3104,"PHASE4":3106,"NA":3119},{"trials":3099,"activeCount":102},[],{"trials":3101,"activeCount":102},[],{"trials":3103,"activeCount":102},[],{"trials":3105,"activeCount":102},[],{"trials":3107,"activeCount":102},[3108],{"nctId":3109,"briefTitle":3110,"status":140,"phases":3111,"primaryCompletion":3112,"completion":3113,"start":3114,"enrollment":2386,"conditions":3115,"interventions":3118},"NCT00229450","Estrogen and Perimenopausal Depression",[93],"2003-08","2004-08","2002-04",[3116,3117],"Depressive Disorder, Major","Menopause",[3096],{"trials":3120,"activeCount":102},[],{"intervention":3122,"totalTrials":253,"cells":3123},"Daily Oral PrEP",{"EARLY_PHASE1":3124,"PHASE1":3126,"PHASE2":3128,"PHASE3":3130,"PHASE4":3132,"NA":3143},{"trials":3125,"activeCount":102},[],{"trials":3127,"activeCount":102},[],{"trials":3129,"activeCount":102},[],{"trials":3131,"activeCount":102},[],{"trials":3133,"activeCount":102},[3134],{"nctId":3135,"briefTitle":3136,"status":140,"phases":3137,"primaryCompletion":3138,"completion":3139,"start":2434,"enrollment":3140,"conditions":3141,"interventions":3142},"NCT02584140","Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women",[93],"2019-05-15","2019-06-14",136,[2286],[3122],{"trials":3144,"activeCount":102},[],{"intervention":2608,"totalTrials":253,"cells":3146},{"EARLY_PHASE1":3147,"PHASE1":3149,"PHASE2":3151,"PHASE3":3153,"PHASE4":3155,"NA":3161},{"trials":3148,"activeCount":102},[],{"trials":3150,"activeCount":102},[],{"trials":3152,"activeCount":102},[],{"trials":3154,"activeCount":102},[],{"trials":3156,"activeCount":102},[3157],{"nctId":2599,"briefTitle":2600,"status":140,"phases":3158,"primaryCompletion":2602,"completion":2603,"start":2604,"enrollment":2605,"conditions":3159,"interventions":3160},[93],[30],[2608,2576],{"trials":3162,"activeCount":102},[],{"intervention":3164,"totalTrials":253,"cells":3165},"TDF-FTC",{"EARLY_PHASE1":3166,"PHASE1":3168,"PHASE2":3170,"PHASE3":3172,"PHASE4":3174,"NA":3186},{"trials":3167,"activeCount":102},[],{"trials":3169,"activeCount":102},[],{"trials":3171,"activeCount":102},[],{"trials":3173,"activeCount":102},[],{"trials":3175,"activeCount":102},[3176],{"nctId":3177,"briefTitle":3178,"status":140,"phases":3179,"primaryCompletion":2613,"completion":3180,"start":3181,"enrollment":3182,"conditions":3183,"interventions":3185},"NCT03826199","Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town (Formative Study)",[93],"2023-09-30","2019-08-23",200,[3184],"Hiv",[3164],{"trials":3187,"activeCount":102},[],{"intervention":3189,"totalTrials":253,"cells":3190},"Levothyroxine",{"EARLY_PHASE1":3191,"PHASE1":3193,"PHASE2":3195,"PHASE3":3197,"PHASE4":3199,"NA":3211},{"trials":3192,"activeCount":102},[],{"trials":3194,"activeCount":102},[],{"trials":3196,"activeCount":102},[],{"trials":3198,"activeCount":102},[],{"trials":3200,"activeCount":102},[3201],{"nctId":3202,"briefTitle":3203,"status":108,"phases":3204,"primaryCompletion":3205,"completion":3205,"start":3206,"enrollment":208,"conditions":3207,"interventions":3209},"NCT04878614","Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding",[93],"2022-02-16","2021-05-05",[3208],"Hypothyroidism",[3189,3210],"Levothyroxine Sodium",{"trials":3212,"activeCount":102},[],{"intervention":3210,"totalTrials":253,"cells":3214},{"EARLY_PHASE1":3215,"PHASE1":3217,"PHASE2":3219,"PHASE3":3221,"PHASE4":3223,"NA":3229},{"trials":3216,"activeCount":102},[],{"trials":3218,"activeCount":102},[],{"trials":3220,"activeCount":102},[],{"trials":3222,"activeCount":102},[],{"trials":3224,"activeCount":102},[3225],{"nctId":3202,"briefTitle":3203,"status":108,"phases":3226,"primaryCompletion":3205,"completion":3205,"start":3206,"enrollment":208,"conditions":3227,"interventions":3228},[93],[3208],[3189,3210],{"trials":3230,"activeCount":102},[],{"intervention":3232,"totalTrials":253,"cells":3233},"Tocilizumab",{"EARLY_PHASE1":3234,"PHASE1":3236,"PHASE2":3238,"PHASE3":3240,"PHASE4":3242,"NA":3253},{"trials":3235,"activeCount":102},[],{"trials":3237,"activeCount":102},[],{"trials":3239,"activeCount":102},[],{"trials":3241,"activeCount":102},[],{"trials":3243,"activeCount":102},[3244],{"nctId":3245,"briefTitle":3246,"status":140,"phases":3247,"primaryCompletion":3248,"completion":3248,"start":3249,"enrollment":3250,"conditions":3251,"interventions":3252},"NCT01717859","Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab",[93],"2017-04","2014-09",74,[3005],[3232],{"trials":3254,"activeCount":102},[],{"intervention":2653,"totalTrials":253,"cells":3256},{"EARLY_PHASE1":3257,"PHASE1":3259,"PHASE2":3261,"PHASE3":3263,"PHASE4":3265,"NA":3271},{"trials":3258,"activeCount":102},[],{"trials":3260,"activeCount":102},[],{"trials":3262,"activeCount":102},[],{"trials":3264,"activeCount":102},[],{"trials":3266,"activeCount":102},[3267],{"nctId":2645,"briefTitle":2646,"status":140,"phases":3268,"primaryCompletion":2648,"completion":2648,"start":2649,"enrollment":2650,"conditions":3269,"interventions":3270},[93],[15],[2632,2653],{"trials":3272,"activeCount":102},[],{"intervention":3274,"totalTrials":253,"cells":3275},"Belatacept",{"EARLY_PHASE1":3276,"PHASE1":3278,"PHASE2":3280,"PHASE3":3282,"PHASE4":3284,"NA":3294},{"trials":3277,"activeCount":102},[],{"trials":3279,"activeCount":102},[],{"trials":3281,"activeCount":102},[],{"trials":3283,"activeCount":102},[],{"trials":3285,"activeCount":102},[3286],{"nctId":3287,"briefTitle":3288,"status":140,"phases":3289,"primaryCompletion":3290,"completion":3291,"start":2666,"enrollment":34,"conditions":3292,"interventions":3293},"NCT01953120","Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)",[93],"2021-04","2021-04-21",[228],[3274],{"trials":3295,"activeCount":102},[],{"intervention":3297,"totalTrials":253,"cells":3298},"Oxytocin nasal spray",{"EARLY_PHASE1":3299,"PHASE1":3301,"PHASE2":3303,"PHASE3":3305,"PHASE4":3307,"NA":3317},{"trials":3300,"activeCount":102},[],{"trials":3302,"activeCount":102},[],{"trials":3304,"activeCount":102},[],{"trials":3306,"activeCount":102},[],{"trials":3308,"activeCount":102},[3309],{"nctId":3310,"briefTitle":3311,"status":140,"phases":3312,"primaryCompletion":3313,"completion":3313,"start":3314,"enrollment":196,"conditions":3315,"interventions":3316},"NCT03245437","Target Engagement and Response to Oxytocin",[93],"2024-07-31","2018-01-04",[30],[3297],{"trials":3318,"activeCount":102},[],{"intervention":3320,"totalTrials":253,"cells":3321},"Milnacipran",{"EARLY_PHASE1":3322,"PHASE1":3324,"PHASE2":3326,"PHASE3":3328,"PHASE4":3330,"NA":3342},{"trials":3323,"activeCount":102},[],{"trials":3325,"activeCount":102},[],{"trials":3327,"activeCount":102},[],{"trials":3329,"activeCount":102},[],{"trials":3331,"activeCount":102},[3332],{"nctId":3333,"briefTitle":3334,"status":140,"phases":3335,"primaryCompletion":3336,"completion":3337,"start":3338,"enrollment":3339,"conditions":3340,"interventions":3341},"NCT01225991","Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis",[93],"2013-05","2013-06","2010-11",18,[3005],[3320],{"trials":3343,"activeCount":102},[],{"intervention":3345,"totalTrials":253,"cells":3346},"Group 1 or Orencia treated group",{"EARLY_PHASE1":3347,"PHASE1":3349,"PHASE2":3351,"PHASE3":3353,"PHASE4":3355,"NA":3367},{"trials":3348,"activeCount":102},[],{"trials":3350,"activeCount":102},[],{"trials":3352,"activeCount":102},[],{"trials":3354,"activeCount":102},[],{"trials":3356,"activeCount":102},[3357],{"nctId":3358,"briefTitle":3359,"status":267,"phases":3360,"primaryCompletion":3361,"completion":3362,"start":2722,"enrollment":102,"conditions":3363,"interventions":3366},"NCT01717846","Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis",[93],"2013-11","2014-11",[3364,3005,3365],"Apoptotic DNA Damage","T-cell Lymphocytosis",[3345],{"trials":3368,"activeCount":102},[],{"intervention":230,"totalTrials":253,"cells":3370},{"EARLY_PHASE1":3371,"PHASE1":3373,"PHASE2":3375,"PHASE3":3377,"PHASE4":3379,"NA":3385},{"trials":3372,"activeCount":102},[],{"trials":3374,"activeCount":102},[],{"trials":3376,"activeCount":102},[],{"trials":3378,"activeCount":102},[],{"trials":3380,"activeCount":102},[3381],{"nctId":221,"briefTitle":222,"status":140,"phases":3382,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":3383,"interventions":3384},[93],[228],[230,207],{"trials":3386,"activeCount":102},[],{"intervention":3388,"totalTrials":253,"cells":3389},"Aripiprazole Lauroxil",{"EARLY_PHASE1":3390,"PHASE1":3392,"PHASE2":3394,"PHASE3":3396,"PHASE4":3398,"NA":3412},{"trials":3391,"activeCount":102},[],{"trials":3393,"activeCount":102},[],{"trials":3395,"activeCount":102},[],{"trials":3397,"activeCount":102},[],{"trials":3399,"activeCount":102},[3400],{"nctId":3401,"briefTitle":3402,"status":108,"phases":3403,"primaryCompletion":3404,"completion":3404,"start":3405,"enrollment":37,"conditions":3406,"interventions":3409},"NCT04203056","Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode",[93],"2022-10-01","2019-12-16",[30,3407,3408],"Schizoaffective Disorder, Depressive Type","Schizophreniform Disorder",[3388,3410,3411],"ARI-ORAL","AL-NCD",{"trials":3413,"activeCount":102},[],{"intervention":3410,"totalTrials":253,"cells":3415},{"EARLY_PHASE1":3416,"PHASE1":3418,"PHASE2":3420,"PHASE3":3422,"PHASE4":3424,"NA":3430},{"trials":3417,"activeCount":102},[],{"trials":3419,"activeCount":102},[],{"trials":3421,"activeCount":102},[],{"trials":3423,"activeCount":102},[],{"trials":3425,"activeCount":102},[3426],{"nctId":3401,"briefTitle":3402,"status":108,"phases":3427,"primaryCompletion":3404,"completion":3404,"start":3405,"enrollment":37,"conditions":3428,"interventions":3429},[93],[30,3407,3408],[3388,3410,3411],{"trials":3431,"activeCount":102},[],{"intervention":3411,"totalTrials":253,"cells":3433},{"EARLY_PHASE1":3434,"PHASE1":3436,"PHASE2":3438,"PHASE3":3440,"PHASE4":3442,"NA":3448},{"trials":3435,"activeCount":102},[],{"trials":3437,"activeCount":102},[],{"trials":3439,"activeCount":102},[],{"trials":3441,"activeCount":102},[],{"trials":3443,"activeCount":102},[3444],{"nctId":3401,"briefTitle":3402,"status":108,"phases":3445,"primaryCompletion":3404,"completion":3404,"start":3405,"enrollment":37,"conditions":3446,"interventions":3447},[93],[30,3407,3408],[3388,3410,3411],{"trials":3449,"activeCount":102},[],{"intervention":3451,"totalTrials":253,"cells":3452},"Aflibercept Ophthalmic",{"EARLY_PHASE1":3453,"PHASE1":3455,"PHASE2":3457,"PHASE3":3459,"PHASE4":3461,"NA":3473},{"trials":3454,"activeCount":102},[],{"trials":3456,"activeCount":102},[],{"trials":3458,"activeCount":102},[],{"trials":3460,"activeCount":102},[],{"trials":3462,"activeCount":102},[3463],{"nctId":3464,"briefTitle":3465,"status":140,"phases":3466,"primaryCompletion":3467,"completion":3468,"start":3469,"enrollment":22,"conditions":3470,"interventions":3472},"NCT03022292","The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy",[93],"2020-06-25","2020-08-31","2017-03-30",[3471],"Wet Macular Degeneration",[3451],{"trials":3474,"activeCount":102},[],{"intervention":675,"totalTrials":253,"cells":3476},{"EARLY_PHASE1":3477,"PHASE1":3479,"PHASE2":3481,"PHASE3":3483,"PHASE4":3485,"NA":3491},{"trials":3478,"activeCount":102},[],{"trials":3480,"activeCount":102},[],{"trials":3482,"activeCount":102},[],{"trials":3484,"activeCount":102},[],{"trials":3486,"activeCount":102},[3487],{"nctId":667,"briefTitle":668,"status":108,"phases":3488,"primaryCompletion":670,"completion":670,"start":671,"enrollment":161,"conditions":3489,"interventions":3490},[93],[673],[675,629],{"trials":3492,"activeCount":102},[],{"intervention":3494,"totalTrials":253,"cells":3495},"Vitamin D2",{"EARLY_PHASE1":3496,"PHASE1":3498,"PHASE2":3500,"PHASE3":3502,"PHASE4":3504,"NA":3513},{"trials":3497,"activeCount":102},[],{"trials":3499,"activeCount":102},[],{"trials":3501,"activeCount":102},[],{"trials":3503,"activeCount":102},[],{"trials":3505,"activeCount":102},[3506],{"nctId":3507,"briefTitle":3508,"status":553,"phases":3509,"primaryCompletion":2930,"completion":2930,"start":3090,"enrollment":1032,"conditions":3510,"interventions":3512},"NCT01799317","How Bone is Made in Children Receiving Dialysis",[93],[3511],"Bone Mineralization Defect",[3494],{"trials":3514,"activeCount":102},[],{"intervention":3516,"totalTrials":253,"cells":3517},"Local anaesthetic",{"EARLY_PHASE1":3518,"PHASE1":3520,"PHASE2":3522,"PHASE3":3524,"PHASE4":3526,"NA":3538},{"trials":3519,"activeCount":102},[],{"trials":3521,"activeCount":102},[],{"trials":3523,"activeCount":102},[],{"trials":3525,"activeCount":102},[],{"trials":3527,"activeCount":102},[3528],{"nctId":3529,"briefTitle":3530,"status":140,"phases":3531,"primaryCompletion":3532,"completion":3532,"start":3533,"enrollment":2512,"conditions":3534,"interventions":3536},"NCT04171050","Pudendal Enhancement of Enhanced Recovery After Surgery (ERAS) for Reconstructive Surgery (PEERS)",[93],"2023-08-28","2019-11-14",[3535],"Pain Management",[3516,3537],"Pudendal Nerve Block plus anesthesia",{"trials":3539,"activeCount":102},[],{"intervention":3537,"totalTrials":253,"cells":3541},{"EARLY_PHASE1":3542,"PHASE1":3544,"PHASE2":3546,"PHASE3":3548,"PHASE4":3550,"NA":3556},{"trials":3543,"activeCount":102},[],{"trials":3545,"activeCount":102},[],{"trials":3547,"activeCount":102},[],{"trials":3549,"activeCount":102},[],{"trials":3551,"activeCount":102},[3552],{"nctId":3529,"briefTitle":3530,"status":140,"phases":3553,"primaryCompletion":3532,"completion":3532,"start":3533,"enrollment":2512,"conditions":3554,"interventions":3555},[93],[3535],[3516,3537],{"trials":3557,"activeCount":102},[],{"intervention":3559,"totalTrials":253,"cells":3560},"emtricitabine 200mg\u002Ftenofovir 300mg",{"EARLY_PHASE1":3561,"PHASE1":3563,"PHASE2":3565,"PHASE3":3567,"PHASE4":3569,"NA":3578},{"trials":3562,"activeCount":102},[],{"trials":3564,"activeCount":102},[],{"trials":3566,"activeCount":102},[],{"trials":3568,"activeCount":102},[],{"trials":3570,"activeCount":102},[3571],{"nctId":3572,"briefTitle":3573,"status":140,"phases":3574,"primaryCompletion":2434,"completion":2434,"start":3336,"enrollment":3575,"conditions":3576,"interventions":3577},"NCT01781806","A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services",[93],328,[2286],[3559],{"trials":3579,"activeCount":102},[],{"intervention":3581,"totalTrials":253,"cells":3582},"Buccal Misoprostol",{"EARLY_PHASE1":3583,"PHASE1":3585,"PHASE2":3587,"PHASE3":3589,"PHASE4":3591,"NA":3602},{"trials":3584,"activeCount":102},[],{"trials":3586,"activeCount":102},[],{"trials":3588,"activeCount":102},[],{"trials":3590,"activeCount":102},[],{"trials":3592,"activeCount":102},[3593],{"nctId":3594,"briefTitle":3595,"status":108,"phases":3596,"primaryCompletion":617,"completion":617,"start":2847,"enrollment":3597,"conditions":3598,"interventions":3600},"NCT01519765","Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor",[93],73,[3599],"Pregnancy",[3581,3601],"Vaginal misoprostol",{"trials":3603,"activeCount":102},[],{"intervention":3601,"totalTrials":253,"cells":3605},{"EARLY_PHASE1":3606,"PHASE1":3608,"PHASE2":3610,"PHASE3":3612,"PHASE4":3614,"NA":3620},{"trials":3607,"activeCount":102},[],{"trials":3609,"activeCount":102},[],{"trials":3611,"activeCount":102},[],{"trials":3613,"activeCount":102},[],{"trials":3615,"activeCount":102},[3616],{"nctId":3594,"briefTitle":3595,"status":108,"phases":3617,"primaryCompletion":617,"completion":617,"start":2847,"enrollment":3597,"conditions":3618,"interventions":3619},[93],[3599],[3581,3601],{"trials":3621,"activeCount":102},[],{"intervention":3623,"totalTrials":253,"cells":3624},"Medical weight loss",{"EARLY_PHASE1":3625,"PHASE1":3627,"PHASE2":3629,"PHASE3":3631,"PHASE4":3633,"NA":3645},{"trials":3626,"activeCount":102},[],{"trials":3628,"activeCount":102},[],{"trials":3630,"activeCount":102},[],{"trials":3632,"activeCount":102},[],{"trials":3634,"activeCount":102},[3635],{"nctId":3636,"briefTitle":3637,"status":267,"phases":3638,"primaryCompletion":3639,"completion":3639,"start":3640,"enrollment":102,"conditions":3641,"interventions":3644},"NCT05812183","Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity",[93],"2025-02-12","2023-07-09",[3642,3643],"Dyspnea","Quality of Life",[3623],{"trials":3646,"activeCount":102},[],{"intervention":2905,"totalTrials":253,"cells":3648},{"EARLY_PHASE1":3649,"PHASE1":3651,"PHASE2":3653,"PHASE3":3655,"PHASE4":3657,"NA":3663},{"trials":3650,"activeCount":102},[],{"trials":3652,"activeCount":102},[],{"trials":3654,"activeCount":102},[],{"trials":3656,"activeCount":102},[],{"trials":3658,"activeCount":102},[3659],{"nctId":2896,"briefTitle":2897,"status":108,"phases":3660,"primaryCompletion":2899,"completion":671,"start":2648,"enrollment":2900,"conditions":3661,"interventions":3662},[93],[2902],[2883,2904,2905,2906],{"trials":3664,"activeCount":102},[],{"intervention":2906,"totalTrials":253,"cells":3666},{"EARLY_PHASE1":3667,"PHASE1":3669,"PHASE2":3671,"PHASE3":3673,"PHASE4":3675,"NA":3681},{"trials":3668,"activeCount":102},[],{"trials":3670,"activeCount":102},[],{"trials":3672,"activeCount":102},[],{"trials":3674,"activeCount":102},[],{"trials":3676,"activeCount":102},[3677],{"nctId":2896,"briefTitle":2897,"status":108,"phases":3678,"primaryCompletion":2899,"completion":671,"start":2648,"enrollment":2900,"conditions":3679,"interventions":3680},[93],[2902],[2883,2904,2905,2906],{"trials":3682,"activeCount":102},[],{"intervention":3684,"totalTrials":253,"cells":3685},"Abdominal wall block with liposomal bupivicaine",{"EARLY_PHASE1":3686,"PHASE1":3688,"PHASE2":3690,"PHASE3":3692,"PHASE4":3694,"NA":3711},{"trials":3687,"activeCount":102},[],{"trials":3689,"activeCount":102},[],{"trials":3691,"activeCount":102},[],{"trials":3693,"activeCount":102},[],{"trials":3695,"activeCount":102},[3696],{"nctId":3697,"briefTitle":3698,"status":140,"phases":3699,"primaryCompletion":3700,"completion":3700,"start":3701,"enrollment":2615,"conditions":3702,"interventions":3710},"NCT03294109","Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy",[93],"2020-06-24","2018-01-01",[148,3703,3704,3705,3706,3707,3708,3709],"Analgesics, Opioid","Analgesics, Non-Narcotic","Physiological Effects of Drugs","Peripheral Nervous System Agents","Patient Satisfaction","Return to Work","Activity, Sexual",[3684],{"trials":3712,"activeCount":102},[],{"intervention":3714,"totalTrials":253,"cells":3715},"Intralipid",{"EARLY_PHASE1":3716,"PHASE1":3718,"PHASE2":3720,"PHASE3":3722,"PHASE4":3724,"NA":3734},{"trials":3717,"activeCount":102},[],{"trials":3719,"activeCount":102},[],{"trials":3721,"activeCount":102},[],{"trials":3723,"activeCount":102},[],{"trials":3725,"activeCount":102},[3726],{"nctId":3727,"briefTitle":3728,"status":108,"phases":3729,"primaryCompletion":2825,"completion":2825,"start":3730,"enrollment":2590,"conditions":3731,"interventions":3733},"NCT01373918","Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders",[93],"2010-12",[3732],"Cholestasis",[3714,3714],{"trials":3735,"activeCount":102},[],{"intervention":2842,"totalTrials":253,"cells":3737},{"EARLY_PHASE1":3738,"PHASE1":3740,"PHASE2":3742,"PHASE3":3744,"PHASE4":3746,"NA":3752},{"trials":3739,"activeCount":102},[],{"trials":3741,"activeCount":102},[],{"trials":3743,"activeCount":102},[],{"trials":3745,"activeCount":102},[],{"trials":3747,"activeCount":102},[3748],{"nctId":2835,"briefTitle":2836,"status":140,"phases":3749,"primaryCompletion":2548,"completion":2838,"start":2520,"enrollment":2839,"conditions":3750,"interventions":3751},[93],[15],[2842,2813],{"trials":3753,"activeCount":102},[],{"intervention":3755,"totalTrials":253,"cells":3756},"Risperidone, administered orally",{"EARLY_PHASE1":3757,"PHASE1":3759,"PHASE2":3761,"PHASE3":3763,"PHASE4":3765,"NA":3775},{"trials":3758,"activeCount":102},[],{"trials":3760,"activeCount":102},[],{"trials":3762,"activeCount":102},[],{"trials":3764,"activeCount":102},[],{"trials":3766,"activeCount":102},[3767],{"nctId":3768,"briefTitle":3769,"status":140,"phases":3770,"primaryCompletion":2548,"completion":2548,"start":2962,"enrollment":3771,"conditions":3772,"interventions":3773},"NCT00333177","Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia",[93],92,[30],[3755,3774],"Risperidone, administered via",{"trials":3776,"activeCount":102},[],{"intervention":3774,"totalTrials":253,"cells":3778},{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3783,"PHASE3":3785,"PHASE4":3787,"NA":3793},{"trials":3780,"activeCount":102},[],{"trials":3782,"activeCount":102},[],{"trials":3784,"activeCount":102},[],{"trials":3786,"activeCount":102},[],{"trials":3788,"activeCount":102},[3789],{"nctId":3768,"briefTitle":3769,"status":140,"phases":3790,"primaryCompletion":2548,"completion":2548,"start":2962,"enrollment":3771,"conditions":3791,"interventions":3792},[93],[30],[3755,3774],{"trials":3794,"activeCount":102},[],{"intervention":2619,"totalTrials":253,"cells":3796},{"EARLY_PHASE1":3797,"PHASE1":3799,"PHASE2":3801,"PHASE3":3803,"PHASE4":3805,"NA":3811},{"trials":3798,"activeCount":102},[],{"trials":3800,"activeCount":102},[],{"trials":3802,"activeCount":102},[],{"trials":3804,"activeCount":102},[],{"trials":3806,"activeCount":102},[3807],{"nctId":2610,"briefTitle":2611,"status":140,"phases":3808,"primaryCompletion":2613,"completion":2614,"start":2562,"enrollment":2615,"conditions":3809,"interventions":3810},[93],[2617],[2619,2620],{"trials":3812,"activeCount":102},[],{"intervention":3814,"totalTrials":253,"cells":3815},"N-acetylcysteine",{"EARLY_PHASE1":3816,"PHASE1":3818,"PHASE2":3820,"PHASE3":3822,"PHASE4":3824,"NA":3837},{"trials":3817,"activeCount":102},[],{"trials":3819,"activeCount":102},[],{"trials":3821,"activeCount":102},[],{"trials":3823,"activeCount":102},[],{"trials":3825,"activeCount":102},[3826],{"nctId":3827,"briefTitle":3828,"status":140,"phases":3829,"primaryCompletion":3830,"completion":3830,"start":3831,"enrollment":3832,"conditions":3833,"interventions":3836},"NCT02505477","Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine",[93],"2023-01-31","2017-02-06",51,[30,3834,3835],"Cognitive Deficits","Schizophrenia; Negative Type",[3814],{"trials":3838,"activeCount":102},[],{"intervention":3840,"totalTrials":253,"cells":3841},"sildenafil",{"EARLY_PHASE1":3842,"PHASE1":3844,"PHASE2":3846,"PHASE3":3848,"PHASE4":3850,"NA":3863},{"trials":3843,"activeCount":102},[],{"trials":3845,"activeCount":102},[],{"trials":3847,"activeCount":102},[],{"trials":3849,"activeCount":102},[],{"trials":3851,"activeCount":102},[3852],{"nctId":3853,"briefTitle":3854,"status":267,"phases":3855,"primaryCompletion":2479,"completion":3856,"start":3857,"enrollment":102,"conditions":3858,"interventions":3862},"NCT00625079","Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil",[93],"2009-12","2007-02",[3859,3860,2007,3861],"Pulmonary Arterial Hypertension","Idiopathic Pulmonary Fibrosis","Pulmonary Hypertension",[3840],{"trials":3864,"activeCount":102},[],{"intervention":3866,"totalTrials":253,"cells":3867},"levomilnacipran",{"EARLY_PHASE1":3868,"PHASE1":3870,"PHASE2":3872,"PHASE3":3874,"PHASE4":3876,"NA":3885},{"trials":3869,"activeCount":102},[],{"trials":3871,"activeCount":102},[],{"trials":3873,"activeCount":102},[],{"trials":3875,"activeCount":102},[],{"trials":3877,"activeCount":102},[3878],{"nctId":3879,"briefTitle":3880,"status":140,"phases":3881,"primaryCompletion":3882,"completion":3882,"start":2547,"enrollment":2762,"conditions":3883,"interventions":3884},"NCT02466958","Trial of Levomilnacipran in Geriatric Depression",[93],"2018-12-09",[27],[3866],{"trials":3886,"activeCount":102},[],{"intervention":3888,"totalTrials":253,"cells":3889},"Botulinum toxin serotype A",{"EARLY_PHASE1":3890,"PHASE1":3892,"PHASE2":3894,"PHASE3":3896,"PHASE4":3898,"NA":3910},{"trials":3891,"activeCount":102},[],{"trials":3893,"activeCount":102},[],{"trials":3895,"activeCount":102},[],{"trials":3897,"activeCount":102},[],{"trials":3899,"activeCount":102},[3900],{"nctId":3901,"briefTitle":3902,"status":140,"phases":3903,"primaryCompletion":2509,"start":3904,"enrollment":3905,"conditions":3906,"interventions":3909},"NCT00241215","Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome",[93],"2003-06",132,[3907,3908],"Cervicobrachial Neuralgia","Myofascial Pain Syndromes",[3888],{"trials":3911,"activeCount":102},[],{"intervention":2852,"totalTrials":253,"cells":3913},{"EARLY_PHASE1":3914,"PHASE1":3916,"PHASE2":3918,"PHASE3":3920,"PHASE4":3922,"NA":3928},{"trials":3915,"activeCount":102},[],{"trials":3917,"activeCount":102},[],{"trials":3919,"activeCount":102},[],{"trials":3921,"activeCount":102},[],{"trials":3923,"activeCount":102},[3924],{"nctId":2844,"briefTitle":2845,"status":140,"phases":3925,"primaryCompletion":2847,"completion":2847,"start":798,"enrollment":2848,"conditions":3926,"interventions":3927},[93],[2850],[2852,2813],{"trials":3929,"activeCount":102},[],{"intervention":3931,"totalTrials":253,"cells":3932},"Doxycycline",{"EARLY_PHASE1":3933,"PHASE1":3935,"PHASE2":3937,"PHASE3":3939,"PHASE4":3941,"NA":3952},{"trials":3934,"activeCount":102},[],{"trials":3936,"activeCount":102},[],{"trials":3938,"activeCount":102},[],{"trials":3940,"activeCount":102},[],{"trials":3942,"activeCount":102},[3943],{"nctId":3944,"briefTitle":3945,"status":140,"phases":3946,"primaryCompletion":3947,"completion":3947,"start":3948,"enrollment":22,"conditions":3949,"interventions":3951},"NCT04167085","NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL Trial",[93],"2021-06-01","2017-12-18",[3950],"Epistaxis",[3931],{"trials":3953,"activeCount":102},[],{"intervention":3955,"totalTrials":253,"cells":3956},"Clonidine Patch",{"EARLY_PHASE1":3957,"PHASE1":3959,"PHASE2":3961,"PHASE3":3963,"PHASE4":3965,"NA":3974},{"trials":3958,"activeCount":102},[],{"trials":3960,"activeCount":102},[],{"trials":3962,"activeCount":102},[],{"trials":3964,"activeCount":102},[],{"trials":3966,"activeCount":102},[3967],{"nctId":3968,"briefTitle":3969,"status":140,"phases":3970,"primaryCompletion":789,"completion":2722,"start":2677,"enrollment":2868,"conditions":3971,"interventions":3973},"NCT00858845","Using Clonidine to Improve Leg Weakness in People With Heart Failure",[93],[3972],"Heart Failure",[3955],{"trials":3975,"activeCount":102},[],{"intervention":3977,"totalTrials":253,"cells":3978},"IV Ibuprofen",{"EARLY_PHASE1":3979,"PHASE1":3981,"PHASE2":3983,"PHASE3":3985,"PHASE4":3987,"NA":3998},{"trials":3980,"activeCount":102},[],{"trials":3982,"activeCount":102},[],{"trials":3984,"activeCount":102},[],{"trials":3986,"activeCount":102},[],{"trials":3988,"activeCount":102},[3989],{"nctId":3990,"briefTitle":3991,"status":140,"phases":3992,"primaryCompletion":2140,"completion":2140,"start":2415,"enrollment":659,"conditions":3993,"interventions":3995},"NCT02227316","Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure",[93],[3994],"Symptomatic Uterine Fibroids and Adenomyosis",[3977,3996,3997],"IV Acetaminophen","Intravenous placebo\u002FIntravenous placebo",{"trials":3999,"activeCount":102},[],{"intervention":3996,"totalTrials":253,"cells":4001},{"EARLY_PHASE1":4002,"PHASE1":4004,"PHASE2":4006,"PHASE3":4008,"PHASE4":4010,"NA":4016},{"trials":4003,"activeCount":102},[],{"trials":4005,"activeCount":102},[],{"trials":4007,"activeCount":102},[],{"trials":4009,"activeCount":102},[],{"trials":4011,"activeCount":102},[4012],{"nctId":3990,"briefTitle":3991,"status":140,"phases":4013,"primaryCompletion":2140,"completion":2140,"start":2415,"enrollment":659,"conditions":4014,"interventions":4015},[93],[3994],[3977,3996,3997],{"trials":4017,"activeCount":102},[],{"intervention":3997,"totalTrials":253,"cells":4019},{"EARLY_PHASE1":4020,"PHASE1":4022,"PHASE2":4024,"PHASE3":4026,"PHASE4":4028,"NA":4034},{"trials":4021,"activeCount":102},[],{"trials":4023,"activeCount":102},[],{"trials":4025,"activeCount":102},[],{"trials":4027,"activeCount":102},[],{"trials":4029,"activeCount":102},[4030],{"nctId":3990,"briefTitle":3991,"status":140,"phases":4031,"primaryCompletion":2140,"completion":2140,"start":2415,"enrollment":659,"conditions":4032,"interventions":4033},[93],[3994],[3977,3996,3997],{"trials":4035,"activeCount":102},[],{"intervention":2966,"totalTrials":253,"cells":4037},{"EARLY_PHASE1":4038,"PHASE1":4040,"PHASE2":4042,"PHASE3":4044,"PHASE4":4046,"NA":4052},{"trials":4039,"activeCount":102},[],{"trials":4041,"activeCount":102},[],{"trials":4043,"activeCount":102},[],{"trials":4045,"activeCount":102},[],{"trials":4047,"activeCount":102},[4048],{"nctId":2959,"briefTitle":2960,"status":140,"phases":4049,"primaryCompletion":539,"completion":539,"start":2962,"enrollment":2963,"conditions":4050,"interventions":4051},[93],[30],[2946,2966],{"trials":4053,"activeCount":102},[],{"intervention":251,"totalTrials":253,"cells":4055},{"EARLY_PHASE1":4056,"PHASE1":4058,"PHASE2":4060,"PHASE3":4062,"PHASE4":4064,"NA":4070},{"trials":4057,"activeCount":102},[],{"trials":4059,"activeCount":102},[],{"trials":4061,"activeCount":102},[],{"trials":4063,"activeCount":102},[],{"trials":4065,"activeCount":102},[4066],{"nctId":242,"briefTitle":243,"status":140,"phases":4067,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":4068,"interventions":4069},[93],[249],[251,207,207,252],{"trials":4071,"activeCount":102},[],{"intervention":252,"totalTrials":253,"cells":4073},{"EARLY_PHASE1":4074,"PHASE1":4076,"PHASE2":4078,"PHASE3":4080,"PHASE4":4082,"NA":4088},{"trials":4075,"activeCount":102},[],{"trials":4077,"activeCount":102},[],{"trials":4079,"activeCount":102},[],{"trials":4081,"activeCount":102},[],{"trials":4083,"activeCount":102},[4084],{"nctId":242,"briefTitle":243,"status":140,"phases":4085,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":4086,"interventions":4087},[93],[249],[251,207,207,252],{"trials":4089,"activeCount":102},[],{"intervention":4091,"totalTrials":253,"cells":4092},"LAAM",{"EARLY_PHASE1":4093,"PHASE1":4095,"PHASE2":4097,"PHASE3":4099,"PHASE4":4101,"NA":4111},{"trials":4094,"activeCount":102},[],{"trials":4096,"activeCount":102},[],{"trials":4098,"activeCount":102},[],{"trials":4100,"activeCount":102},[],{"trials":4102,"activeCount":102},[4103],{"nctId":4104,"briefTitle":4105,"status":140,"phases":4106,"start":4107,"enrollment":102,"conditions":4108,"interventions":4110},"NCT00000300","Feasibility Study of Take-Home LAAM Medication - 3",[93],"1995-03",[4109],"Opioid-Related Disorders",[4091],{"trials":4112,"activeCount":102},[],{"intervention":4114,"totalTrials":253,"cells":4115},"sertraline",{"EARLY_PHASE1":4116,"PHASE1":4118,"PHASE2":4120,"PHASE3":4122,"PHASE4":4124,"NA":4133},{"trials":4117,"activeCount":102},[],{"trials":4119,"activeCount":102},[],{"trials":4121,"activeCount":102},[],{"trials":4123,"activeCount":102},[],{"trials":4125,"activeCount":102},[4126],{"nctId":4127,"briefTitle":4128,"status":140,"phases":4129,"primaryCompletion":2962,"start":4130,"enrollment":1032,"conditions":4131,"interventions":4132},"NCT00229476","Study of Medication and Placebo Response in Major Depression",[93],"2003-12",[3116],[4114],{"trials":4134,"activeCount":102},[],{"intervention":4136,"totalTrials":253,"cells":4137},"formoterol fumarate",{"EARLY_PHASE1":4138,"PHASE1":4140,"PHASE2":4142,"PHASE3":4144,"PHASE4":4146,"NA":4159},{"trials":4139,"activeCount":102},[],{"trials":4141,"activeCount":102},[],{"trials":4143,"activeCount":102},[],{"trials":4145,"activeCount":102},[],{"trials":4147,"activeCount":102},[4148],{"nctId":4149,"briefTitle":4150,"status":267,"phases":4151,"primaryCompletion":2743,"completion":2743,"start":4152,"enrollment":102,"conditions":4153,"interventions":4158},"NCT00633776","Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)",[93],"2008-03",[4154,4155,4156,4157],"Chronic Obstructive Pulmonary Disease","COPD","Chronic Bronchitis","Emphysema",[4136],{"trials":4160,"activeCount":102},[],{"intervention":4162,"totalTrials":253,"cells":4163},"Standard Dose of Unfractionated Heparin",{"EARLY_PHASE1":4164,"PHASE1":4166,"PHASE2":4168,"PHASE3":4170,"PHASE4":4172,"NA":4187},{"trials":4165,"activeCount":102},[],{"trials":4167,"activeCount":102},[],{"trials":4169,"activeCount":102},[],{"trials":4171,"activeCount":102},[],{"trials":4173,"activeCount":102},[4174],{"nctId":4175,"briefTitle":4176,"status":140,"phases":4177,"primaryCompletion":4178,"completion":4179,"start":4180,"enrollment":4181,"conditions":4182,"interventions":4185},"NCT04635839","Heparin Prophylaxis Dosing for Antepartum Hospitalizations (HEPDOSE)",[93],"2022-03-31","2022-05-01","2020-12-15",46,[4183,4184],"Pregnancy Related","Antepartum DVT",[4162,4186],"Gestational Age-Based Dose of Unfractionated Heparin",{"trials":4188,"activeCount":102},[],{"intervention":4186,"totalTrials":253,"cells":4190},{"EARLY_PHASE1":4191,"PHASE1":4193,"PHASE2":4195,"PHASE3":4197,"PHASE4":4199,"NA":4205},{"trials":4192,"activeCount":102},[],{"trials":4194,"activeCount":102},[],{"trials":4196,"activeCount":102},[],{"trials":4198,"activeCount":102},[],{"trials":4200,"activeCount":102},[4201],{"nctId":4175,"briefTitle":4176,"status":140,"phases":4202,"primaryCompletion":4178,"completion":4179,"start":4180,"enrollment":4181,"conditions":4203,"interventions":4204},[93],[4183,4184],[4162,4186],{"trials":4206,"activeCount":102},[],{"intervention":4208,"totalTrials":253,"cells":4209},"Elbasvir\u002Fgrazoprevir",{"EARLY_PHASE1":4210,"PHASE1":4212,"PHASE2":4214,"PHASE3":4216,"PHASE4":4218,"NA":4230},{"trials":4211,"activeCount":102},[],{"trials":4213,"activeCount":102},[],{"trials":4215,"activeCount":102},[],{"trials":4217,"activeCount":102},[],{"trials":4219,"activeCount":102},[4220],{"nctId":4221,"briefTitle":4222,"status":267,"phases":4223,"primaryCompletion":4224,"completion":4225,"start":4226,"enrollment":102,"conditions":4227,"interventions":4229},"NCT03585101","A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk",[93],"2019-06","2020-04","2018-08",[4228],"Hepatitis C",[4208],{"trials":4231,"activeCount":102},[],{"intervention":4233,"totalTrials":253,"cells":4234},"Ambrisentan",{"EARLY_PHASE1":4235,"PHASE1":4237,"PHASE2":4239,"PHASE3":4241,"PHASE4":4243,"NA":4254},{"trials":4236,"activeCount":102},[],{"trials":4238,"activeCount":102},[],{"trials":4240,"activeCount":102},[],{"trials":4242,"activeCount":102},[],{"trials":4244,"activeCount":102},[4245],{"nctId":4246,"briefTitle":4247,"status":140,"phases":4248,"primaryCompletion":4249,"completion":246,"start":3090,"enrollment":618,"conditions":4250,"interventions":4253},"NCT01051960","Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan",[93],"2010-06",[4251,4252,3861],"Systemic Sclerosis","Shortness of Breath",[4233],{"trials":4255,"activeCount":102},[],{"intervention":4257,"totalTrials":253,"cells":4258},"myfortic",{"EARLY_PHASE1":4259,"PHASE1":4261,"PHASE2":4263,"PHASE3":4265,"PHASE4":4267,"NA":4279},{"trials":4260,"activeCount":102},[],{"trials":4262,"activeCount":102},[],{"trials":4264,"activeCount":102},[],{"trials":4266,"activeCount":102},[],{"trials":4268,"activeCount":102},[4269],{"nctId":4270,"briefTitle":4271,"status":140,"phases":4272,"primaryCompletion":789,"completion":4273,"start":4274,"enrollment":28,"conditions":4275,"interventions":4278},"NCT00652834","Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®",[93],"2011-05","2009-04",[4276,4277],"Gastrointestinal Lesions","Signs and Symptoms, Digestive",[4257],{"trials":4280,"activeCount":102},[],{"intervention":4282,"totalTrials":253,"cells":4283},"Mitomycin C",{"EARLY_PHASE1":4284,"PHASE1":4286,"PHASE2":4288,"PHASE3":4290,"PHASE4":4292,"NA":4305},{"trials":4285,"activeCount":102},[],{"trials":4287,"activeCount":102},[],{"trials":4289,"activeCount":102},[],{"trials":4291,"activeCount":102},[],{"trials":4293,"activeCount":102},[4294],{"nctId":4295,"briefTitle":4296,"status":108,"phases":4297,"primaryCompletion":4298,"completion":4298,"start":4299,"enrollment":3065,"conditions":4300,"interventions":4304},"NCT03875911","Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy",[93],"2022-12-31","2019-03-30",[4301,2240,4302,4303],"Glaucoma Open-Angle Primary","Open Angle Glaucoma","Glaucoma, Open-Angle",[4282],{"trials":4306,"activeCount":102},[],{"intervention":2916,"totalTrials":253,"cells":4308},{"EARLY_PHASE1":4309,"PHASE1":4311,"PHASE2":4313,"PHASE3":4315,"PHASE4":4317,"NA":4323},{"trials":4310,"activeCount":102},[],{"trials":4312,"activeCount":102},[],{"trials":4314,"activeCount":102},[],{"trials":4316,"activeCount":102},[],{"trials":4318,"activeCount":102},[4319],{"nctId":2908,"briefTitle":2909,"status":267,"phases":4320,"primaryCompletion":2911,"completion":2911,"start":2911,"enrollment":102,"conditions":4321,"interventions":4322},[93],[2913,2914],[2916,593,2883],{"trials":4324,"activeCount":102},[],{"intervention":4326,"totalTrials":253,"cells":4327},"Sugammadex 100 MG\u002FML [Bridion]",{"EARLY_PHASE1":4328,"PHASE1":4330,"PHASE2":4332,"PHASE3":4334,"PHASE4":4336,"NA":4349},{"trials":4329,"activeCount":102},[],{"trials":4331,"activeCount":102},[],{"trials":4333,"activeCount":102},[],{"trials":4335,"activeCount":102},[],{"trials":4337,"activeCount":102},[4338],{"nctId":4339,"briefTitle":4340,"status":140,"phases":4341,"primaryCompletion":4342,"completion":4343,"start":4344,"enrollment":4345,"conditions":4346,"interventions":4348},"NCT04263363","Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications",[93],"2024-05-07","2025-05-07","2022-02-18",12248,[4347,911],"Respiratory Complication",[4326],{"trials":4350,"activeCount":102},[],{"intervention":4352,"totalTrials":253,"cells":4353},"lidocaine",{"EARLY_PHASE1":4354,"PHASE1":4356,"PHASE2":4358,"PHASE3":4360,"PHASE4":4362,"NA":4372},{"trials":4355,"activeCount":102},[],{"trials":4357,"activeCount":102},[],{"trials":4359,"activeCount":102},[],{"trials":4361,"activeCount":102},[],{"trials":4363,"activeCount":102},[4364],{"nctId":4365,"briefTitle":4366,"status":108,"phases":4367,"primaryCompletion":2826,"completion":2826,"start":2658,"enrollment":2386,"conditions":4368,"interventions":4370},"NCT00992108","Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques",[93],[4369],"Face Pain",[4352,4371],"chemodenervation",{"trials":4373,"activeCount":102},[],{"intervention":4371,"totalTrials":253,"cells":4375},{"EARLY_PHASE1":4376,"PHASE1":4378,"PHASE2":4380,"PHASE3":4382,"PHASE4":4384,"NA":4390},{"trials":4377,"activeCount":102},[],{"trials":4379,"activeCount":102},[],{"trials":4381,"activeCount":102},[],{"trials":4383,"activeCount":102},[],{"trials":4385,"activeCount":102},[4386],{"nctId":4365,"briefTitle":4366,"status":108,"phases":4387,"primaryCompletion":2826,"completion":2826,"start":2658,"enrollment":2386,"conditions":4388,"interventions":4389},[93],[4369],[4352,4371],{"trials":4391,"activeCount":102},[],{"intervention":4393,"totalTrials":253,"cells":4394},"Cefazolin",{"EARLY_PHASE1":4395,"PHASE1":4397,"PHASE2":4399,"PHASE3":4401,"PHASE4":4403,"NA":4418},{"trials":4396,"activeCount":102},[],{"trials":4398,"activeCount":102},[],{"trials":4400,"activeCount":102},[],{"trials":4402,"activeCount":102},[],{"trials":4404,"activeCount":102},[4405],{"nctId":4406,"briefTitle":4407,"status":267,"phases":4408,"primaryCompletion":4409,"completion":4410,"start":2237,"enrollment":102,"conditions":4411,"interventions":4416},"NCT04834310","Postoperative Antibiotics Following Primary and Secondary Breast Augmentation",[93],"2024-05-30","2024-07-30",[4412,4413,4414,4415],"Surgical Site Infection","Capsular Contracture Associated With Breast Implant","Antibiotic Resistant Infection","Antibiotic Side Effect",[4393,4417],"Cephalexin",{"trials":4419,"activeCount":102},[],{"intervention":4417,"totalTrials":253,"cells":4421},{"EARLY_PHASE1":4422,"PHASE1":4424,"PHASE2":4426,"PHASE3":4428,"PHASE4":4430,"NA":4436},{"trials":4423,"activeCount":102},[],{"trials":4425,"activeCount":102},[],{"trials":4427,"activeCount":102},[],{"trials":4429,"activeCount":102},[],{"trials":4431,"activeCount":102},[4432],{"nctId":4406,"briefTitle":4407,"status":267,"phases":4433,"primaryCompletion":4409,"completion":4410,"start":2237,"enrollment":102,"conditions":4434,"interventions":4435},[93],[4412,4413,4414,4415],[4393,4417],{"trials":4437,"activeCount":102},[],{"intervention":4439,"totalTrials":253,"cells":4440},"Nebulized arformoterol",{"EARLY_PHASE1":4441,"PHASE1":4443,"PHASE2":4445,"PHASE3":4447,"PHASE4":4449,"NA":4459},{"trials":4442,"activeCount":102},[],{"trials":4444,"activeCount":102},[],{"trials":4446,"activeCount":102},[],{"trials":4448,"activeCount":102},[],{"trials":4450,"activeCount":102},[4451],{"nctId":4452,"briefTitle":4453,"status":553,"phases":4454,"primaryCompletion":3337,"completion":3337,"start":4455,"enrollment":34,"conditions":4456,"interventions":4457},"NCT01361984","Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography",[93],"2011-06",[4154,4155,4157,4156],[4439,4458],"Salmeterol",{"trials":4460,"activeCount":102},[],{"intervention":4458,"totalTrials":253,"cells":4462},{"EARLY_PHASE1":4463,"PHASE1":4465,"PHASE2":4467,"PHASE3":4469,"PHASE4":4471,"NA":4477},{"trials":4464,"activeCount":102},[],{"trials":4466,"activeCount":102},[],{"trials":4468,"activeCount":102},[],{"trials":4470,"activeCount":102},[],{"trials":4472,"activeCount":102},[4473],{"nctId":4452,"briefTitle":4453,"status":553,"phases":4474,"primaryCompletion":3337,"completion":3337,"start":4455,"enrollment":34,"conditions":4475,"interventions":4476},[93],[4154,4155,4157,4156],[4439,4458],{"trials":4478,"activeCount":102},[],{"intervention":2681,"totalTrials":253,"cells":4480},{"EARLY_PHASE1":4481,"PHASE1":4483,"PHASE2":4485,"PHASE3":4487,"PHASE4":4489,"NA":4495},{"trials":4482,"activeCount":102},[],{"trials":4484,"activeCount":102},[],{"trials":4486,"activeCount":102},[],{"trials":4488,"activeCount":102},[],{"trials":4490,"activeCount":102},[4491],{"nctId":2673,"briefTitle":2674,"status":553,"phases":4492,"primaryCompletion":2426,"completion":2676,"start":2677,"enrollment":1032,"conditions":4493,"interventions":4494},[93],[27,2679],[2681,2682,2632],{"trials":4496,"activeCount":102},[],{"intervention":2682,"totalTrials":253,"cells":4498},{"EARLY_PHASE1":4499,"PHASE1":4501,"PHASE2":4503,"PHASE3":4505,"PHASE4":4507,"NA":4513},{"trials":4500,"activeCount":102},[],{"trials":4502,"activeCount":102},[],{"trials":4504,"activeCount":102},[],{"trials":4506,"activeCount":102},[],{"trials":4508,"activeCount":102},[4509],{"nctId":2673,"briefTitle":2674,"status":553,"phases":4510,"primaryCompletion":2426,"completion":2676,"start":2677,"enrollment":1032,"conditions":4511,"interventions":4512},[93],[27,2679],[2681,2682,2632],{"trials":4514,"activeCount":102},[],{"intervention":4516,"totalTrials":253,"cells":4517},"Xolair injections",{"EARLY_PHASE1":4518,"PHASE1":4520,"PHASE2":4522,"PHASE3":4524,"PHASE4":4526,"NA":4537},{"trials":4519,"activeCount":102},[],{"trials":4521,"activeCount":102},[],{"trials":4523,"activeCount":102},[],{"trials":4525,"activeCount":102},[],{"trials":4527,"activeCount":102},[4528],{"nctId":4529,"briefTitle":4530,"status":108,"phases":4531,"primaryCompletion":4532,"completion":4532,"start":2519,"enrollment":4533,"conditions":4534,"interventions":4536},"NCT00784485","Non-invasive Measures of Effects of Xolair in Asthma",[93],"2011-02",13,[4535],"Asthma",[4516],{"trials":4538,"activeCount":102},[],{"intervention":4540,"totalTrials":253,"cells":4541},"tofacitinib 5mg po bid",{"EARLY_PHASE1":4542,"PHASE1":4544,"PHASE2":4546,"PHASE3":4548,"PHASE4":4550,"NA":4560},{"trials":4543,"activeCount":102},[],{"trials":4545,"activeCount":102},[],{"trials":4547,"activeCount":102},[],{"trials":4549,"activeCount":102},[],{"trials":4551,"activeCount":102},[4552],{"nctId":4553,"briefTitle":4554,"status":140,"phases":4555,"primaryCompletion":4556,"completion":4556,"start":4557,"enrollment":2492,"conditions":4558,"interventions":4559},"NCT02321930","Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients",[93],"2017-09-29","2016-02-16",[3005],[4540],{"trials":4561,"activeCount":102},[],{"intervention":2809,"totalTrials":253,"cells":4563},{"EARLY_PHASE1":4564,"PHASE1":4566,"PHASE2":4568,"PHASE3":4570,"PHASE4":4572,"NA":4578},{"trials":4565,"activeCount":102},[],{"trials":4567,"activeCount":102},[],{"trials":4569,"activeCount":102},[],{"trials":4571,"activeCount":102},[],{"trials":4573,"activeCount":102},[4574],{"nctId":2800,"briefTitle":2801,"status":140,"phases":4575,"primaryCompletion":2803,"completion":2803,"start":2804,"enrollment":2805,"conditions":4576,"interventions":4577},[93],[2807],[2768,2809],{"trials":4579,"activeCount":102},[],{"intervention":4581,"totalTrials":253,"cells":4582},"Repatha",{"EARLY_PHASE1":4583,"PHASE1":4585,"PHASE2":4587,"PHASE3":4589,"PHASE4":4591,"NA":4602},{"trials":4584,"activeCount":102},[],{"trials":4586,"activeCount":102},[],{"trials":4588,"activeCount":102},[],{"trials":4590,"activeCount":102},[],{"trials":4592,"activeCount":102},[4593],{"nctId":4594,"briefTitle":4595,"status":108,"phases":4596,"primaryCompletion":4597,"completion":4597,"start":4598,"enrollment":735,"conditions":4599,"interventions":4601},"NCT04573777","Reducing Intracranial atheroSclErosis With Repatha",[93],"2021-12-16","2021-04-23",[4600],"Ischemic Stroke",[4581],{"trials":4603,"activeCount":102},[],{"intervention":4605,"totalTrials":253,"cells":4606},"Vilazodone; Viibryd",{"EARLY_PHASE1":4607,"PHASE1":4609,"PHASE2":4611,"PHASE3":4613,"PHASE4":4615,"NA":4626},{"trials":4608,"activeCount":102},[],{"trials":4610,"activeCount":102},[],{"trials":4612,"activeCount":102},[],{"trials":4614,"activeCount":102},[],{"trials":4616,"activeCount":102},[4617],{"nctId":4618,"briefTitle":4619,"status":140,"phases":4620,"primaryCompletion":4621,"completion":4621,"start":2761,"enrollment":4622,"conditions":4623,"interventions":4624},"NCT01608295","Vilazodone for Treatment of Geriatric Depression",[93],"2015-09",65,[27],[4605,4625],"Paroxetine; Paxil",{"trials":4627,"activeCount":102},[],{"intervention":4625,"totalTrials":253,"cells":4629},{"EARLY_PHASE1":4630,"PHASE1":4632,"PHASE2":4634,"PHASE3":4636,"PHASE4":4638,"NA":4644},{"trials":4631,"activeCount":102},[],{"trials":4633,"activeCount":102},[],{"trials":4635,"activeCount":102},[],{"trials":4637,"activeCount":102},[],{"trials":4639,"activeCount":102},[4640],{"nctId":4618,"briefTitle":4619,"status":140,"phases":4641,"primaryCompletion":4621,"completion":4621,"start":2761,"enrollment":4622,"conditions":4642,"interventions":4643},[93],[27],[4605,4625],{"trials":4645,"activeCount":102},[],{"intervention":4647,"totalTrials":208,"cells":4648},"Sugar Pill",{"EARLY_PHASE1":4649,"PHASE1":4651,"PHASE2":4653,"PHASE3":4666,"PHASE4":4690,"NA":4692},{"trials":4650,"activeCount":102},[],{"trials":4652,"activeCount":102},[],{"trials":4654,"activeCount":102},[4655],{"nctId":4656,"briefTitle":4657,"status":267,"phases":4658,"primaryCompletion":225,"completion":225,"start":4659,"enrollment":102,"conditions":4660,"interventions":4663},"NCT03244592","Minocycline for Alcohol Use Disorder",[90,91],"2018-01-15",[36,820,4661,842,4662],"Neurocognitive Dysfunction","Alcohol Drinking",[4664,4665],"Minocycline","Sugar pill",{"trials":4667,"activeCount":102},[4668,4679],{"nctId":4669,"briefTitle":4670,"status":108,"phases":4671,"primaryCompletion":4672,"completion":4672,"start":4673,"enrollment":4533,"conditions":4674,"interventions":4676},"NCT02634606","Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood",[92],"2015-11-13","2011-03-22",[4675],"Hypercholesterolemia",[4677,4678,4647],"Gamma Delta Tocotrienols - Low Dose","Gamma Delta Tocotrienols - High Dose",{"nctId":4680,"briefTitle":4681,"status":267,"phases":4682,"primaryCompletion":4683,"completion":4683,"start":4684,"enrollment":102,"conditions":4685,"interventions":4687},"NCT02142569","Effects of a Supplement Derived From Palm Oil on Cholesterol Levels and Chinese Red Yeast Rice in the Blood",[91,92],"2016-02-09","2013-10-30",[4686],"Cholesterol Lowering",[4647,4688,4689],"Chinese Red Yeast Rice","CRYR + TRF",{"trials":4691,"activeCount":102},[],{"trials":4693,"activeCount":102},[],{"intervention":4664,"totalTrials":208,"cells":4695},{"EARLY_PHASE1":4696,"PHASE1":4698,"PHASE2":4709,"PHASE3":4715,"PHASE4":4724,"NA":4726},{"trials":4697,"activeCount":102},[],{"trials":4699,"activeCount":102},[4700],{"nctId":4701,"briefTitle":4702,"status":730,"phases":4703,"primaryCompletion":4704,"completion":4704,"start":4705,"enrollment":19,"conditions":4706,"interventions":4708},"NCT03117530","Measuring Brain Inflammation in Autism",[90],"2022-12","2017-04-11",[4707],"Autism Spectrum Disorder",[4664],{"trials":4710,"activeCount":102},[4711],{"nctId":4656,"briefTitle":4657,"status":267,"phases":4712,"primaryCompletion":225,"completion":225,"start":4659,"enrollment":102,"conditions":4713,"interventions":4714},[90,91],[36,820,4661,842,4662],[4664,4665],{"trials":4716,"activeCount":102},[4717],{"nctId":4718,"briefTitle":4719,"status":553,"phases":4720,"conditions":4721,"interventions":4722},"NCT00203697","Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study",[92],[3860],[4723],"minocycline",{"trials":4725,"activeCount":102},[],{"trials":4727,"activeCount":102},[],{"intervention":4729,"totalTrials":161,"cells":4730},"Matched Placebo",{"EARLY_PHASE1":4731,"PHASE1":4733,"PHASE2":4735,"PHASE3":4747,"PHASE4":4759,"NA":4761},{"trials":4732,"activeCount":102},[],{"trials":4734,"activeCount":102},[],{"trials":4736,"activeCount":102},[4737],{"nctId":4738,"briefTitle":4739,"status":267,"phases":4740,"primaryCompletion":4741,"completion":4742,"start":4225,"enrollment":102,"conditions":4743,"interventions":4744},"NCT04311294","Development of a Selective ALDH2 Inhibitor to Treat AUD",[91],"2022-01","2022-03",[36],[4745,4746,4729],"ANS-6637 Low Dose","ANS-6637 High Dose",{"trials":4748,"activeCount":102},[4749],{"nctId":4750,"briefTitle":4751,"status":553,"phases":4752,"primaryCompletion":4753,"completion":3249,"start":2648,"enrollment":659,"conditions":4754,"interventions":4756},"NCT01599975","A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV",[92],"2014-05",[4755],"HIV Dementia",[4757,4757,4758],"Long acting methylphenidate","Matched placebo",{"trials":4760,"activeCount":102},[],{"trials":4762,"activeCount":102},[],{"intervention":4764,"totalTrials":253,"cells":4765},"thymoglobulin",{"EARLY_PHASE1":4766,"PHASE1":4768,"PHASE2":4770,"PHASE3":4772,"PHASE4":4784,"NA":4786},{"trials":4767,"activeCount":102},[],{"trials":4769,"activeCount":102},[],{"trials":4771,"activeCount":102},[],{"trials":4773,"activeCount":102},[4774],{"nctId":4775,"briefTitle":4776,"status":267,"phases":4777,"primaryCompletion":4778,"completion":4779,"start":4780,"enrollment":102,"conditions":4781,"interventions":4783},"NCT00592306","Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation",[92],"2009-09","2010-09","2006-01",[4782],"Lung Transplant",[4764,4764],{"trials":4785,"activeCount":102},[],{"trials":4787,"activeCount":102},[],{"intervention":4789,"totalTrials":253,"cells":4790},"Buprenorphine + Naltrexone",{"EARLY_PHASE1":4791,"PHASE1":4793,"PHASE2":4795,"PHASE3":4797,"PHASE4":4808,"NA":4810},{"trials":4792,"activeCount":102},[],{"trials":4794,"activeCount":102},[],{"trials":4796,"activeCount":102},[],{"trials":4798,"activeCount":102},[4799],{"nctId":4800,"briefTitle":4801,"status":140,"phases":4802,"primaryCompletion":2548,"completion":3089,"start":4803,"enrollment":4804,"conditions":4805,"interventions":4807},"NCT01402492","Cocaine Use Reduction With Buprenorphine",[91,92],"2011-09",302,[4806],"Cocaine Dependence",[4789],{"trials":4809,"activeCount":102},[],{"trials":4811,"activeCount":102},[],{"intervention":4677,"totalTrials":253,"cells":4813},{"EARLY_PHASE1":4814,"PHASE1":4816,"PHASE2":4818,"PHASE3":4820,"PHASE4":4826,"NA":4828},{"trials":4815,"activeCount":102},[],{"trials":4817,"activeCount":102},[],{"trials":4819,"activeCount":102},[],{"trials":4821,"activeCount":102},[4822],{"nctId":4669,"briefTitle":4670,"status":108,"phases":4823,"primaryCompletion":4672,"completion":4672,"start":4673,"enrollment":4533,"conditions":4824,"interventions":4825},[92],[4675],[4677,4678,4647],{"trials":4827,"activeCount":102},[],{"trials":4829,"activeCount":102},[],{"intervention":4678,"totalTrials":253,"cells":4831},{"EARLY_PHASE1":4832,"PHASE1":4834,"PHASE2":4836,"PHASE3":4838,"PHASE4":4844,"NA":4846},{"trials":4833,"activeCount":102},[],{"trials":4835,"activeCount":102},[],{"trials":4837,"activeCount":102},[],{"trials":4839,"activeCount":102},[4840],{"nctId":4669,"briefTitle":4670,"status":108,"phases":4841,"primaryCompletion":4672,"completion":4672,"start":4673,"enrollment":4533,"conditions":4842,"interventions":4843},[92],[4675],[4677,4678,4647],{"trials":4845,"activeCount":102},[],{"trials":4847,"activeCount":102},[],{"intervention":4849,"totalTrials":253,"cells":4850},"XR-NTX",{"EARLY_PHASE1":4851,"PHASE1":4853,"PHASE2":4855,"PHASE3":4857,"PHASE4":4870,"NA":4872},{"trials":4852,"activeCount":102},[],{"trials":4854,"activeCount":102},[],{"trials":4856,"activeCount":102},[],{"trials":4858,"activeCount":102},[4859],{"nctId":4860,"briefTitle":4861,"status":140,"phases":4862,"primaryCompletion":4863,"completion":4864,"start":4865,"enrollment":4866,"conditions":4867,"interventions":4869},"NCT02110264","Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)",[92],"2018-12","2019-05","2015-06",151,[4868],"Opioid Use Disorders",[4849],{"trials":4871,"activeCount":102},[],{"trials":4873,"activeCount":102},[],{"intervention":4875,"totalTrials":253,"cells":4876},"ND and AMOX modified Gutta Percha",{"EARLY_PHASE1":4877,"PHASE1":4879,"PHASE2":4881,"PHASE3":4883,"PHASE4":4896,"NA":4898},{"trials":4878,"activeCount":102},[],{"trials":4880,"activeCount":102},[],{"trials":4882,"activeCount":102},[],{"trials":4884,"activeCount":102},[4885],{"nctId":4886,"briefTitle":4887,"status":267,"phases":4888,"primaryCompletion":4889,"completion":57,"start":4890,"enrollment":102,"conditions":4891,"interventions":4895},"NCT03376984","Nanodiamond-Gutta Percha Composite Biomaterials for Root Canal Therapy",[91,92],"2024-12","2023-06",[4892,4893,4894],"Dental Pulp Diseases","Dental Pulp Necrosis","Nerve Root Pain Nec",[4875],{"trials":4897,"activeCount":102},[],{"trials":4899,"activeCount":102},[],{"intervention":4688,"totalTrials":253,"cells":4901},{"EARLY_PHASE1":4902,"PHASE1":4904,"PHASE2":4906,"PHASE3":4908,"PHASE4":4914,"NA":4916},{"trials":4903,"activeCount":102},[],{"trials":4905,"activeCount":102},[],{"trials":4907,"activeCount":102},[],{"trials":4909,"activeCount":102},[4910],{"nctId":4680,"briefTitle":4681,"status":267,"phases":4911,"primaryCompletion":4683,"completion":4683,"start":4684,"enrollment":102,"conditions":4912,"interventions":4913},[91,92],[4686],[4647,4688,4689],{"trials":4915,"activeCount":102},[],{"trials":4917,"activeCount":102},[],{"intervention":4689,"totalTrials":253,"cells":4919},{"EARLY_PHASE1":4920,"PHASE1":4922,"PHASE2":4924,"PHASE3":4926,"PHASE4":4932,"NA":4934},{"trials":4921,"activeCount":102},[],{"trials":4923,"activeCount":102},[],{"trials":4925,"activeCount":102},[],{"trials":4927,"activeCount":102},[4928],{"nctId":4680,"briefTitle":4681,"status":267,"phases":4929,"primaryCompletion":4683,"completion":4683,"start":4684,"enrollment":102,"conditions":4930,"interventions":4931},[91,92],[4686],[4647,4688,4689],{"trials":4933,"activeCount":102},[],{"trials":4935,"activeCount":102},[],{"intervention":4937,"totalTrials":253,"cells":4938},"Routine Care",{"EARLY_PHASE1":4939,"PHASE1":4941,"PHASE2":4943,"PHASE3":4945,"PHASE4":4959,"NA":4961},{"trials":4940,"activeCount":102},[],{"trials":4942,"activeCount":102},[],{"trials":4944,"activeCount":102},[],{"trials":4946,"activeCount":102},[4947],{"nctId":4948,"briefTitle":4949,"status":553,"phases":4950,"primaryCompletion":4951,"completion":4951,"start":4952,"enrollment":659,"conditions":4953,"interventions":4958},"NCT01013714","Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias",[92],"2024-08-31","2021-07-26",[4954,4955,4956,4957],"Sudden Cardiac Death","Ventricular Tachycardia","Ventricular Fibrillation","Cardiomyopathy",[4937],{"trials":4960,"activeCount":102},[],{"trials":4962,"activeCount":102},[],{"intervention":4964,"totalTrials":253,"cells":4965},"Iodine",{"EARLY_PHASE1":4966,"PHASE1":4968,"PHASE2":4970,"PHASE3":4972,"PHASE4":4987,"NA":4989},{"trials":4967,"activeCount":102},[],{"trials":4969,"activeCount":102},[],{"trials":4971,"activeCount":102},[],{"trials":4973,"activeCount":102},[4974],{"nctId":4975,"briefTitle":4976,"status":140,"phases":4977,"primaryCompletion":4978,"completion":4979,"start":4980,"enrollment":4981,"conditions":4982,"interventions":4985},"NCT03062605","Reducing Bacteria That Cause Tooth Decay",[92],"2012-02-11","2012-02-17","2011-05-21",48,[4983,4984],"Caries, Dental","Cariostatic Agents",[4964,4986],"NaOCL",{"trials":4988,"activeCount":102},[],{"trials":4990,"activeCount":102},[],{"intervention":4986,"totalTrials":253,"cells":4992},{"EARLY_PHASE1":4993,"PHASE1":4995,"PHASE2":4997,"PHASE3":4999,"PHASE4":5005,"NA":5007},{"trials":4994,"activeCount":102},[],{"trials":4996,"activeCount":102},[],{"trials":4998,"activeCount":102},[],{"trials":5000,"activeCount":102},[5001],{"nctId":4975,"briefTitle":4976,"status":140,"phases":5002,"primaryCompletion":4978,"completion":4979,"start":4980,"enrollment":4981,"conditions":5003,"interventions":5004},[92],[4983,4984],[4964,4986],{"trials":5006,"activeCount":102},[],{"trials":5008,"activeCount":102},[],{"intervention":5010,"totalTrials":253,"cells":5011},"Tenofovir alafenamide",{"EARLY_PHASE1":5012,"PHASE1":5014,"PHASE2":5016,"PHASE3":5018,"PHASE4":5031,"NA":5033},{"trials":5013,"activeCount":102},[],{"trials":5015,"activeCount":102},[],{"trials":5017,"activeCount":102},[],{"trials":5019,"activeCount":102},[5020],{"nctId":5021,"briefTitle":5022,"status":140,"phases":5023,"primaryCompletion":5024,"completion":5025,"start":5026,"enrollment":5027,"conditions":5028,"interventions":5029},"NCT04937881","PK of TAF and TDF for PrEP in Pregnant and Postpartum Women",[92],"2023-04-17","2023-09-01","2022-06-13",39,[3184],[5010,5030],"Tenofovir Disoproxil Fumarate",{"trials":5032,"activeCount":102},[],{"trials":5034,"activeCount":102},[],{"intervention":5030,"totalTrials":253,"cells":5036},{"EARLY_PHASE1":5037,"PHASE1":5039,"PHASE2":5041,"PHASE3":5043,"PHASE4":5049,"NA":5051},{"trials":5038,"activeCount":102},[],{"trials":5040,"activeCount":102},[],{"trials":5042,"activeCount":102},[],{"trials":5044,"activeCount":102},[5045],{"nctId":5021,"briefTitle":5022,"status":140,"phases":5046,"primaryCompletion":5024,"completion":5025,"start":5026,"enrollment":5027,"conditions":5047,"interventions":5048},[92],[3184],[5010,5030],{"trials":5050,"activeCount":102},[],{"trials":5052,"activeCount":102},[],{"intervention":5054,"totalTrials":253,"cells":5055},"Maraviroc 300 mg",{"EARLY_PHASE1":5056,"PHASE1":5058,"PHASE2":5060,"PHASE3":5062,"PHASE4":5072,"NA":5074},{"trials":5057,"activeCount":102},[],{"trials":5059,"activeCount":102},[],{"trials":5061,"activeCount":102},[],{"trials":5063,"activeCount":102},[5064],{"nctId":5065,"briefTitle":5066,"status":108,"phases":5067,"primaryCompletion":5068,"completion":5068,"start":556,"enrollment":161,"conditions":5069,"interventions":5071},"NCT03172026","Maraviroc to Augment Rehabilitation Outcomes After Stroke",[91,92],"2020-10-01",[5070],"Stroke",[5054],{"trials":5073,"activeCount":102},[],{"trials":5075,"activeCount":102},[],{"intervention":4757,"totalTrials":253,"cells":5077},{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5082,"PHASE3":5084,"PHASE4":5090,"NA":5092},{"trials":5079,"activeCount":102},[],{"trials":5081,"activeCount":102},[],{"trials":5083,"activeCount":102},[],{"trials":5085,"activeCount":102},[5086],{"nctId":4750,"briefTitle":4751,"status":553,"phases":5087,"primaryCompletion":4753,"completion":3249,"start":2648,"enrollment":659,"conditions":5088,"interventions":5089},[92],[4755],[4757,4757,4758],{"trials":5091,"activeCount":102},[],{"trials":5093,"activeCount":102},[],{"intervention":5095,"totalTrials":253,"cells":5096},"OTL-101",{"EARLY_PHASE1":5097,"PHASE1":5099,"PHASE2":5101,"PHASE3":5103,"PHASE4":5114,"NA":5116},{"trials":5098,"activeCount":102},[],{"trials":5100,"activeCount":102},[],{"trials":5102,"activeCount":102},[],{"trials":5104,"activeCount":102},[5105],{"nctId":5106,"briefTitle":5107,"status":267,"phases":5108,"primaryCompletion":5109,"completion":5109,"start":5110,"enrollment":102,"conditions":5111,"interventions":5113},"NCT04140539","A Clinical Study to Enable Process Validation of Commercial Grade OTL-101",[91,92],"2021-08-30","2019-10-15",[5112],"Severe Combined Immunodeficiency Due to ADA Deficiency",[5095],{"trials":5115,"activeCount":102},[],{"trials":5117,"activeCount":102},[],{"intervention":5119,"totalTrials":253,"cells":5120},"Nitrous Oxide",{"EARLY_PHASE1":5121,"PHASE1":5123,"PHASE2":5125,"PHASE3":5127,"PHASE4":5136,"NA":5138},{"trials":5122,"activeCount":102},[],{"trials":5124,"activeCount":102},[],{"trials":5126,"activeCount":102},[],{"trials":5128,"activeCount":102},[5129],{"nctId":5130,"briefTitle":5131,"status":267,"phases":5132,"enrollment":102,"conditions":5133,"interventions":5135},"NCT00250692","A Study to Test the Pain-relieving Effect of Laughing Gas in Infants",[92],[5134],"Analgesic Affect",[5119],{"trials":5137,"activeCount":102},[],{"trials":5139,"activeCount":102},[],{"intervention":5141,"totalTrials":253,"cells":5142},"Acute normovolemic hemodilution",{"EARLY_PHASE1":5143,"PHASE1":5145,"PHASE2":5147,"PHASE3":5149,"PHASE4":5164,"NA":5166},{"trials":5144,"activeCount":102},[],{"trials":5146,"activeCount":102},[],{"trials":5148,"activeCount":102},[],{"trials":5150,"activeCount":102},[5151],{"nctId":5152,"briefTitle":5153,"status":140,"phases":5154,"primaryCompletion":5155,"completion":5156,"start":5157,"enrollment":5158,"conditions":5159,"interventions":5163},"NCT05049590","Acute Normovolemic Hemodilution in Complex Cardiac Surgery",[92],"2023-05-22","2023-06-22","2022-02-28",63,[5160,292,5161,5162],"Cardiac Surgery","Congenital Heart Disease","Aortic Surgery",[5141],{"trials":5165,"activeCount":102},[],{"trials":5167,"activeCount":102},[],{"intervention":5169,"totalTrials":253,"cells":5170},"povidone-iodine 1.25% ophthalmic solution",{"EARLY_PHASE1":5171,"PHASE1":5173,"PHASE2":5175,"PHASE3":5177,"PHASE4":5188,"NA":5190},{"trials":5172,"activeCount":102},[],{"trials":5174,"activeCount":102},[],{"trials":5176,"activeCount":102},[],{"trials":5178,"activeCount":102},[5179],{"nctId":5180,"briefTitle":5181,"status":108,"phases":5182,"primaryCompletion":4779,"completion":3730,"start":4152,"enrollment":5183,"conditions":5184,"interventions":5186},"NCT00516399","A Clinical Trial of the Treatment of Fungal Corneal Ulcers With Povidone-Iodine",[92],78,[5185],"Fungal Keratitis",[5169,5187],"natamycin ophthalmic suspension, USP 5%",{"trials":5189,"activeCount":102},[],{"trials":5191,"activeCount":102},[],{"intervention":5187,"totalTrials":253,"cells":5193},{"EARLY_PHASE1":5194,"PHASE1":5196,"PHASE2":5198,"PHASE3":5200,"PHASE4":5206,"NA":5208},{"trials":5195,"activeCount":102},[],{"trials":5197,"activeCount":102},[],{"trials":5199,"activeCount":102},[],{"trials":5201,"activeCount":102},[5202],{"nctId":5180,"briefTitle":5181,"status":108,"phases":5203,"primaryCompletion":4779,"completion":3730,"start":4152,"enrollment":5183,"conditions":5204,"interventions":5205},[92],[5185],[5169,5187],{"trials":5207,"activeCount":102},[],{"trials":5209,"activeCount":102},[],{"intervention":5211,"totalTrials":253,"cells":5212},"Calcipotriene",{"EARLY_PHASE1":5213,"PHASE1":5215,"PHASE2":5217,"PHASE3":5219,"PHASE4":5230,"NA":5232},{"trials":5214,"activeCount":102},[],{"trials":5216,"activeCount":102},[],{"trials":5218,"activeCount":102},[],{"trials":5220,"activeCount":102},[5221],{"nctId":5222,"briefTitle":5223,"status":140,"phases":5224,"primaryCompletion":5225,"completion":5225,"start":2838,"enrollment":5226,"conditions":5227,"interventions":5229},"NCT01694433","\"Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy\"",[91,92],"2014-01-09",66,[5228],"Acne Vulgaris",[5211],{"trials":5231,"activeCount":102},[],{"trials":5233,"activeCount":102},[],{"intervention":5235,"totalTrials":253,"cells":5236},"clartihromycin, amoxicillin, and omeprazole",{"EARLY_PHASE1":5237,"PHASE1":5239,"PHASE2":5241,"PHASE3":5243,"PHASE4":5255,"NA":5257},{"trials":5238,"activeCount":102},[],{"trials":5240,"activeCount":102},[],{"trials":5242,"activeCount":102},[],{"trials":5244,"activeCount":102},[5245],{"nctId":5246,"briefTitle":5247,"status":108,"phases":5248,"primaryCompletion":4455,"completion":5249,"start":3024,"enrollment":852,"conditions":5250,"interventions":5254},"NCT00664209","Treating H. Pylori in Parkinson's Patients With Motor Fluctuations",[92],"2012-06",[5251,5252,5253],"Parkinson's Disease","Helicobacter Infections","Motor Fluctuations",[5235],{"trials":5256,"activeCount":102},[],{"trials":5258,"activeCount":102},[],{"intervention":5260,"totalTrials":253,"cells":5261},"Prometa",{"EARLY_PHASE1":5262,"PHASE1":5264,"PHASE2":5266,"PHASE3":5268,"PHASE4":5278,"NA":5280},{"trials":5263,"activeCount":102},[],{"trials":5265,"activeCount":102},[],{"trials":5267,"activeCount":102},[],{"trials":5269,"activeCount":102},[5270],{"nctId":5271,"briefTitle":5272,"status":140,"phases":5273,"primaryCompletion":5274,"completion":5274,"start":4780,"enrollment":196,"conditions":5275,"interventions":5277},"NCT00260481","Prometa Pharmacotherapy for Methamphetamine Dependence",[91,92],"2008-06",[1455,5276],"Drug Dependence",[5260],{"trials":5279,"activeCount":102},[],{"trials":5281,"activeCount":102},[],{"intervention":5283,"totalTrials":253,"cells":5284},"Phenoxybenzamine",{"EARLY_PHASE1":5285,"PHASE1":5287,"PHASE2":5289,"PHASE3":5291,"PHASE4":5305,"NA":5307},{"trials":5286,"activeCount":102},[],{"trials":5288,"activeCount":102},[],{"trials":5290,"activeCount":102},[],{"trials":5292,"activeCount":102},[5293],{"nctId":5294,"briefTitle":5295,"status":140,"phases":5296,"primaryCompletion":5297,"completion":5298,"start":5299,"enrollment":5027,"conditions":5300,"interventions":5303},"NCT03176693","Preoperative Alpha Blockade for Pheochromocytoma",[92],"2020-01-31","2021-10-10","2017-05-05",[5301,5302],"Pheochromocytoma","Paraganglioma",[5283,5304],"Doxazosin",{"trials":5306,"activeCount":102},[],{"trials":5308,"activeCount":102},[],{"intervention":5304,"totalTrials":253,"cells":5310},{"EARLY_PHASE1":5311,"PHASE1":5313,"PHASE2":5315,"PHASE3":5317,"PHASE4":5323,"NA":5325},{"trials":5312,"activeCount":102},[],{"trials":5314,"activeCount":102},[],{"trials":5316,"activeCount":102},[],{"trials":5318,"activeCount":102},[5319],{"nctId":5294,"briefTitle":5295,"status":140,"phases":5320,"primaryCompletion":5297,"completion":5298,"start":5299,"enrollment":5027,"conditions":5321,"interventions":5322},[92],[5301,5302],[5283,5304],{"trials":5324,"activeCount":102},[],{"trials":5326,"activeCount":102},[],{"intervention":5328,"totalTrials":253,"cells":5329},"antiepileptic drugs",{"EARLY_PHASE1":5330,"PHASE1":5332,"PHASE2":5334,"PHASE3":5336,"PHASE4":5349,"NA":5351},{"trials":5331,"activeCount":102},[],{"trials":5333,"activeCount":102},[],{"trials":5335,"activeCount":102},[],{"trials":5337,"activeCount":102},[5338],{"nctId":5339,"briefTitle":5340,"status":140,"phases":5341,"primaryCompletion":5342,"completion":5342,"start":5343,"enrollment":3182,"conditions":5344,"interventions":5348},"NCT00040326","Early Surgical Intervention to Treat Epilepsy",[92],"2007-11","2002-07",[5345,5346,5347],"Epilepsy","Epilepsy, Temporal Lobe","Seizures",[5328],{"trials":5350,"activeCount":102},[],{"trials":5352,"activeCount":102},[],{"intervention":5354,"totalTrials":98,"cells":5355},"Ibudilast",{"EARLY_PHASE1":5356,"PHASE1":5358,"PHASE2":5367,"PHASE3":5395,"PHASE4":5397,"NA":5399},{"trials":5357,"activeCount":102},[],{"trials":5359,"activeCount":102},[5360],{"nctId":5361,"briefTitle":5362,"status":140,"phases":5363,"primaryCompletion":4865,"completion":4865,"start":671,"enrollment":709,"conditions":5364,"interventions":5366},"NCT02025998","Development of Ibudilast for Alcohol Use Disorder",[90],[5365],"Alcohol Use Disorders",[5354],{"trials":5368,"activeCount":102},[5369,5378,5386],{"nctId":5370,"briefTitle":5371,"status":140,"phases":5372,"primaryCompletion":5373,"completion":5373,"start":1172,"enrollment":5374,"conditions":5375,"interventions":5377},"NCT01860807","Trial of Ibudilast for Methamphetamine Dependence",[91],"2017-12-31",125,[2418,5376],"HIV Infection",[5354],{"nctId":5379,"briefTitle":5380,"status":140,"phases":5381,"primaryCompletion":5382,"completion":5382,"start":5383,"enrollment":1954,"conditions":5384,"interventions":5385},"NCT03489850","Ibudilast and Withdrawal-Related Dysphoria",[91],"2020-03-31","2018-07-16",[36],[5354],{"nctId":5387,"briefTitle":5388,"status":140,"phases":5389,"primaryCompletion":5390,"completion":5390,"start":5391,"enrollment":5392,"conditions":5393,"interventions":5394},"NCT03594435","Ibudilast for the Treatment of Alcohol Use Disorder",[91],"2023-04-19","2018-10-01",102,[36],[5354],{"trials":5396,"activeCount":102},[],{"trials":5398,"activeCount":102},[],{"trials":5400,"activeCount":102},[],{"intervention":5402,"totalTrials":208,"cells":5403},"Bupropion",{"EARLY_PHASE1":5404,"PHASE1":5418,"PHASE2":5430,"PHASE3":5442,"PHASE4":5444,"NA":5446},{"trials":5405,"activeCount":102},[5406],{"nctId":5407,"briefTitle":5408,"status":267,"phases":5409,"primaryCompletion":5410,"completion":5410,"start":5411,"enrollment":102,"conditions":5412,"interventions":5416},"NCT04553263","Relapse Prevention in Stimulant Use Disorder",[89],"2025-01-11","2023-06-11",[5413,5414,2406,5415],"Stimulant Use","Relapse","ADHD",[5417,5402],"Contrave 8Mg-90Mg Extended-Release",{"trials":5419,"activeCount":102},[5420],{"nctId":5421,"briefTitle":5422,"status":140,"phases":5423,"primaryCompletion":5424,"completion":5424,"start":5425,"enrollment":144,"conditions":5426,"interventions":5429},"NCT03920319","Bupropion and Cigarette-Related Cues in Smokers",[90],"2005-12-31","2004-01-01",[5427,5428],"Smoking","Smoking, Tobacco",[5402],{"trials":5431,"activeCount":102},[5432],{"nctId":5433,"briefTitle":5434,"status":140,"phases":5435,"primaryCompletion":2722,"completion":1172,"start":2743,"enrollment":5436,"conditions":5437,"interventions":5441},"NCT00833443","Study of Medical Treatment for Methamphetamine Addiction",[91],84,[5438,5439,5440,2418,2419],"Methamphetamine","Amphetamine Dependence","Pharmacogenetics",[5402],{"trials":5443,"activeCount":102},[],{"trials":5445,"activeCount":102},[],{"trials":5447,"activeCount":102},[],{"intervention":5449,"totalTrials":161,"cells":5450},"Telmisartan",{"EARLY_PHASE1":5451,"PHASE1":5453,"PHASE2":5455,"PHASE3":5471,"PHASE4":5473,"NA":5475},{"trials":5452,"activeCount":102},[],{"trials":5454,"activeCount":102},[],{"trials":5456,"activeCount":102},[5457,5463],{"nctId":5458,"briefTitle":5459,"status":140,"phases":5460,"primaryCompletion":4455,"completion":4455,"start":2425,"enrollment":2900,"conditions":5461,"interventions":5462},"NCT01088295","HIV and Fat Accumulation",[91],[5376],[5449],{"nctId":5464,"briefTitle":5465,"status":140,"phases":5466,"primaryCompletion":3089,"completion":3089,"start":5467,"enrollment":2386,"conditions":5468,"interventions":5470},"NCT01578772","A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease",[91],"2012-08",[5469],"Endothelial Dysfunction",[5449],{"trials":5472,"activeCount":102},[],{"trials":5474,"activeCount":102},[],{"trials":5476,"activeCount":102},[],{"intervention":5478,"totalTrials":161,"cells":5479},"busulfan",{"EARLY_PHASE1":5480,"PHASE1":5482,"PHASE2":5484,"PHASE3":5506,"PHASE4":5508,"NA":5510},{"trials":5481,"activeCount":102},[],{"trials":5483,"activeCount":102},[],{"trials":5485,"activeCount":102},[5486,5496],{"nctId":5487,"briefTitle":5488,"status":140,"phases":5489,"primaryCompletion":5490,"completion":2362,"start":5491,"enrollment":735,"conditions":5492,"interventions":5493},"NCT02999984","Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID",[90,91],"2018-10-11","2016-12-16",[5112],[5494,5478,5495],"Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells","PEG-ADA ERT",{"nctId":5497,"briefTitle":5498,"status":140,"phases":5499,"primaryCompletion":5500,"completion":5500,"start":5501,"enrollment":4181,"conditions":5502,"interventions":5504},"NCT01852071","Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene",[90,91],"2018-08-27","2013-08-02",[5503],"ADA-SCID",[5505,5478,5495],"Infusion of autologous EFS-ADA LV CD34+",{"trials":5507,"activeCount":102},[],{"trials":5509,"activeCount":102},[],{"trials":5511,"activeCount":102},[],{"intervention":5495,"totalTrials":161,"cells":5513},{"EARLY_PHASE1":5514,"PHASE1":5516,"PHASE2":5518,"PHASE3":5528,"PHASE4":5530,"NA":5532},{"trials":5515,"activeCount":102},[],{"trials":5517,"activeCount":102},[],{"trials":5519,"activeCount":102},[5520,5524],{"nctId":5487,"briefTitle":5488,"status":140,"phases":5521,"primaryCompletion":5490,"completion":2362,"start":5491,"enrollment":735,"conditions":5522,"interventions":5523},[90,91],[5112],[5494,5478,5495],{"nctId":5497,"briefTitle":5498,"status":140,"phases":5525,"primaryCompletion":5500,"completion":5500,"start":5501,"enrollment":4181,"conditions":5526,"interventions":5527},[90,91],[5503],[5505,5478,5495],{"trials":5529,"activeCount":102},[],{"trials":5531,"activeCount":102},[],{"trials":5533,"activeCount":102},[],{"intervention":5535,"totalTrials":161,"cells":5536},"Curcumin",{"EARLY_PHASE1":5537,"PHASE1":5548,"PHASE2":5550,"PHASE3":5560,"PHASE4":5562,"NA":5564},{"trials":5538,"activeCount":102},[5539],{"nctId":5540,"briefTitle":5541,"status":140,"phases":5542,"primaryCompletion":5543,"completion":5544,"start":5545,"enrollment":659,"conditions":5546,"interventions":5547},"NCT00752154","Curcumin in Rheumatoid Arthritis",[89],"2010-12-01","2011-01-01","2010-01",[3005],[5535],{"trials":5549,"activeCount":102},[],{"trials":5551,"activeCount":102},[5552],{"nctId":5553,"briefTitle":5554,"status":140,"phases":5555,"primaryCompletion":3248,"completion":3248,"start":5556,"enrollment":4181,"conditions":5557,"interventions":5559},"NCT01383161","18-Month Study of Memory Effects of Curcumin",[91],"2012-03",[5558,2669],"Age-associated Cognitive Impairment",[5535],{"trials":5561,"activeCount":102},[],{"trials":5563,"activeCount":102},[],{"trials":5565,"activeCount":102},[],{"intervention":5567,"totalTrials":161,"cells":5568},"Estriol",{"EARLY_PHASE1":5569,"PHASE1":5571,"PHASE2":5573,"PHASE3":5598,"PHASE4":5600,"NA":5602},{"trials":5570,"activeCount":102},[],{"trials":5572,"activeCount":102},[],{"trials":5574,"activeCount":102},[5575,5585],{"nctId":5576,"briefTitle":5577,"status":140,"phases":5578,"primaryCompletion":2825,"completion":2825,"start":5579,"enrollment":5580,"conditions":5581,"interventions":5583},"NCT00451204","A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)",[91],"2007-03",158,[5582],"Relapsing Remitting Multiple Sclerosis",[5567,5584],"Copaxone",{"nctId":5586,"briefTitle":5587,"status":553,"phases":5588,"primaryCompletion":5589,"completion":5590,"start":2562,"enrollment":852,"conditions":5591,"interventions":5595},"NCT01466114","Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition",[91],"2021-12","2022-04",[5592,5593,5594],"Relapsing-remitting Multiple Sclerosis","Secondary-progressive Multiple Sclerosis","Primary-progressive Multiple Sclerosis",[5596,5597],"estriol","Norethindrone",{"trials":5599,"activeCount":102},[],{"trials":5601,"activeCount":102},[],{"trials":5603,"activeCount":102},[],{"intervention":5605,"totalTrials":253,"cells":5606},"Aripiprazole",{"EARLY_PHASE1":5607,"PHASE1":5609,"PHASE2":5611,"PHASE3":5620,"PHASE4":5622,"NA":5624},{"trials":5608,"activeCount":102},[],{"trials":5610,"activeCount":102},[],{"trials":5612,"activeCount":102},[5613],{"nctId":5614,"briefTitle":5615,"status":140,"phases":5616,"primaryCompletion":2433,"completion":2433,"start":5249,"enrollment":5617,"conditions":5618,"interventions":5619},"NCT02574741","Combination Treatment for Augmenting Language in Children With ASD",[91],58,[4707],[5605],{"trials":5621,"activeCount":102},[],{"trials":5623,"activeCount":102},[],{"trials":5625,"activeCount":102},[],{"intervention":5627,"totalTrials":253,"cells":5628},"tenofovir + emtricitabine, lopinavir\u002Fritonavir",{"EARLY_PHASE1":5629,"PHASE1":5631,"PHASE2":5633,"PHASE3":5644,"PHASE4":5646,"NA":5648},{"trials":5630,"activeCount":102},[],{"trials":5632,"activeCount":102},[],{"trials":5634,"activeCount":102},[5635],{"nctId":5636,"briefTitle":5637,"status":140,"phases":5638,"primaryCompletion":4249,"completion":5639,"start":5640,"enrollment":5641,"conditions":5642,"interventions":5643},"NCT00949234","Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV",[91],"2011-08","2010-03",267,[2286,24],[5627],{"trials":5645,"activeCount":102},[],{"trials":5647,"activeCount":102},[],{"trials":5649,"activeCount":102},[],{"intervention":5651,"totalTrials":253,"cells":5652},"Mitoquinone\u002Fmitoquinol mesylate",{"EARLY_PHASE1":5653,"PHASE1":5655,"PHASE2":5657,"PHASE3":5670,"PHASE4":5672,"NA":5674},{"trials":5654,"activeCount":102},[],{"trials":5656,"activeCount":102},[],{"trials":5658,"activeCount":102},[5659],{"nctId":5660,"briefTitle":5661,"status":140,"phases":5662,"primaryCompletion":5663,"completion":5663,"start":5664,"enrollment":2035,"conditions":5665,"interventions":5669},"NCT05381454","An Open Label Study in Adults to Test the Efficacy of Mitoquinone\u002FMitoquinol Mesylate to Prevent Severe Viral Illness",[90,91],"2023-05-09","2022-04-28",[5666,5667,5668],"Respiratory Viral Infection","Antiviral Treatment","COVID-19",[5651],{"trials":5671,"activeCount":102},[],{"trials":5673,"activeCount":102},[],{"trials":5675,"activeCount":102},[],{"intervention":5677,"totalTrials":253,"cells":5678},"Sinemet Pill",{"EARLY_PHASE1":5679,"PHASE1":5681,"PHASE2":5683,"PHASE3":5693,"PHASE4":5695,"NA":5697},{"trials":5680,"activeCount":102},[],{"trials":5682,"activeCount":102},[],{"trials":5684,"activeCount":102},[5685],{"nctId":5686,"briefTitle":5687,"status":140,"phases":5688,"primaryCompletion":5689,"completion":5689,"start":5690,"enrollment":25,"conditions":5691,"interventions":5692},"NCT05369533","Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke",[90,91],"2024-03-11","2022-08-01",[5070],[5677],{"trials":5694,"activeCount":102},[],{"trials":5696,"activeCount":102},[],{"trials":5698,"activeCount":102},[],{"intervention":5700,"totalTrials":253,"cells":5701},"Gabapentin;",{"EARLY_PHASE1":5702,"PHASE1":5704,"PHASE2":5706,"PHASE3":5715,"PHASE4":5717,"NA":5719},{"trials":5703,"activeCount":102},[],{"trials":5705,"activeCount":102},[],{"trials":5707,"activeCount":102},[5708],{"nctId":5709,"briefTitle":5710,"status":140,"phases":5711,"primaryCompletion":4152,"completion":2425,"start":2490,"enrollment":22,"conditions":5712,"interventions":5714},"NCT01210079","Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?",[91],[5713],"Opioid-Induced Hyperalgesia",[5700],{"trials":5716,"activeCount":102},[],{"trials":5718,"activeCount":102},[],{"trials":5720,"activeCount":102},[],{"intervention":5722,"totalTrials":253,"cells":5723},"testosterone",{"EARLY_PHASE1":5724,"PHASE1":5726,"PHASE2":5728,"PHASE3":5737,"PHASE4":5739,"NA":5741},{"trials":5725,"activeCount":102},[],{"trials":5727,"activeCount":102},[],{"trials":5729,"activeCount":102},[5730],{"nctId":5731,"briefTitle":5732,"status":267,"phases":5733,"primaryCompletion":5734,"completion":5734,"enrollment":102,"conditions":5735,"interventions":5736},"NCT02317263","A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis",[91],"2099-01",[2711],[5722],{"trials":5738,"activeCount":102},[],{"trials":5740,"activeCount":102},[],{"trials":5742,"activeCount":102},[],{"intervention":2871,"totalTrials":253,"cells":5744},{"EARLY_PHASE1":5745,"PHASE1":5747,"PHASE2":5749,"PHASE3":5755,"PHASE4":5757,"NA":5759},{"trials":5746,"activeCount":102},[],{"trials":5748,"activeCount":102},[],{"trials":5750,"activeCount":102},[5751],{"nctId":2864,"briefTitle":2865,"status":140,"phases":5752,"primaryCompletion":2867,"completion":2867,"start":2163,"enrollment":2868,"conditions":5753,"interventions":5754},[90,91],[36],[2871,2458],{"trials":5756,"activeCount":102},[],{"trials":5758,"activeCount":102},[],{"trials":5760,"activeCount":102},[],{"intervention":5762,"totalTrials":253,"cells":5763},"rapamycin",{"EARLY_PHASE1":5764,"PHASE1":5766,"PHASE2":5768,"PHASE3":5778,"PHASE4":5780,"NA":5782},{"trials":5765,"activeCount":102},[],{"trials":5767,"activeCount":102},[],{"trials":5769,"activeCount":102},[5770],{"nctId":5771,"briefTitle":5772,"status":140,"phases":5773,"primaryCompletion":5774,"completion":5774,"start":2489,"enrollment":2386,"conditions":5775,"interventions":5776},"NCT00241189","Rapamycin vs Methotrexate in Diffuse SSc",[90,91],"2006-06",[4251],[5762,5777],"methotrexate",{"trials":5779,"activeCount":102},[],{"trials":5781,"activeCount":102},[],{"trials":5783,"activeCount":102},[],{"intervention":5777,"totalTrials":253,"cells":5785},{"EARLY_PHASE1":5786,"PHASE1":5788,"PHASE2":5790,"PHASE3":5796,"PHASE4":5798,"NA":5800},{"trials":5787,"activeCount":102},[],{"trials":5789,"activeCount":102},[],{"trials":5791,"activeCount":102},[5792],{"nctId":5771,"briefTitle":5772,"status":140,"phases":5793,"primaryCompletion":5774,"completion":5774,"start":2489,"enrollment":2386,"conditions":5794,"interventions":5795},[90,91],[4251],[5762,5777],{"trials":5797,"activeCount":102},[],{"trials":5799,"activeCount":102},[],{"trials":5801,"activeCount":102},[],{"intervention":5803,"totalTrials":253,"cells":5804},"AL-108",{"EARLY_PHASE1":5805,"PHASE1":5807,"PHASE2":5809,"PHASE3":5818,"PHASE4":5820,"NA":5822},{"trials":5806,"activeCount":102},[],{"trials":5808,"activeCount":102},[],{"trials":5810,"activeCount":102},[5811],{"nctId":5812,"briefTitle":5813,"status":140,"phases":5814,"primaryCompletion":4274,"completion":4274,"start":5815,"enrollment":5158,"conditions":5816,"interventions":5817},"NCT00505765","A Multicenter Study of NAP (AL-108) in Schizophrenia",[91],"2007-07",[30],[5803,5803],{"trials":5819,"activeCount":102},[],{"trials":5821,"activeCount":102},[],{"trials":5823,"activeCount":102},[],{"intervention":5494,"totalTrials":253,"cells":5825},{"EARLY_PHASE1":5826,"PHASE1":5828,"PHASE2":5830,"PHASE3":5836,"PHASE4":5838,"NA":5840},{"trials":5827,"activeCount":102},[],{"trials":5829,"activeCount":102},[],{"trials":5831,"activeCount":102},[5832],{"nctId":5487,"briefTitle":5488,"status":140,"phases":5833,"primaryCompletion":5490,"completion":2362,"start":5491,"enrollment":735,"conditions":5834,"interventions":5835},[90,91],[5112],[5494,5478,5495],{"trials":5837,"activeCount":102},[],{"trials":5839,"activeCount":102},[],{"trials":5841,"activeCount":102},[],{"intervention":5843,"totalTrials":253,"cells":5844},"mRNA-1273",{"EARLY_PHASE1":5845,"PHASE1":5847,"PHASE2":5849,"PHASE3":5862,"PHASE4":5864,"NA":5866},{"trials":5846,"activeCount":102},[],{"trials":5848,"activeCount":102},[],{"trials":5850,"activeCount":102},[5851],{"nctId":5852,"briefTitle":5853,"status":108,"phases":5854,"primaryCompletion":5855,"completion":5855,"start":5856,"enrollment":3065,"conditions":5857,"interventions":5861},"NCT05280158","High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients",[90,91],"2023-02-27","2022-03-10",[5858,5859,5860],"Lung Transplant Recipient","SARS-CoV-2","Immunosuppression",[5843],{"trials":5863,"activeCount":102},[],{"trials":5865,"activeCount":102},[],{"trials":5867,"activeCount":102},[],{"intervention":5869,"totalTrials":253,"cells":5870},"inhaled nitric oxide",{"EARLY_PHASE1":5871,"PHASE1":5873,"PHASE2":5875,"PHASE3":5886,"PHASE4":5888,"NA":5890},{"trials":5872,"activeCount":102},[],{"trials":5874,"activeCount":102},[],{"trials":5876,"activeCount":102},[5877],{"nctId":5878,"briefTitle":5879,"status":267,"phases":5880,"primaryCompletion":1324,"completion":952,"start":5881,"enrollment":102,"conditions":5882,"interventions":5885},"NCT04996667","Effect of iNO in Patients With Submassive and Massive PE",[91],"2026-06-01",[5883,5884],"Pulmonary Embolism","Pulmonary Embolism Subacute Massive",[5869],{"trials":5887,"activeCount":102},[],{"trials":5889,"activeCount":102},[],{"trials":5891,"activeCount":102},[],{"intervention":5893,"totalTrials":253,"cells":5894},"Cannabidiol (CBD) 600 mg",{"EARLY_PHASE1":5895,"PHASE1":5897,"PHASE2":5899,"PHASE3":5909,"PHASE4":5911,"NA":5913},{"trials":5896,"activeCount":102},[],{"trials":5898,"activeCount":102},[],{"trials":5900,"activeCount":102},[5901],{"nctId":5902,"briefTitle":5903,"status":140,"phases":5904,"primaryCompletion":5905,"completion":5905,"start":3064,"enrollment":2900,"conditions":5906,"interventions":5908},"NCT03787628","Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder",[91],"2024-03-12",[5907],"Opioid-use Disorder",[5893],{"trials":5910,"activeCount":102},[],{"trials":5912,"activeCount":102},[],{"trials":5914,"activeCount":102},[],{"intervention":5916,"totalTrials":253,"cells":5917},"Revefenacin Inhalation Solution [Yupelri]",{"EARLY_PHASE1":5918,"PHASE1":5920,"PHASE2":5922,"PHASE3":5935,"PHASE4":5937,"NA":5939},{"trials":5919,"activeCount":102},[],{"trials":5921,"activeCount":102},[],{"trials":5923,"activeCount":102},[5924],{"nctId":5925,"briefTitle":5926,"status":140,"phases":5927,"primaryCompletion":5928,"completion":5928,"start":5929,"enrollment":5930,"conditions":5931,"interventions":5933},"NCT04315558","Revefenacin in Acute Respiratory Insufficiency in COPD",[91],"2025-01-01","2020-11-01",21,[4155,5932],"Acute Respiratory Failure",[5916,5934],"Ipratropium Bromide",{"trials":5936,"activeCount":102},[],{"trials":5938,"activeCount":102},[],{"trials":5940,"activeCount":102},[],{"intervention":5934,"totalTrials":253,"cells":5942},{"EARLY_PHASE1":5943,"PHASE1":5945,"PHASE2":5947,"PHASE3":5953,"PHASE4":5955,"NA":5957},{"trials":5944,"activeCount":102},[],{"trials":5946,"activeCount":102},[],{"trials":5948,"activeCount":102},[5949],{"nctId":5925,"briefTitle":5926,"status":140,"phases":5950,"primaryCompletion":5928,"completion":5928,"start":5929,"enrollment":5930,"conditions":5951,"interventions":5952},[91],[4155,5932],[5916,5934],{"trials":5954,"activeCount":102},[],{"trials":5956,"activeCount":102},[],{"trials":5958,"activeCount":102},[],{"intervention":5960,"totalTrials":253,"cells":5961},"abatacept also known as Orencia also known as CTLA4-Ig",{"EARLY_PHASE1":5962,"PHASE1":5964,"PHASE2":5966,"PHASE3":5977,"PHASE4":5979,"NA":5981},{"trials":5963,"activeCount":102},[],{"trials":5965,"activeCount":102},[],{"trials":5967,"activeCount":102},[5968],{"nctId":5969,"briefTitle":5970,"status":108,"phases":5971,"primaryCompletion":5972,"completion":5972,"start":5973,"enrollment":235,"conditions":5974,"interventions":5976},"NCT02429934","Abatacept for SLE Arthritis (IM101-330)",[90,91],"2019-09-01","2015-10",[5975],"Systemic Lupus Erythematosus Arthritis",[5960],{"trials":5978,"activeCount":102},[],{"trials":5980,"activeCount":102},[],{"trials":5982,"activeCount":102},[],{"intervention":5984,"totalTrials":253,"cells":5985},"Cefixime 400 milligram Oral Capsule [Suprax]",{"EARLY_PHASE1":5986,"PHASE1":5988,"PHASE2":5990,"PHASE3":6003,"PHASE4":6005,"NA":6007},{"trials":5987,"activeCount":102},[],{"trials":5989,"activeCount":102},[],{"trials":5991,"activeCount":102},[5992],{"nctId":5993,"briefTitle":5994,"status":140,"phases":5995,"primaryCompletion":5996,"completion":5996,"start":5997,"enrollment":5617,"conditions":5998,"interventions":6001},"NCT03660488","Cefixime for Alternative Syphilis Treatment",[91],"2021-01-30","2018-09-03",[5999,6000],"Syphilis","Early Syphilis",[5984,6002],"Benzathine Penicillin G",{"trials":6004,"activeCount":102},[],{"trials":6006,"activeCount":102},[],{"trials":6008,"activeCount":102},[],{"intervention":6002,"totalTrials":253,"cells":6010},{"EARLY_PHASE1":6011,"PHASE1":6013,"PHASE2":6015,"PHASE3":6021,"PHASE4":6023,"NA":6025},{"trials":6012,"activeCount":102},[],{"trials":6014,"activeCount":102},[],{"trials":6016,"activeCount":102},[6017],{"nctId":5993,"briefTitle":5994,"status":140,"phases":6018,"primaryCompletion":5996,"completion":5996,"start":5997,"enrollment":5617,"conditions":6019,"interventions":6020},[91],[5999,6000],[5984,6002],{"trials":6022,"activeCount":102},[],{"trials":6024,"activeCount":102},[],{"trials":6026,"activeCount":102},[],{"intervention":6028,"totalTrials":253,"cells":6029},"Baclofen",{"EARLY_PHASE1":6030,"PHASE1":6032,"PHASE2":6034,"PHASE3":6044,"PHASE4":6046,"NA":6048},{"trials":6031,"activeCount":102},[],{"trials":6033,"activeCount":102},[],{"trials":6035,"activeCount":102},[6036],{"nctId":6037,"briefTitle":6038,"status":140,"phases":6039,"primaryCompletion":2972,"start":6040,"enrollment":102,"conditions":6041,"interventions":6043},"NCT00000303","Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse\u002FDependence - 6",[91],"1997-10",[6042],"Cocaine-Related Disorders",[6028],{"trials":6045,"activeCount":102},[],{"trials":6047,"activeCount":102},[],{"trials":6049,"activeCount":102},[],{"intervention":6051,"totalTrials":253,"cells":6052},"AZD7325",{"EARLY_PHASE1":6053,"PHASE1":6055,"PHASE2":6057,"PHASE3":6066,"PHASE4":6068,"NA":6070},{"trials":6054,"activeCount":102},[],{"trials":6056,"activeCount":102},[],{"trials":6058,"activeCount":102},[6059],{"nctId":6060,"briefTitle":6061,"status":140,"phases":6062,"primaryCompletion":6063,"completion":6063,"start":2666,"enrollment":659,"conditions":6064,"interventions":6065},"NCT01966679","Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial",[91],"2015-07",[4707],[6051],{"trials":6067,"activeCount":102},[],{"trials":6069,"activeCount":102},[],{"trials":6071,"activeCount":102},[],{"intervention":6073,"totalTrials":253,"cells":6074},"Org 24448",{"EARLY_PHASE1":6075,"PHASE1":6077,"PHASE2":6079,"PHASE3":6087,"PHASE4":6089,"NA":6091},{"trials":6076,"activeCount":102},[],{"trials":6078,"activeCount":102},[],{"trials":6080,"activeCount":102},[6081],{"nctId":6082,"briefTitle":6083,"status":267,"phases":6084,"primaryCompletion":4274,"completion":4274,"start":4274,"enrollment":102,"conditions":6085,"interventions":6086},"NCT00425815","Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia",[91],[30],[6073],{"trials":6088,"activeCount":102},[],{"trials":6090,"activeCount":102},[],{"trials":6092,"activeCount":102},[],{"intervention":6094,"totalTrials":253,"cells":6095},"MDMA",{"EARLY_PHASE1":6096,"PHASE1":6098,"PHASE2":6100,"PHASE3":6112,"PHASE4":6114,"NA":6116},{"trials":6097,"activeCount":102},[],{"trials":6099,"activeCount":102},[],{"trials":6101,"activeCount":102},[6102],{"nctId":6103,"briefTitle":6104,"status":267,"phases":6105,"primaryCompletion":6106,"completion":1197,"start":1273,"enrollment":102,"conditions":6107,"interventions":6111},"NCT06353282","MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents",[91],"2026-01-31",[6108,6109,6110],"PTSD, Post Traumatic Stress Disorder","Adolescents","Psychotherapy",[6094],{"trials":6113,"activeCount":102},[],{"trials":6115,"activeCount":102},[],{"trials":6117,"activeCount":102},[],{"intervention":5505,"totalTrials":253,"cells":6119},{"EARLY_PHASE1":6120,"PHASE1":6122,"PHASE2":6124,"PHASE3":6130,"PHASE4":6132,"NA":6134},{"trials":6121,"activeCount":102},[],{"trials":6123,"activeCount":102},[],{"trials":6125,"activeCount":102},[6126],{"nctId":5497,"briefTitle":5498,"status":140,"phases":6127,"primaryCompletion":5500,"completion":5500,"start":5501,"enrollment":4181,"conditions":6128,"interventions":6129},[90,91],[5503],[5505,5478,5495],{"trials":6131,"activeCount":102},[],{"trials":6133,"activeCount":102},[],{"trials":6135,"activeCount":102},[],{"intervention":277,"totalTrials":253,"cells":6137},{"EARLY_PHASE1":6138,"PHASE1":6140,"PHASE2":6142,"PHASE3":6148,"PHASE4":6150,"NA":6152},{"trials":6139,"activeCount":102},[],{"trials":6141,"activeCount":102},[],{"trials":6143,"activeCount":102},[6144],{"nctId":265,"briefTitle":266,"status":267,"phases":6145,"primaryCompletion":269,"completion":270,"start":271,"enrollment":102,"conditions":6146,"interventions":6147},[91],[273,274,275],[82,277,278,279],{"trials":6149,"activeCount":102},[],{"trials":6151,"activeCount":102},[],{"trials":6153,"activeCount":102},[],{"intervention":278,"totalTrials":253,"cells":6155},{"EARLY_PHASE1":6156,"PHASE1":6158,"PHASE2":6160,"PHASE3":6166,"PHASE4":6168,"NA":6170},{"trials":6157,"activeCount":102},[],{"trials":6159,"activeCount":102},[],{"trials":6161,"activeCount":102},[6162],{"nctId":265,"briefTitle":266,"status":267,"phases":6163,"primaryCompletion":269,"completion":270,"start":271,"enrollment":102,"conditions":6164,"interventions":6165},[91],[273,274,275],[82,277,278,279],{"trials":6167,"activeCount":102},[],{"trials":6169,"activeCount":102},[],{"trials":6171,"activeCount":102},[],{"intervention":279,"totalTrials":253,"cells":6173},{"EARLY_PHASE1":6174,"PHASE1":6176,"PHASE2":6178,"PHASE3":6184,"PHASE4":6186,"NA":6188},{"trials":6175,"activeCount":102},[],{"trials":6177,"activeCount":102},[],{"trials":6179,"activeCount":102},[6180],{"nctId":265,"briefTitle":266,"status":267,"phases":6181,"primaryCompletion":269,"completion":270,"start":271,"enrollment":102,"conditions":6182,"interventions":6183},[91],[273,274,275],[82,277,278,279],{"trials":6185,"activeCount":102},[],{"trials":6187,"activeCount":102},[],{"trials":6189,"activeCount":102},[],{"intervention":2713,"totalTrials":253,"cells":6191},{"EARLY_PHASE1":6192,"PHASE1":6194,"PHASE2":6196,"PHASE3":6202,"PHASE4":6204,"NA":6206},{"trials":6193,"activeCount":102},[],{"trials":6195,"activeCount":102},[],{"trials":6197,"activeCount":102},[6198],{"nctId":2706,"briefTitle":2707,"status":267,"phases":6199,"primaryCompletion":269,"completion":658,"start":2709,"enrollment":102,"conditions":6200,"interventions":6201},[91],[2711],[2713,2686],{"trials":6203,"activeCount":102},[],{"trials":6205,"activeCount":102},[],{"trials":6207,"activeCount":102},[],{"intervention":6209,"totalTrials":253,"cells":6210},"raltegravir",{"EARLY_PHASE1":6211,"PHASE1":6213,"PHASE2":6215,"PHASE3":6225,"PHASE4":6227,"NA":6229},{"trials":6212,"activeCount":102},[],{"trials":6214,"activeCount":102},[],{"trials":6216,"activeCount":102},[6217],{"nctId":6218,"briefTitle":6219,"status":140,"phases":6220,"primaryCompletion":6221,"completion":6221,"start":2589,"enrollment":5027,"conditions":6222,"interventions":6224},"NCT00656175","Raltegravir Therapy for Women With HIV and Fat Accumulation",[91],"2011-12",[24,6223],"Lipodystrophy",[6209],{"trials":6226,"activeCount":102},[],{"trials":6228,"activeCount":102},[],{"trials":6230,"activeCount":102},[],{"intervention":4745,"totalTrials":253,"cells":6232},{"EARLY_PHASE1":6233,"PHASE1":6235,"PHASE2":6237,"PHASE3":6243,"PHASE4":6245,"NA":6247},{"trials":6234,"activeCount":102},[],{"trials":6236,"activeCount":102},[],{"trials":6238,"activeCount":102},[6239],{"nctId":4738,"briefTitle":4739,"status":267,"phases":6240,"primaryCompletion":4741,"completion":4742,"start":4225,"enrollment":102,"conditions":6241,"interventions":6242},[91],[36],[4745,4746,4729],{"trials":6244,"activeCount":102},[],{"trials":6246,"activeCount":102},[],{"trials":6248,"activeCount":102},[],{"intervention":4746,"totalTrials":253,"cells":6250},{"EARLY_PHASE1":6251,"PHASE1":6253,"PHASE2":6255,"PHASE3":6261,"PHASE4":6263,"NA":6265},{"trials":6252,"activeCount":102},[],{"trials":6254,"activeCount":102},[],{"trials":6256,"activeCount":102},[6257],{"nctId":4738,"briefTitle":4739,"status":267,"phases":6258,"primaryCompletion":4741,"completion":4742,"start":4225,"enrollment":102,"conditions":6259,"interventions":6260},[91],[36],[4745,4746,4729],{"trials":6262,"activeCount":102},[],{"trials":6264,"activeCount":102},[],{"trials":6266,"activeCount":102},[],{"intervention":6268,"totalTrials":253,"cells":6269},"MK-0777",{"EARLY_PHASE1":6270,"PHASE1":6272,"PHASE2":6274,"PHASE3":6282,"PHASE4":6284,"NA":6286},{"trials":6271,"activeCount":102},[],{"trials":6273,"activeCount":102},[],{"trials":6275,"activeCount":102},[6276],{"nctId":6277,"briefTitle":6278,"status":140,"phases":6279,"primaryCompletion":4778,"completion":4778,"start":5815,"enrollment":5158,"conditions":6280,"interventions":6281},"NCT00505076","Treatment Study for Cognitive Deficits in Schizophrenia",[91],[30],[6268,6268],{"trials":6283,"activeCount":102},[],{"trials":6285,"activeCount":102},[],{"trials":6287,"activeCount":102},[],{"intervention":6289,"totalTrials":253,"cells":6290},"Microplasmin",{"EARLY_PHASE1":6291,"PHASE1":6293,"PHASE2":6295,"PHASE3":6304,"PHASE4":6306,"NA":6308},{"trials":6292,"activeCount":102},[],{"trials":6294,"activeCount":102},[],{"trials":6296,"activeCount":102},[6297],{"nctId":6298,"briefTitle":6299,"status":553,"phases":6300,"primaryCompletion":4803,"completion":6221,"start":2658,"enrollment":19,"conditions":6301,"interventions":6303},"NCT00996684","Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration",[91],[6302],"Macular Degeneration",[6289],{"trials":6305,"activeCount":102},[],{"trials":6307,"activeCount":102},[],{"trials":6309,"activeCount":102},[],{"intervention":6311,"totalTrials":253,"cells":6312},"L-DOPA versus Placebo",{"EARLY_PHASE1":6313,"PHASE1":6315,"PHASE2":6317,"PHASE3":6328,"PHASE4":6330,"NA":6332},{"trials":6314,"activeCount":102},[],{"trials":6316,"activeCount":102},[],{"trials":6318,"activeCount":102},[6319],{"nctId":6320,"briefTitle":6321,"status":553,"phases":6322,"primaryCompletion":6323,"completion":6323,"start":6324,"enrollment":16,"conditions":6325,"interventions":6327},"NCT03243552","Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD",[91],"2023-12","2017-06-01",[6326],"ASD",[6311],{"trials":6329,"activeCount":102},[],{"trials":6331,"activeCount":102},[],{"trials":6333,"activeCount":102},[],{"intervention":5584,"totalTrials":253,"cells":6335},{"EARLY_PHASE1":6336,"PHASE1":6338,"PHASE2":6340,"PHASE3":6346,"PHASE4":6348,"NA":6350},{"trials":6337,"activeCount":102},[],{"trials":6339,"activeCount":102},[],{"trials":6341,"activeCount":102},[6342],{"nctId":5576,"briefTitle":5577,"status":140,"phases":6343,"primaryCompletion":2825,"completion":2825,"start":5579,"enrollment":5580,"conditions":6344,"interventions":6345},[91],[5582],[5567,5584],{"trials":6347,"activeCount":102},[],{"trials":6349,"activeCount":102},[],{"trials":6351,"activeCount":102},[],{"intervention":2552,"totalTrials":253,"cells":6353},{"EARLY_PHASE1":6354,"PHASE1":6356,"PHASE2":6358,"PHASE3":6364,"PHASE4":6366,"NA":6368},{"trials":6355,"activeCount":102},[],{"trials":6357,"activeCount":102},[],{"trials":6359,"activeCount":102},[6360],{"nctId":2544,"briefTitle":2545,"status":140,"phases":6361,"primaryCompletion":2547,"completion":2547,"start":2548,"enrollment":144,"conditions":6362,"interventions":6363},[91],[2550],[2552,2553],{"trials":6365,"activeCount":102},[],{"trials":6367,"activeCount":102},[],{"trials":6369,"activeCount":102},[],{"intervention":6371,"totalTrials":253,"cells":6372},"Imatinib",{"EARLY_PHASE1":6373,"PHASE1":6375,"PHASE2":6377,"PHASE3":6389,"PHASE4":6391,"NA":6393},{"trials":6374,"activeCount":102},[],{"trials":6376,"activeCount":102},[],{"trials":6378,"activeCount":102},[6379],{"nctId":6380,"briefTitle":6381,"status":140,"phases":6382,"primaryCompletion":6383,"completion":6384,"start":6385,"enrollment":34,"conditions":6386,"interventions":6388},"NCT00512902","A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis",[90,91],"2008-11","2008-12","2007-08",[6387,4251],"Alveolitis",[6371,6371],{"trials":6390,"activeCount":102},[],{"trials":6392,"activeCount":102},[],{"trials":6394,"activeCount":102},[],{"intervention":6396,"totalTrials":253,"cells":6397},"Listerine Antiseptic Mouthwash Product",{"EARLY_PHASE1":6398,"PHASE1":6400,"PHASE2":6402,"PHASE3":6416,"PHASE4":6418,"NA":6420},{"trials":6399,"activeCount":102},[],{"trials":6401,"activeCount":102},[],{"trials":6403,"activeCount":102},[6404],{"nctId":6405,"briefTitle":6406,"status":140,"phases":6407,"primaryCompletion":6408,"completion":6409,"start":6410,"enrollment":6411,"conditions":6412,"interventions":6414},"NCT04966507","Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention",[91],"2025-05-16","2025-12-12","2022-02-17",89,[6413],"Gonorrhea",[6396,6415],"Biotene Mouthwash",{"trials":6417,"activeCount":102},[],{"trials":6419,"activeCount":102},[],{"trials":6421,"activeCount":102},[],{"intervention":6415,"totalTrials":253,"cells":6423},{"EARLY_PHASE1":6424,"PHASE1":6426,"PHASE2":6428,"PHASE3":6434,"PHASE4":6436,"NA":6438},{"trials":6425,"activeCount":102},[],{"trials":6427,"activeCount":102},[],{"trials":6429,"activeCount":102},[6430],{"nctId":6405,"briefTitle":6406,"status":140,"phases":6431,"primaryCompletion":6408,"completion":6409,"start":6410,"enrollment":6411,"conditions":6432,"interventions":6433},[91],[6413],[6396,6415],{"trials":6435,"activeCount":102},[],{"trials":6437,"activeCount":102},[],{"trials":6439,"activeCount":102},[],{"intervention":2439,"totalTrials":253,"cells":6441},{"EARLY_PHASE1":6442,"PHASE1":6444,"PHASE2":6446,"PHASE3":6452,"PHASE4":6454,"NA":6456},{"trials":6443,"activeCount":102},[],{"trials":6445,"activeCount":102},[],{"trials":6447,"activeCount":102},[6448],{"nctId":2430,"briefTitle":2431,"status":140,"phases":6449,"primaryCompletion":2433,"completion":2433,"start":2434,"enrollment":2435,"conditions":6450,"interventions":6451},[91],[2437,36],[2152,2439],{"trials":6453,"activeCount":102},[],{"trials":6455,"activeCount":102},[],{"trials":6457,"activeCount":102},[],{"intervention":6459,"totalTrials":253,"cells":6460},"Lorazepam",{"EARLY_PHASE1":6461,"PHASE1":6463,"PHASE2":6465,"PHASE3":6476,"PHASE4":6478,"NA":6480},{"trials":6462,"activeCount":102},[],{"trials":6464,"activeCount":102},[],{"trials":6466,"activeCount":102},[6467],{"nctId":6468,"briefTitle":6469,"status":267,"phases":6470,"primaryCompletion":6471,"completion":6471,"start":3113,"enrollment":102,"conditions":6472,"interventions":6474},"NCT00123578","GHB Withdrawal Symptoms and Effectiveness of Treatment With Lorazepam Versus Pentobarbital - 1",[90,91],"2008-08",[6473],"Substance-Related Disorders",[6459,6475],"Pentobarbital",{"trials":6477,"activeCount":102},[],{"trials":6479,"activeCount":102},[],{"trials":6481,"activeCount":102},[],{"intervention":6475,"totalTrials":253,"cells":6483},{"EARLY_PHASE1":6484,"PHASE1":6486,"PHASE2":6488,"PHASE3":6494,"PHASE4":6496,"NA":6498},{"trials":6485,"activeCount":102},[],{"trials":6487,"activeCount":102},[],{"trials":6489,"activeCount":102},[6490],{"nctId":6468,"briefTitle":6469,"status":267,"phases":6491,"primaryCompletion":6471,"completion":6471,"start":3113,"enrollment":102,"conditions":6492,"interventions":6493},[90,91],[6473],[6459,6475],{"trials":6495,"activeCount":102},[],{"trials":6497,"activeCount":102},[],{"trials":6499,"activeCount":102},[],{"intervention":6501,"totalTrials":253,"cells":6502},"4-Aminopyridine",{"EARLY_PHASE1":6503,"PHASE1":6505,"PHASE2":6507,"PHASE3":6516,"PHASE4":6518,"NA":6520},{"trials":6504,"activeCount":102},[],{"trials":6506,"activeCount":102},[],{"trials":6508,"activeCount":102},[6509],{"nctId":6510,"briefTitle":6511,"status":267,"phases":6512,"enrollment":102,"conditions":6513,"interventions":6515},"NCT01543750","4-Aminopyridine in Episodic Ataxia Type 2",[91],[6514],"Episodic Ataxia Type 2",[6501],{"trials":6517,"activeCount":102},[],{"trials":6519,"activeCount":102},[],{"trials":6521,"activeCount":102},[],{"intervention":5597,"totalTrials":253,"cells":6523},{"EARLY_PHASE1":6524,"PHASE1":6526,"PHASE2":6528,"PHASE3":6534,"PHASE4":6536,"NA":6538},{"trials":6525,"activeCount":102},[],{"trials":6527,"activeCount":102},[],{"trials":6529,"activeCount":102},[6530],{"nctId":5586,"briefTitle":5587,"status":553,"phases":6531,"primaryCompletion":5589,"completion":5590,"start":2562,"enrollment":852,"conditions":6532,"interventions":6533},[91],[5592,5593,5594],[5596,5597],{"trials":6535,"activeCount":102},[],{"trials":6537,"activeCount":102},[],{"trials":6539,"activeCount":102},[],{"intervention":6541,"totalTrials":253,"cells":6542},"Switch to E\u002FC\u002FFTC\u002FTAF daily",{"EARLY_PHASE1":6543,"PHASE1":6545,"PHASE2":6547,"PHASE3":6560,"PHASE4":6562,"NA":6564},{"trials":6544,"activeCount":102},[],{"trials":6546,"activeCount":102},[],{"trials":6548,"activeCount":102},[6549],{"nctId":6550,"briefTitle":6551,"status":140,"phases":6552,"primaryCompletion":271,"completion":271,"start":6553,"enrollment":22,"conditions":6554,"interventions":6559},"NCT03251144","Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)",[90,91],"2019-04-01",[6555,6556,6557,6558],"HIV\u002FAIDS","Antiviral Toxicity","Antiviral Drug Adverse Reaction","Mitochondrial Alteration",[6541],{"trials":6561,"activeCount":102},[],{"trials":6563,"activeCount":102},[],{"trials":6565,"activeCount":102},[],{"intervention":6567,"totalTrials":253,"cells":6568},"Colchicine",{"EARLY_PHASE1":6569,"PHASE1":6571,"PHASE2":6573,"PHASE3":6584,"PHASE4":6586,"NA":6588},{"trials":6570,"activeCount":102},[],{"trials":6572,"activeCount":102},[],{"trials":6574,"activeCount":102},[6575],{"nctId":6576,"briefTitle":6577,"status":140,"phases":6578,"primaryCompletion":6579,"completion":6579,"start":6580,"enrollment":6581,"conditions":6582,"interventions":6583},"NCT04355143","Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)",[91],"2021-07-21","2020-05-01",93,[5668],[6567],{"trials":6585,"activeCount":102},[],{"trials":6587,"activeCount":102},[],{"trials":6589,"activeCount":102},[],{"intervention":6591,"totalTrials":253,"cells":6592},"MA09-hRPE Cellular Therapy",{"EARLY_PHASE1":6593,"PHASE1":6595,"PHASE2":6597,"PHASE3":6607,"PHASE4":6609,"NA":6611},{"trials":6594,"activeCount":102},[],{"trials":6596,"activeCount":102},[],{"trials":6598,"activeCount":102},[6599],{"nctId":6600,"briefTitle":6601,"status":267,"phases":6602,"primaryCompletion":6603,"completion":6603,"start":3089,"enrollment":102,"conditions":6604,"interventions":6606},"NCT02122159","Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration",[90,91],"2016-07",[6605],"Myopic Macular Degeneration",[6591],{"trials":6608,"activeCount":102},[],{"trials":6610,"activeCount":102},[],{"trials":6612,"activeCount":102},[],{"intervention":6614,"totalTrials":253,"cells":6615},"Glycerly Trinitrate",{"EARLY_PHASE1":6616,"PHASE1":6618,"PHASE2":6620,"PHASE3":6632,"PHASE4":6634,"NA":6636},{"trials":6617,"activeCount":102},[],{"trials":6619,"activeCount":102},[],{"trials":6621,"activeCount":102},[6622],{"nctId":6623,"briefTitle":6624,"status":108,"phases":6625,"primaryCompletion":6626,"completion":6627,"start":6628,"enrollment":98,"conditions":6629,"interventions":6631},"NCT01811693","Field Administration of Stroke Therapy-Blood Pressure Lowering",[91],"2013-09-10","2013-12-09","2013-04",[6630,4600],"Intracerebral Hemorrhage",[6614,6614,6614],{"trials":6633,"activeCount":102},[],{"trials":6635,"activeCount":102},[],{"trials":6637,"activeCount":102},[],{"intervention":6639,"totalTrials":253,"cells":6640},"Flutamide",{"EARLY_PHASE1":6641,"PHASE1":6643,"PHASE2":6645,"PHASE3":6655,"PHASE4":6657,"NA":6659},{"trials":6642,"activeCount":102},[],{"trials":6644,"activeCount":102},[],{"trials":6646,"activeCount":102},[6647],{"nctId":6648,"briefTitle":6649,"status":140,"phases":6650,"primaryCompletion":6651,"completion":6651,"start":6628,"enrollment":28,"conditions":6652,"interventions":6654},"NCT01889199","Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women",[91],"2023-07-06",[6653],"Polycystic Ovary Syndrome (PCOS)",[6639],{"trials":6656,"activeCount":102},[],{"trials":6658,"activeCount":102},[],{"trials":6660,"activeCount":102},[],{"intervention":6662,"totalTrials":253,"cells":6663},"Omegaven",{"EARLY_PHASE1":6664,"PHASE1":6666,"PHASE2":6668,"PHASE3":6679,"PHASE4":6681,"NA":6683},{"trials":6665,"activeCount":102},[],{"trials":6667,"activeCount":102},[],{"trials":6669,"activeCount":102},[6670],{"nctId":6671,"briefTitle":6672,"status":108,"phases":6673,"primaryCompletion":6674,"completion":6675,"start":6676,"enrollment":2403,"conditions":6677,"interventions":6678},"NCT00969332","A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease",[91],"2019-01-12","2019-02-12","2009-08",[3732],[6662],{"trials":6680,"activeCount":102},[],{"trials":6682,"activeCount":102},[],{"trials":6684,"activeCount":102},[],{"intervention":6686,"totalTrials":253,"cells":6687},"Bupropion SR 150mg tabs",{"EARLY_PHASE1":6688,"PHASE1":6690,"PHASE2":6692,"PHASE3":6701,"PHASE4":6703,"NA":6705},{"trials":6689,"activeCount":102},[],{"trials":6691,"activeCount":102},[],{"trials":6693,"activeCount":102},[6694],{"nctId":6695,"briefTitle":6696,"status":140,"phases":6697,"primaryCompletion":6221,"completion":6221,"start":2658,"enrollment":3065,"conditions":6698,"interventions":6700},"NCT00994448","Pilot Trial of Bupropion Versus Placebo for Methamphetamine Abuse in Adolescents",[91],[6699],"Adolescent Methamphetamine Abuse",[6686],{"trials":6702,"activeCount":102},[],{"trials":6704,"activeCount":102},[],{"trials":6706,"activeCount":102},[],{"intervention":6708,"totalTrials":253,"cells":6709},"Lentiviral G1XCGD Gene Therapy",{"EARLY_PHASE1":6710,"PHASE1":6712,"PHASE2":6714,"PHASE3":6726,"PHASE4":6728,"NA":6730},{"trials":6711,"activeCount":102},[],{"trials":6713,"activeCount":102},[],{"trials":6715,"activeCount":102},[6716],{"nctId":6717,"briefTitle":6718,"status":140,"phases":6719,"primaryCompletion":6720,"completion":6721,"start":6722,"enrollment":735,"conditions":6723,"interventions":6725},"NCT02234934","Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease",[90,91],"2024-09-01","2024-12-01","2015-10-29",[6724],"Granulomatous Disease, Chronic, X-linked",[6708],{"trials":6727,"activeCount":102},[],{"trials":6729,"activeCount":102},[],{"trials":6731,"activeCount":102},[],{"intervention":6733,"totalTrials":253,"cells":6734},"Amantadine",{"EARLY_PHASE1":6735,"PHASE1":6737,"PHASE2":6739,"PHASE3":6749,"PHASE4":6751,"NA":6753},{"trials":6736,"activeCount":102},[],{"trials":6738,"activeCount":102},[],{"trials":6740,"activeCount":102},[6741],{"nctId":6742,"briefTitle":6743,"status":140,"phases":6744,"primaryCompletion":6745,"start":6746,"enrollment":102,"conditions":6747,"interventions":6748},"NCT00000301","Rapid Evaluation of Amantadine for Treatment of Cocaine Abuse\u002FDependence - 4",[91],"1998-06","1996-03",[6042],[6733],{"trials":6750,"activeCount":102},[],{"trials":6752,"activeCount":102},[],{"trials":6754,"activeCount":102},[],{"intervention":6756,"totalTrials":253,"cells":6757},"Androgel 10 grams of gel containing 100 mg of testosterone",{"EARLY_PHASE1":6758,"PHASE1":6760,"PHASE2":6762,"PHASE3":6770,"PHASE4":6772,"NA":6774},{"trials":6759,"activeCount":102},[],{"trials":6761,"activeCount":102},[],{"trials":6763,"activeCount":102},[6764],{"nctId":6765,"briefTitle":6766,"status":140,"phases":6767,"primaryCompletion":5579,"completion":5579,"start":3114,"enrollment":735,"conditions":6768,"interventions":6769},"NCT00405353","Testosterone Treatment for Multiple Sclerosis",[90,91],[2711],[6756],{"trials":6771,"activeCount":102},[],{"trials":6773,"activeCount":102},[],{"trials":6775,"activeCount":102},[],{"intervention":6777,"totalTrials":2463,"cells":6778},"Intranasal placebo",{"EARLY_PHASE1":6779,"PHASE1":6809,"PHASE2":6820,"PHASE3":6822,"PHASE4":6824,"NA":6826},{"trials":6780,"activeCount":102},[6781,6790,6796,6803],{"nctId":6782,"briefTitle":6783,"status":140,"phases":6784,"primaryCompletion":6603,"completion":6603,"start":245,"enrollment":6785,"conditions":6786,"interventions":6788},"NCT02393456","Oxytocin and the Social Brain",[89],161,[6787],"Social Psychology",[6789,6777],"Intranasal oxytocin",{"nctId":6791,"briefTitle":6792,"status":140,"phases":6793,"primaryCompletion":6603,"completion":6603,"start":245,"enrollment":6785,"conditions":6794,"interventions":6795},"NCT02393443","Oxytocin and Learning for Teaching",[89],[6787],[6789,6777],{"nctId":6797,"briefTitle":6798,"status":140,"phases":6799,"primaryCompletion":6603,"completion":6603,"start":245,"enrollment":5436,"conditions":6800,"interventions":6801},"NCT02394054","Vasopressin and the Social Brain",[89],[6787],[6802,6777],"Intranasal vasopressin",{"nctId":6804,"briefTitle":6805,"status":140,"phases":6806,"primaryCompletion":2899,"completion":2899,"start":2164,"enrollment":1249,"conditions":6807,"interventions":6808},"NCT01680718","Neuropeptides and Social Behavior",[89],[6787],[6789,6802,6777],{"trials":6810,"activeCount":102},[6811],{"nctId":6812,"briefTitle":6813,"status":140,"phases":6814,"primaryCompletion":2911,"completion":2911,"start":788,"enrollment":1032,"conditions":6815,"interventions":6817},"NCT01900301","Generalization of Extinction Learning",[90],[6816],"Social Anxiety Disorder",[6818,6819],"Scopolamine","intranasal placebo",{"trials":6821,"activeCount":102},[],{"trials":6823,"activeCount":102},[],{"trials":6825,"activeCount":102},[],{"trials":6827,"activeCount":102},[],{"intervention":6829,"totalTrials":253,"cells":6830},"Ibudilast 20mg",{"EARLY_PHASE1":6831,"PHASE1":6833,"PHASE2":6843,"PHASE3":6845,"PHASE4":6847,"NA":6849},{"trials":6832,"activeCount":102},[],{"trials":6834,"activeCount":102},[6835],{"nctId":6836,"briefTitle":6837,"status":140,"phases":6838,"primaryCompletion":3089,"completion":3089,"start":246,"enrollment":2868,"conditions":6839,"interventions":6841},"NCT01217970","Safety Interaction Trial Ibudilast and Methamphetamine",[90],[6840,2419],"Methamphetamine-dependence",[6829,6842],"Ibudilast 50mg",{"trials":6844,"activeCount":102},[],{"trials":6846,"activeCount":102},[],{"trials":6848,"activeCount":102},[],{"trials":6850,"activeCount":102},[],{"intervention":6842,"totalTrials":253,"cells":6852},{"EARLY_PHASE1":6853,"PHASE1":6855,"PHASE2":6861,"PHASE3":6863,"PHASE4":6865,"NA":6867},{"trials":6854,"activeCount":102},[],{"trials":6856,"activeCount":102},[6857],{"nctId":6836,"briefTitle":6837,"status":140,"phases":6858,"primaryCompletion":3089,"completion":3089,"start":246,"enrollment":2868,"conditions":6859,"interventions":6860},[90],[6840,2419],[6829,6842],{"trials":6862,"activeCount":102},[],{"trials":6864,"activeCount":102},[],{"trials":6866,"activeCount":102},[],{"trials":6868,"activeCount":102},[],{"intervention":6870,"totalTrials":253,"cells":6871},"Pomaglumetad methionil",{"EARLY_PHASE1":6872,"PHASE1":6874,"PHASE2":6884,"PHASE3":6886,"PHASE4":6888,"NA":6890},{"trials":6873,"activeCount":102},[],{"trials":6875,"activeCount":102},[6876],{"nctId":6877,"briefTitle":6878,"status":108,"phases":6879,"primaryCompletion":555,"completion":555,"start":6880,"enrollment":3065,"conditions":6881,"interventions":6883},"NCT03106571","Study of Pomaglumetad and Methamphetamine",[90],"2017-08-01",[6882],"Methamphetamine Use Disorder",[6870,5438],{"trials":6885,"activeCount":102},[],{"trials":6887,"activeCount":102},[],{"trials":6889,"activeCount":102},[],{"trials":6891,"activeCount":102},[],{"intervention":5438,"totalTrials":253,"cells":6893},{"EARLY_PHASE1":6894,"PHASE1":6896,"PHASE2":6902,"PHASE3":6904,"PHASE4":6906,"NA":6908},{"trials":6895,"activeCount":102},[],{"trials":6897,"activeCount":102},[6898],{"nctId":6877,"briefTitle":6878,"status":108,"phases":6899,"primaryCompletion":555,"completion":555,"start":6880,"enrollment":3065,"conditions":6900,"interventions":6901},[90],[6882],[6870,5438],{"trials":6903,"activeCount":102},[],{"trials":6905,"activeCount":102},[],{"trials":6907,"activeCount":102},[],{"trials":6909,"activeCount":102},[],{"intervention":6911,"totalTrials":253,"cells":6912},"Flunisolide-HFA",{"EARLY_PHASE1":6913,"PHASE1":6915,"PHASE2":6926,"PHASE3":6928,"PHASE4":6930,"NA":6932},{"trials":6914,"activeCount":102},[],{"trials":6916,"activeCount":102},[6917],{"nctId":6918,"briefTitle":6919,"status":140,"phases":6920,"enrollment":6921,"conditions":6922,"interventions":6924},"NCT00203684","Mentored Patient-Oriented Research Career Development Award",[90],57,[4535,6923],"Distal Lung Inflammation",[6911,6925],"Flunisolide-CFC",{"trials":6927,"activeCount":102},[],{"trials":6929,"activeCount":102},[],{"trials":6931,"activeCount":102},[],{"trials":6933,"activeCount":102},[],{"intervention":6925,"totalTrials":253,"cells":6935},{"EARLY_PHASE1":6936,"PHASE1":6938,"PHASE2":6944,"PHASE3":6946,"PHASE4":6948,"NA":6950},{"trials":6937,"activeCount":102},[],{"trials":6939,"activeCount":102},[6940],{"nctId":6918,"briefTitle":6919,"status":140,"phases":6941,"enrollment":6921,"conditions":6942,"interventions":6943},[90],[4535,6923],[6911,6925],{"trials":6945,"activeCount":102},[],{"trials":6947,"activeCount":102},[],{"trials":6949,"activeCount":102},[],{"trials":6951,"activeCount":102},[],{"intervention":6953,"totalTrials":253,"cells":6954},"anti-SARS-CoV-2 human convalescent plasma",{"EARLY_PHASE1":6955,"PHASE1":6957,"PHASE2":6968,"PHASE3":6970,"PHASE4":6972,"NA":6974},{"trials":6956,"activeCount":102},[],{"trials":6958,"activeCount":102},[6959],{"nctId":6960,"briefTitle":6961,"status":553,"phases":6962,"primaryCompletion":6963,"completion":4889,"start":6964,"enrollment":19,"conditions":6965,"interventions":6967},"NCT04462848","Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions",[90],"2024-09","2020-08",[6966],"Corona Virus Infection",[6953],{"trials":6969,"activeCount":102},[],{"trials":6971,"activeCount":102},[],{"trials":6973,"activeCount":102},[],{"trials":6975,"activeCount":102},[],{"intervention":6977,"totalTrials":253,"cells":6978},"Varenicline, then placebo",{"EARLY_PHASE1":6979,"PHASE1":6981,"PHASE2":6994,"PHASE3":6996,"PHASE4":6998,"NA":7000},{"trials":6980,"activeCount":102},[],{"trials":6982,"activeCount":102},[6983],{"nctId":6984,"briefTitle":6985,"status":140,"phases":6986,"primaryCompletion":6676,"completion":4778,"start":6987,"enrollment":6988,"conditions":6989,"interventions":6993},"NCT00713479","An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers",[90],"2008-07",8,[6990,6991,6992],"Methamphetamine Addiction","Crystal Meth Addiction","Amphetamine Addiction",[6977],{"trials":6995,"activeCount":102},[],{"trials":6997,"activeCount":102},[],{"trials":6999,"activeCount":102},[],{"trials":7001,"activeCount":102},[],{"intervention":7003,"totalTrials":253,"cells":7004},"Rituximab",{"EARLY_PHASE1":7005,"PHASE1":7007,"PHASE2":7018,"PHASE3":7020,"PHASE4":7022,"NA":7024},{"trials":7006,"activeCount":102},[],{"trials":7008,"activeCount":102},[7009],{"nctId":7010,"briefTitle":7011,"status":140,"phases":7012,"primaryCompletion":7013,"completion":7013,"start":7014,"enrollment":161,"conditions":7015,"interventions":7017},"NCT06186219","Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout",[90],"2024-11-22","2024-04-10",[7016],"Tophaceous Gout",[7003],{"trials":7019,"activeCount":102},[],{"trials":7021,"activeCount":102},[],{"trials":7023,"activeCount":102},[],{"trials":7025,"activeCount":102},[],{"intervention":7027,"totalTrials":253,"cells":7028},"LAIV",{"EARLY_PHASE1":7029,"PHASE1":7031,"PHASE2":7040,"PHASE3":7042,"PHASE4":7044,"NA":7046},{"trials":7030,"activeCount":102},[],{"trials":7032,"activeCount":102},[7033],{"nctId":7034,"briefTitle":7035,"status":140,"phases":7036,"primaryCompletion":538,"completion":538,"start":4532,"enrollment":2386,"conditions":7037,"interventions":7039},"NCT02597647","Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection",[90],[7038],"Influenza",[7027],{"trials":7041,"activeCount":102},[],{"trials":7043,"activeCount":102},[],{"trials":7045,"activeCount":102},[],{"trials":7047,"activeCount":102},[],{"intervention":7049,"totalTrials":253,"cells":7050},"20 mg CBD Cannabis",{"EARLY_PHASE1":7051,"PHASE1":7053,"PHASE2":7066,"PHASE3":7068,"PHASE4":7070,"NA":7072},{"trials":7052,"activeCount":102},[],{"trials":7054,"activeCount":102},[7055],{"nctId":7056,"briefTitle":7057,"status":140,"phases":7058,"primaryCompletion":7059,"completion":7060,"start":7061,"enrollment":3065,"conditions":7062,"interventions":7063},"NCT05037487","Evaluation of Smoked THC and CBD in Men and Women",[90],"2025-01-07","2025-06-08","2022-09-01",[1455,1456,1457],[7049,7064,7065],"20 mg CBD + 20 mg THC Cannabis","20 mg THC Cannabis",{"trials":7067,"activeCount":102},[],{"trials":7069,"activeCount":102},[],{"trials":7071,"activeCount":102},[],{"trials":7073,"activeCount":102},[],{"intervention":7064,"totalTrials":253,"cells":7075},{"EARLY_PHASE1":7076,"PHASE1":7078,"PHASE2":7084,"PHASE3":7086,"PHASE4":7088,"NA":7090},{"trials":7077,"activeCount":102},[],{"trials":7079,"activeCount":102},[7080],{"nctId":7056,"briefTitle":7057,"status":140,"phases":7081,"primaryCompletion":7059,"completion":7060,"start":7061,"enrollment":3065,"conditions":7082,"interventions":7083},[90],[1455,1456,1457],[7049,7064,7065],{"trials":7085,"activeCount":102},[],{"trials":7087,"activeCount":102},[],{"trials":7089,"activeCount":102},[],{"trials":7091,"activeCount":102},[],{"intervention":7065,"totalTrials":253,"cells":7093},{"EARLY_PHASE1":7094,"PHASE1":7096,"PHASE2":7102,"PHASE3":7104,"PHASE4":7106,"NA":7108},{"trials":7095,"activeCount":102},[],{"trials":7097,"activeCount":102},[7098],{"nctId":7056,"briefTitle":7057,"status":140,"phases":7099,"primaryCompletion":7059,"completion":7060,"start":7061,"enrollment":3065,"conditions":7100,"interventions":7101},[90],[1455,1456,1457],[7049,7064,7065],{"trials":7103,"activeCount":102},[],{"trials":7105,"activeCount":102},[],{"trials":7107,"activeCount":102},[],{"trials":7109,"activeCount":102},[],{"intervention":7111,"totalTrials":253,"cells":7112},"Exenatide",{"EARLY_PHASE1":7113,"PHASE1":7115,"PHASE2":7124,"PHASE3":7126,"PHASE4":7128,"NA":7130},{"trials":7114,"activeCount":102},[],{"trials":7116,"activeCount":102},[7117],{"nctId":7118,"briefTitle":7119,"status":140,"phases":7120,"primaryCompletion":2722,"completion":2838,"start":6221,"enrollment":144,"conditions":7121,"interventions":7122},"NCT01501084","Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women",[90],[33],[7111,7123],"Normal saline .2cc subcutaneous",{"trials":7125,"activeCount":102},[],{"trials":7127,"activeCount":102},[],{"trials":7129,"activeCount":102},[],{"trials":7131,"activeCount":102},[],{"intervention":7123,"totalTrials":253,"cells":7133},{"EARLY_PHASE1":7134,"PHASE1":7136,"PHASE2":7142,"PHASE3":7144,"PHASE4":7146,"NA":7148},{"trials":7135,"activeCount":102},[],{"trials":7137,"activeCount":102},[7138],{"nctId":7118,"briefTitle":7119,"status":140,"phases":7139,"primaryCompletion":2722,"completion":2838,"start":6221,"enrollment":144,"conditions":7140,"interventions":7141},[90],[33],[7111,7123],{"trials":7143,"activeCount":102},[],{"trials":7145,"activeCount":102},[],{"trials":7147,"activeCount":102},[],{"trials":7149,"activeCount":102},[],{"intervention":7151,"totalTrials":253,"cells":7152},"UC-781 microbicide gel",{"EARLY_PHASE1":7153,"PHASE1":7155,"PHASE2":7165,"PHASE3":7167,"PHASE4":7169,"NA":7171},{"trials":7154,"activeCount":102},[],{"trials":7156,"activeCount":102},[7157],{"nctId":7158,"briefTitle":7159,"status":140,"phases":7160,"completion":7161,"start":2971,"enrollment":7162,"conditions":7163,"interventions":7164},"NCT00408538","Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally",[90],"2008-04",36,[24],[7151],{"trials":7166,"activeCount":102},[],{"trials":7168,"activeCount":102},[],{"trials":7170,"activeCount":102},[],{"trials":7172,"activeCount":102},[],{"intervention":7174,"totalTrials":253,"cells":7175},"Lovastatin",{"EARLY_PHASE1":7176,"PHASE1":7178,"PHASE2":7188,"PHASE3":7190,"PHASE4":7192,"NA":7194},{"trials":7177,"activeCount":102},[],{"trials":7179,"activeCount":102},[7180],{"nctId":7181,"briefTitle":7182,"status":140,"phases":7183,"primaryCompletion":7184,"completion":7184,"start":4778,"enrollment":2512,"conditions":7185,"interventions":7187},"NCT00352599","Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)",[90],"2014-03",[7186],"Neurofibromatosis 1",[7174,7174],{"trials":7189,"activeCount":102},[],{"trials":7191,"activeCount":102},[],{"trials":7193,"activeCount":102},[],{"trials":7195,"activeCount":102},[],{"intervention":645,"totalTrials":253,"cells":7197},{"EARLY_PHASE1":7198,"PHASE1":7200,"PHASE2":7206,"PHASE3":7208,"PHASE4":7210,"NA":7212},{"trials":7199,"activeCount":102},[],{"trials":7201,"activeCount":102},[7202],{"nctId":636,"briefTitle":637,"status":140,"phases":7203,"primaryCompletion":639,"completion":639,"start":640,"enrollment":25,"conditions":7204,"interventions":7205},[90],[642,643],[645,646,647,648,629],{"trials":7207,"activeCount":102},[],{"trials":7209,"activeCount":102},[],{"trials":7211,"activeCount":102},[],{"trials":7213,"activeCount":102},[],{"intervention":646,"totalTrials":253,"cells":7215},{"EARLY_PHASE1":7216,"PHASE1":7218,"PHASE2":7224,"PHASE3":7226,"PHASE4":7228,"NA":7230},{"trials":7217,"activeCount":102},[],{"trials":7219,"activeCount":102},[7220],{"nctId":636,"briefTitle":637,"status":140,"phases":7221,"primaryCompletion":639,"completion":639,"start":640,"enrollment":25,"conditions":7222,"interventions":7223},[90],[642,643],[645,646,647,648,629],{"trials":7225,"activeCount":102},[],{"trials":7227,"activeCount":102},[],{"trials":7229,"activeCount":102},[],{"trials":7231,"activeCount":102},[],{"intervention":647,"totalTrials":253,"cells":7233},{"EARLY_PHASE1":7234,"PHASE1":7236,"PHASE2":7242,"PHASE3":7244,"PHASE4":7246,"NA":7248},{"trials":7235,"activeCount":102},[],{"trials":7237,"activeCount":102},[7238],{"nctId":636,"briefTitle":637,"status":140,"phases":7239,"primaryCompletion":639,"completion":639,"start":640,"enrollment":25,"conditions":7240,"interventions":7241},[90],[642,643],[645,646,647,648,629],{"trials":7243,"activeCount":102},[],{"trials":7245,"activeCount":102},[],{"trials":7247,"activeCount":102},[],{"trials":7249,"activeCount":102},[],{"intervention":648,"totalTrials":253,"cells":7251},{"EARLY_PHASE1":7252,"PHASE1":7254,"PHASE2":7260,"PHASE3":7262,"PHASE4":7264,"NA":7266},{"trials":7253,"activeCount":102},[],{"trials":7255,"activeCount":102},[7256],{"nctId":636,"briefTitle":637,"status":140,"phases":7257,"primaryCompletion":639,"completion":639,"start":640,"enrollment":25,"conditions":7258,"interventions":7259},[90],[642,643],[645,646,647,648,629],{"trials":7261,"activeCount":102},[],{"trials":7263,"activeCount":102},[],{"trials":7265,"activeCount":102},[],{"trials":7267,"activeCount":102},[],{"intervention":7269,"totalTrials":253,"cells":7270},"Atomoxetine",{"EARLY_PHASE1":7271,"PHASE1":7273,"PHASE2":7283,"PHASE3":7285,"PHASE4":7287,"NA":7289},{"trials":7272,"activeCount":102},[],{"trials":7274,"activeCount":102},[7275],{"nctId":7276,"briefTitle":7277,"status":140,"phases":7278,"primaryCompletion":5467,"completion":5467,"start":6676,"enrollment":2590,"conditions":7279,"interventions":7282},"NCT02014064","Safety Study to Assess Atomoxetine With MA Abusers and Healthy Controls",[90],[7280,7281],"Continuous Methamphetamine Dependence","Methamphetamine Dependence in Remission",[7269],{"trials":7284,"activeCount":102},[],{"trials":7286,"activeCount":102},[],{"trials":7288,"activeCount":102},[],{"trials":7290,"activeCount":102},[],{"intervention":7292,"totalTrials":253,"cells":7293},"Atomoxetine, then Placebo",{"EARLY_PHASE1":7294,"PHASE1":7296,"PHASE2":7304,"PHASE3":7306,"PHASE4":7308,"NA":7310},{"trials":7295,"activeCount":102},[],{"trials":7297,"activeCount":102},[7298],{"nctId":7299,"briefTitle":7300,"status":108,"phases":7301,"primaryCompletion":3730,"completion":3730,"start":2658,"enrollment":2391,"conditions":7302,"interventions":7303},"NCT01019707","Safety Assessment of Atomoxetine With MA IV Administration",[90],[2407,2418],[7292],{"trials":7305,"activeCount":102},[],{"trials":7307,"activeCount":102},[],{"trials":7309,"activeCount":102},[],{"trials":7311,"activeCount":102},[],{"intervention":7313,"totalTrials":253,"cells":7314},"Cholecalciferol",{"EARLY_PHASE1":7315,"PHASE1":7317,"PHASE2":7328,"PHASE3":7330,"PHASE4":7332,"NA":7334},{"trials":7316,"activeCount":102},[],{"trials":7318,"activeCount":102},[7319],{"nctId":7320,"briefTitle":7321,"status":108,"phases":7322,"primaryCompletion":7323,"completion":7323,"start":5545,"enrollment":208,"conditions":7324,"interventions":7327},"NCT01046773","Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease",[90],"2017-05",[7325,7326],"Crohn's Disease","Vitamin D Deficiency",[7313,7313],{"trials":7329,"activeCount":102},[],{"trials":7331,"activeCount":102},[],{"trials":7333,"activeCount":102},[],{"trials":7335,"activeCount":102},[],{"intervention":7337,"totalTrials":253,"cells":7338},"200mg Cannabidiol by capsules twice daily",{"EARLY_PHASE1":7339,"PHASE1":7341,"PHASE2":7352,"PHASE3":7354,"PHASE4":7356,"NA":7358},{"trials":7340,"activeCount":102},[],{"trials":7342,"activeCount":102},[7343],{"nctId":7344,"briefTitle":7345,"status":140,"phases":7346,"primaryCompletion":47,"completion":47,"start":7347,"enrollment":7348,"conditions":7349,"interventions":7350},"NCT04911127","Therapeutic Response of Cannabidiol in Rheumatoid Arthritis",[90],"2021-10-05",67,[3005,1604],[7337,7351],"400mg Cannabidiol by capsules twice daily",{"trials":7353,"activeCount":102},[],{"trials":7355,"activeCount":102},[],{"trials":7357,"activeCount":102},[],{"trials":7359,"activeCount":102},[],{"intervention":7351,"totalTrials":253,"cells":7361},{"EARLY_PHASE1":7362,"PHASE1":7364,"PHASE2":7370,"PHASE3":7372,"PHASE4":7374,"NA":7376},{"trials":7363,"activeCount":102},[],{"trials":7365,"activeCount":102},[7366],{"nctId":7344,"briefTitle":7345,"status":140,"phases":7367,"primaryCompletion":47,"completion":47,"start":7347,"enrollment":7348,"conditions":7368,"interventions":7369},[90],[3005,1604],[7337,7351],{"trials":7371,"activeCount":102},[],{"trials":7373,"activeCount":102},[],{"trials":7375,"activeCount":102},[],{"trials":7377,"activeCount":102},[],{"intervention":7379,"totalTrials":253,"cells":7380},"Nicotine polacrilex",{"EARLY_PHASE1":7381,"PHASE1":7383,"PHASE2":7393,"PHASE3":7395,"PHASE4":7397,"NA":7399},{"trials":7382,"activeCount":102},[],{"trials":7384,"activeCount":102},[7385],{"nctId":7386,"briefTitle":7387,"status":140,"phases":7388,"primaryCompletion":7389,"completion":7389,"start":4455,"enrollment":1032,"conditions":7390,"interventions":7392},"NCT01359709","Effects of Contingency Management and Nicotine Replacement Therapy on Youth Smoking",[90],"2016-01",[7391],"Cigarette Smoking Behavior",[7379],{"trials":7394,"activeCount":102},[],{"trials":7396,"activeCount":102},[],{"trials":7398,"activeCount":102},[],{"trials":7400,"activeCount":102},[],{"intervention":6818,"totalTrials":253,"cells":7402},{"EARLY_PHASE1":7403,"PHASE1":7405,"PHASE2":7411,"PHASE3":7413,"PHASE4":7415,"NA":7417},{"trials":7404,"activeCount":102},[],{"trials":7406,"activeCount":102},[7407],{"nctId":6812,"briefTitle":6813,"status":140,"phases":7408,"primaryCompletion":2911,"completion":2911,"start":788,"enrollment":1032,"conditions":7409,"interventions":7410},[90],[6816],[6818,6819],{"trials":7412,"activeCount":102},[],{"trials":7414,"activeCount":102},[],{"trials":7416,"activeCount":102},[],{"trials":7418,"activeCount":102},[],{"intervention":7420,"totalTrials":161,"cells":7421},"Lipopolysaccharide",{"EARLY_PHASE1":7422,"PHASE1":7441,"PHASE2":7443,"PHASE3":7445,"PHASE4":7447,"NA":7449},{"trials":7423,"activeCount":102},[7424,7432],{"nctId":7425,"briefTitle":7426,"status":267,"phases":7427,"primaryCompletion":57,"completion":57,"start":7428,"enrollment":102,"conditions":7429,"interventions":7430},"NCT04309877","Theophylline for Depression Study",[89],"2023-03",[15],[7431,7420],"Theophylline ER",{"nctId":7433,"briefTitle":7434,"status":108,"phases":7435,"primaryCompletion":7436,"completion":7436,"start":7437,"enrollment":247,"conditions":7438,"interventions":7439},"NCT03557684","Leucine for Depression Study (L-DEP)",[89],"2021-07-31","2018-09-01",[15],[7440],"lipopolysaccharide",{"trials":7442,"activeCount":102},[],{"trials":7444,"activeCount":102},[],{"trials":7446,"activeCount":102},[],{"trials":7448,"activeCount":102},[],{"trials":7450,"activeCount":102},[],{"intervention":6802,"totalTrials":161,"cells":7452},{"EARLY_PHASE1":7453,"PHASE1":7463,"PHASE2":7465,"PHASE3":7467,"PHASE4":7469,"NA":7471},{"trials":7454,"activeCount":102},[7455,7459],{"nctId":6797,"briefTitle":6798,"status":140,"phases":7456,"primaryCompletion":6603,"completion":6603,"start":245,"enrollment":5436,"conditions":7457,"interventions":7458},[89],[6787],[6802,6777],{"nctId":6804,"briefTitle":6805,"status":140,"phases":7460,"primaryCompletion":2899,"completion":2899,"start":2164,"enrollment":1249,"conditions":7461,"interventions":7462},[89],[6787],[6789,6802,6777],{"trials":7464,"activeCount":102},[],{"trials":7466,"activeCount":102},[],{"trials":7468,"activeCount":102},[],{"trials":7470,"activeCount":102},[],{"trials":7472,"activeCount":102},[],{"intervention":2700,"totalTrials":253,"cells":7474},{"EARLY_PHASE1":7475,"PHASE1":7481,"PHASE2":7483,"PHASE3":7485,"PHASE4":7487,"NA":7489},{"trials":7476,"activeCount":102},[7477],{"nctId":2691,"briefTitle":2692,"status":140,"phases":7478,"primaryCompletion":2694,"completion":2695,"start":2696,"enrollment":2697,"conditions":7479,"interventions":7480},[89],[820],[2700,2686],{"trials":7482,"activeCount":102},[],{"trials":7484,"activeCount":102},[],{"trials":7486,"activeCount":102},[],{"trials":7488,"activeCount":102},[],{"trials":7490,"activeCount":102},[],{"intervention":7431,"totalTrials":253,"cells":7492},{"EARLY_PHASE1":7493,"PHASE1":7499,"PHASE2":7501,"PHASE3":7503,"PHASE4":7505,"NA":7507},{"trials":7494,"activeCount":102},[7495],{"nctId":7425,"briefTitle":7426,"status":267,"phases":7496,"primaryCompletion":57,"completion":57,"start":7428,"enrollment":102,"conditions":7497,"interventions":7498},[89],[15],[7431,7420],{"trials":7500,"activeCount":102},[],{"trials":7502,"activeCount":102},[],{"trials":7504,"activeCount":102},[],{"trials":7506,"activeCount":102},[],{"trials":7508,"activeCount":102},[],{"intervention":5417,"totalTrials":253,"cells":7510},{"EARLY_PHASE1":7511,"PHASE1":7517,"PHASE2":7519,"PHASE3":7521,"PHASE4":7523,"NA":7525},{"trials":7512,"activeCount":102},[7513],{"nctId":5407,"briefTitle":5408,"status":267,"phases":7514,"primaryCompletion":5410,"completion":5410,"start":5411,"enrollment":102,"conditions":7515,"interventions":7516},[89],[5413,5414,2406,5415],[5417,5402],{"trials":7518,"activeCount":102},[],{"trials":7520,"activeCount":102},[],{"trials":7522,"activeCount":102},[],{"trials":7524,"activeCount":102},[],{"trials":7526,"activeCount":102},[],{"intervention":7528,"totalTrials":253,"cells":7529},"N acetyl cysteine",{"EARLY_PHASE1":7530,"PHASE1":7540,"PHASE2":7542,"PHASE3":7544,"PHASE4":7546,"NA":7548},{"trials":7531,"activeCount":102},[7532],{"nctId":7533,"briefTitle":7534,"status":108,"phases":7535,"primaryCompletion":6553,"completion":6553,"start":7536,"enrollment":780,"conditions":7537,"interventions":7539},"NCT03451435","N-Acetyl Cysteine Protects Pulpal Stem Cells in Endodontic Revascularization",[89],"2018-06-15",[7538],"Endodontic Disease",[7528],{"trials":7541,"activeCount":102},[],{"trials":7543,"activeCount":102},[],{"trials":7545,"activeCount":102},[],{"trials":7547,"activeCount":102},[],{"trials":7549,"activeCount":102},[],{"intervention":7551,"totalTrials":253,"cells":7552},"Hematopoietic stem cell transplantation",{"EARLY_PHASE1":7553,"PHASE1":7563,"PHASE2":7565,"PHASE3":7567,"PHASE4":7569,"NA":7571},{"trials":7554,"activeCount":102},[7555],{"nctId":7556,"briefTitle":7557,"status":267,"phases":7558,"primaryCompletion":7559,"completion":7560,"start":2163,"enrollment":102,"conditions":7561,"interventions":7562},"NCT01932658","Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment",[89],"2016-03","2017-03",[7325],[7551],{"trials":7564,"activeCount":102},[],{"trials":7566,"activeCount":102},[],{"trials":7568,"activeCount":102},[],{"trials":7570,"activeCount":102},[],{"trials":7572,"activeCount":102},[],{"intervention":7574,"totalTrials":253,"cells":7575},"Metformin 500 Mg Oral Tablet, up to 4 tablets a day",{"EARLY_PHASE1":7576,"PHASE1":7588,"PHASE2":7590,"PHASE3":7592,"PHASE4":7594,"NA":7596},{"trials":7577,"activeCount":102},[7578],{"nctId":7579,"briefTitle":7580,"status":140,"phases":7581,"primaryCompletion":7582,"completion":7582,"start":7583,"enrollment":28,"conditions":7584,"interventions":7587},"NCT05349474","Metformin Treatment in Progressive Multiple Sclerosis",[89],"2025-05-30","2022-04-26",[7585,7586],"Secondary Progressive Multiple Sclerosis","Primary Progressive Multiple Sclerosis",[7574],{"trials":7589,"activeCount":102},[],{"trials":7591,"activeCount":102},[],{"trials":7593,"activeCount":102},[],{"trials":7595,"activeCount":102},[],{"trials":7597,"activeCount":102},[],{"intervention":7599,"totalTrials":253,"cells":7600},"Vitamin D",{"EARLY_PHASE1":7601,"PHASE1":7611,"PHASE2":7613,"PHASE3":7615,"PHASE4":7617,"NA":7619},{"trials":7602,"activeCount":102},[7603],{"nctId":7604,"briefTitle":7605,"status":140,"phases":7606,"primaryCompletion":2433,"completion":7607,"start":2930,"enrollment":2900,"conditions":7608,"interventions":7609},"NCT02091219","Effects of Vitamin D3 Versus 25OHD3 on Mineral Metabolism and Immune Function",[89],"2019-12-07",[7326],[7599,7610],"25(OH)D3",{"trials":7612,"activeCount":102},[],{"trials":7614,"activeCount":102},[],{"trials":7616,"activeCount":102},[],{"trials":7618,"activeCount":102},[],{"trials":7620,"activeCount":102},[],{"intervention":7610,"totalTrials":253,"cells":7622},{"EARLY_PHASE1":7623,"PHASE1":7629,"PHASE2":7631,"PHASE3":7633,"PHASE4":7635,"NA":7637},{"trials":7624,"activeCount":102},[7625],{"nctId":7604,"briefTitle":7605,"status":140,"phases":7626,"primaryCompletion":2433,"completion":7607,"start":2930,"enrollment":2900,"conditions":7627,"interventions":7628},[89],[7326],[7599,7610],{"trials":7630,"activeCount":102},[],{"trials":7632,"activeCount":102},[],{"trials":7634,"activeCount":102},[],{"trials":7636,"activeCount":102},[],{"trials":7638,"activeCount":102},[],{"intervention":7640,"totalTrials":253,"cells":7641},"Fecal Microbiota Transplantation",{"EARLY_PHASE1":7642,"PHASE1":7652,"PHASE2":7654,"PHASE3":7656,"PHASE4":7658,"NA":7660},{"trials":7643,"activeCount":102},[7644],{"nctId":7645,"briefTitle":7646,"status":267,"phases":7647,"primaryCompletion":7648,"completion":7648,"start":4224,"enrollment":102,"conditions":7649,"interventions":7651},"NCT03527056","Pilot Study Using Oral Capsule FMT to Decolonize GI CRE",[89],"2019-09-24",[7650,7640],"Enterobacteriaceae Infections",[7640],{"trials":7653,"activeCount":102},[],{"trials":7655,"activeCount":102},[],{"trials":7657,"activeCount":102},[],{"trials":7659,"activeCount":102},[],{"trials":7661,"activeCount":102},[],{"intervention":7663,"totalTrials":253,"cells":7664},"Lumason",{"EARLY_PHASE1":7665,"PHASE1":7677,"PHASE2":7679,"PHASE3":7681,"PHASE4":7683,"NA":7685},{"trials":7666,"activeCount":102},[7667],{"nctId":7668,"briefTitle":7669,"status":140,"phases":7670,"primaryCompletion":7671,"completion":7672,"start":7673,"enrollment":618,"conditions":7674,"interventions":7676},"NCT03296852","Study: SONAS Ultrasound for Detecting Stroke SONAS Ultrasound for Detecting Stroke",[89],"2018-09-26","2019-01-20","2018-04-19",[7675],"Stroke, Acute",[7663],{"trials":7678,"activeCount":102},[],{"trials":7680,"activeCount":102},[],{"trials":7682,"activeCount":102},[],{"trials":7684,"activeCount":102},[],{"trials":7686,"activeCount":102},[],{"intervention":7688,"totalTrials":253,"cells":7689},"RegenerEyes",{"EARLY_PHASE1":7690,"PHASE1":7700,"PHASE2":7702,"PHASE3":7704,"PHASE4":7706,"NA":7708},{"trials":7691,"activeCount":102},[7692],{"nctId":7693,"briefTitle":7694,"status":267,"phases":7695,"primaryCompletion":5590,"completion":7696,"start":4741,"enrollment":102,"conditions":7697,"interventions":7699},"NCT05169931","Clinical Efficacy of Amniotic Membrane Extract Eye Drops in Dry Eye Treatment",[89],"2022-05",[7698],"Dry Eyes Chronic",[7688],{"trials":7701,"activeCount":102},[],{"trials":7703,"activeCount":102},[],{"trials":7705,"activeCount":102},[],{"trials":7707,"activeCount":102},[],{"trials":7709,"activeCount":102},[],{"intervention":7711,"totalTrials":2391,"cells":7712},"Buprenorphine",{"EARLY_PHASE1":7713,"PHASE1":7715,"PHASE2":7717,"PHASE3":7733,"PHASE4":7759,"NA":7761},{"trials":7714,"activeCount":102},[],{"trials":7716,"activeCount":102},[],{"trials":7718,"activeCount":102},[7719,7726],{"nctId":7720,"briefTitle":7721,"status":140,"phases":7722,"primaryCompletion":2426,"completion":2426,"start":7723,"enrollment":618,"conditions":7724,"interventions":7725},"NCT00000299","Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2",[91],"2008-10",[4109],[7711],{"nctId":7727,"briefTitle":7728,"status":140,"phases":7729,"primaryCompletion":2480,"start":7730,"enrollment":102,"conditions":7731,"interventions":7732},"NCT00000206","Clinical Rescue Protocol - 2",[91],"1991-04",[4109],[7711],{"trials":7734,"activeCount":102},[7735,7743,7750],{"nctId":7736,"briefTitle":7737,"status":140,"phases":7738,"primaryCompletion":7739,"start":7740,"enrollment":102,"conditions":7741,"interventions":7742},"NCT00000207","Multicenter Clinical Trial of Buprenorphine - 3",[92],"1997-04","1992-05",[4109],[7711],{"nctId":7744,"briefTitle":7745,"status":140,"phases":7746,"primaryCompletion":3025,"completion":3025,"start":3904,"enrollment":7747,"conditions":7748,"interventions":7749},"NCT00078117","Suboxone: (Buprenorphine\u002FNaloxone) Comparison of Two Taper Schedules - 1",[92],516,[4109],[7711],{"nctId":7751,"briefTitle":7752,"status":140,"phases":7753,"primaryCompletion":7754,"completion":7755,"start":7756,"enrollment":102,"conditions":7757,"interventions":7758},"NCT00000205","Buprenorphine Maintenance Protocol - 1",[92],"1993-03","1993-09","1990-10",[4109],[7711],{"trials":7760,"activeCount":102},[],{"trials":7762,"activeCount":102},[7763],{"nctId":614,"briefTitle":615,"status":553,"phases":7764,"primaryCompletion":617,"completion":617,"start":538,"enrollment":618,"conditions":7765,"interventions":7766},[94],[620],[622,623,624,595,625,626,627],{"intervention":7768,"totalTrials":98,"cells":7769},"D-Cycloserine",{"EARLY_PHASE1":7770,"PHASE1":7778,"PHASE2":7788,"PHASE3":7796,"PHASE4":7798,"NA":7800},{"trials":7771,"activeCount":102},[7772],{"nctId":7773,"briefTitle":7774,"status":553,"phases":7775,"primaryCompletion":2140,"completion":2588,"start":2722,"enrollment":19,"conditions":7776,"interventions":7777},"NCT02312635","Augmentation of Cognitive Training in Children With TBI With D-Cyloserine",[89],[887],[7768],{"trials":7779,"activeCount":102},[7780],{"nctId":7781,"briefTitle":7782,"status":140,"phases":7783,"primaryCompletion":6063,"completion":7784,"start":3361,"enrollment":416,"conditions":7785,"interventions":7786},"NCT02769936","Glutamate, Learning, and Working Memory",[90],"2015-12",[30],[7787],"D-cycloserine",{"trials":7789,"activeCount":102},[7790],{"nctId":7791,"briefTitle":7792,"status":553,"phases":7793,"primaryCompletion":2825,"completion":2825,"start":2761,"enrollment":22,"conditions":7794,"interventions":7795},"NCT01687140","The Use of D-Cycloserine to Augment CBT for Pediatric OCD",[91],[3027],[7768],{"trials":7797,"activeCount":102},[],{"trials":7799,"activeCount":102},[],{"trials":7801,"activeCount":102},[7802],{"nctId":7803,"briefTitle":7804,"status":140,"phases":7805,"primaryCompletion":2911,"completion":2911,"start":5973,"enrollment":34,"conditions":7806,"interventions":7809},"NCT02582515","Augmentation of Brief Habit Reversal Training With D-cycloserine or Placebo",[94],[7807,7808],"Tourette Disorder","Chronic Tic Disorder",[7787],{"intervention":6789,"totalTrials":98,"cells":7811},{"EARLY_PHASE1":7812,"PHASE1":7826,"PHASE2":7828,"PHASE3":7830,"PHASE4":7832,"NA":7834},{"trials":7813,"activeCount":102},[7814,7818,7822],{"nctId":6782,"briefTitle":6783,"status":140,"phases":7815,"primaryCompletion":6603,"completion":6603,"start":245,"enrollment":6785,"conditions":7816,"interventions":7817},[89],[6787],[6789,6777],{"nctId":6791,"briefTitle":6792,"status":140,"phases":7819,"primaryCompletion":6603,"completion":6603,"start":245,"enrollment":6785,"conditions":7820,"interventions":7821},[89],[6787],[6789,6777],{"nctId":6804,"briefTitle":6805,"status":140,"phases":7823,"primaryCompletion":2899,"completion":2899,"start":2164,"enrollment":1249,"conditions":7824,"interventions":7825},[89],[6787],[6789,6802,6777],{"trials":7827,"activeCount":102},[],{"trials":7829,"activeCount":102},[],{"trials":7831,"activeCount":102},[],{"trials":7833,"activeCount":102},[],{"trials":7835,"activeCount":102},[7836],{"nctId":7837,"briefTitle":7838,"status":140,"phases":7839,"primaryCompletion":7840,"completion":7840,"start":4621,"enrollment":3832,"conditions":7841,"interventions":7843},"NCT02498236","Target Engagement for Oxytocin: Dose Ranging Study",[94],"2017-07-01",[7842],"Schizophrenia Spectrum",[7844],"Intranasal Oxytocin",{"intervention":593,"totalTrials":98,"cells":7846},{"EARLY_PHASE1":7847,"PHASE1":7849,"PHASE2":7860,"PHASE3":7862,"PHASE4":7864,"NA":7878},{"trials":7848,"activeCount":102},[],{"trials":7850,"activeCount":102},[7851],{"nctId":7852,"briefTitle":7853,"status":108,"phases":7854,"primaryCompletion":2648,"completion":2648,"start":7855,"enrollment":5930,"conditions":7856,"interventions":7859},"NCT01210066","Pain, Opioids and Pro-Inflammatory Immune Responses",[90],"2010-07",[7857,7858],"Pro-inflammatory Activity","Immunologic Activity Alteration",[593],{"trials":7861,"activeCount":102},[],{"trials":7863,"activeCount":102},[],{"trials":7865,"activeCount":102},[7866,7874],{"nctId":7867,"briefTitle":7868,"status":267,"phases":7869,"primaryCompletion":6221,"completion":6221,"start":4455,"enrollment":102,"conditions":7870,"interventions":7872},"NCT01881997","Pain Management in ED for Incision and Drainage of Abscess",[93],[7871],"Abscess",[593,7873],"Normal Saline",{"nctId":2908,"briefTitle":2909,"status":267,"phases":7875,"primaryCompletion":2911,"completion":2911,"start":2911,"enrollment":102,"conditions":7876,"interventions":7877},[93],[2913,2914],[2916,593,2883],{"trials":7879,"activeCount":102},[7880],{"nctId":581,"briefTitle":582,"status":267,"phases":7881,"primaryCompletion":584,"completion":584,"start":585,"enrollment":102,"conditions":7882,"interventions":7883},[94],[587,588,589,18,590,591],[593,318],{"intervention":7873,"totalTrials":208,"cells":7885},{"EARLY_PHASE1":7886,"PHASE1":7888,"PHASE2":7890,"PHASE3":7892,"PHASE4":7894,"NA":7904},{"trials":7887,"activeCount":102},[],{"trials":7889,"activeCount":102},[],{"trials":7891,"activeCount":102},[],{"trials":7893,"activeCount":102},[],{"trials":7895,"activeCount":102},[7896,7900],{"nctId":138,"briefTitle":139,"status":140,"phases":7897,"primaryCompletion":42,"completion":142,"start":143,"enrollment":144,"conditions":7898,"interventions":7899},[93],[146,147,148],[97,150],{"nctId":7867,"briefTitle":7868,"status":267,"phases":7901,"primaryCompletion":6221,"completion":6221,"start":4455,"enrollment":102,"conditions":7902,"interventions":7903},[93],[7871],[593,7873],{"trials":7905,"activeCount":102},[7906],{"nctId":7907,"briefTitle":7908,"status":267,"phases":7909,"primaryCompletion":2649,"start":6987,"enrollment":102,"conditions":7910,"interventions":7913},"NCT00709293","Role of Intraoperative Thymoglobulin in Decreasing Ischemia-Reperfusion Injury in Pediatric Heart Transplant Recipients",[94],[7911,7912],"Ischemia Reperfusion Injury","Heart Transplantation",[7914,7873],"Anti-Thymocyte Globulin",{"intervention":7916,"totalTrials":208,"cells":7917},"Celecoxib",{"EARLY_PHASE1":7918,"PHASE1":7920,"PHASE2":7922,"PHASE3":7934,"PHASE4":7943,"NA":7945},{"trials":7919,"activeCount":102},[],{"trials":7921,"activeCount":102},[],{"trials":7923,"activeCount":102},[7924],{"nctId":7925,"briefTitle":7926,"status":140,"phases":7927,"primaryCompletion":4152,"completion":2649,"start":7928,"enrollment":7929,"conditions":7930,"interventions":7932},"NCT00055978","Celecoxib in Preventing Lung Cancer in Former Heavy Smokers",[91],"2002-10",112,[7931],"Lung Cancer",[7933],"celecoxib",{"trials":7935,"activeCount":102},[7936],{"nctId":7937,"briefTitle":7938,"status":140,"phases":7939,"primaryCompletion":2602,"completion":2480,"start":2604,"conditions":7940,"interventions":7942},"NCT00009230","Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind Placebo-Controlled Trial",[92],[7941],"Memory Disorders",[7916],{"trials":7944,"activeCount":102},[],{"trials":7946,"activeCount":102},[7947],{"nctId":7948,"briefTitle":7949,"status":140,"phases":7950,"primaryCompletion":2509,"completion":2509,"start":7951,"enrollment":7952,"conditions":7953,"interventions":7955},"NCT00065169","Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs",[94],"2000-11",138,[1108,7954],"Dementia",[7916],{"intervention":7957,"totalTrials":161,"cells":7958},"Metformin",{"EARLY_PHASE1":7959,"PHASE1":7961,"PHASE2":7963,"PHASE3":7965,"PHASE4":7967,"NA":7969},{"trials":7960,"activeCount":102},[],{"trials":7962,"activeCount":102},[],{"trials":7964,"activeCount":102},[],{"trials":7966,"activeCount":102},[],{"trials":7968,"activeCount":102},[],{"trials":7970,"activeCount":102},[7971,7978],{"nctId":7972,"briefTitle":7973,"status":140,"phases":7974,"primaryCompletion":639,"completion":639,"start":4778,"enrollment":735,"conditions":7975,"interventions":7977},"NCT01122316","Management of Diabetes With Metformin In Patients With Chronic Heart Failure",[94],[3972,7976],"Diabetes",[7957],{"nctId":7979,"briefTitle":7980,"status":140,"phases":7981,"primaryCompletion":2722,"completion":2722,"start":6221,"enrollment":780,"conditions":7982,"interventions":7983},"NCT01573949","A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)",[94],[7976,3972],[7957],{"intervention":7985,"totalTrials":161,"cells":7986},"abatacept",{"EARLY_PHASE1":7987,"PHASE1":7989,"PHASE2":7991,"PHASE3":7993,"PHASE4":8002,"NA":8004},{"trials":7988,"activeCount":102},[],{"trials":7990,"activeCount":102},[],{"trials":7992,"activeCount":102},[],{"trials":7994,"activeCount":102},[7995],{"nctId":7996,"briefTitle":7997,"status":140,"phases":7998,"primaryCompletion":2838,"completion":7999,"start":789,"enrollment":25,"conditions":8000,"interventions":8001},"NCT01299961","Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis",[92],"2015-02",[3005],[7985],{"trials":8003,"activeCount":102},[],{"trials":8005,"activeCount":102},[8006],{"nctId":8007,"briefTitle":8008,"status":267,"phases":8009,"primaryCompletion":8010,"completion":8010,"start":2825,"enrollment":102,"conditions":8011,"interventions":8013},"NCT02053727","Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background",[94],"2018-06-12",[3005,8012],"Chronic Hepatitis B",[8014],"Abatacept",{"intervention":8016,"totalTrials":161,"cells":8017},"cannabidiol",{"EARLY_PHASE1":8018,"PHASE1":8020,"PHASE2":8022,"PHASE3":8032,"PHASE4":8034,"NA":8036},{"trials":8019,"activeCount":102},[],{"trials":8021,"activeCount":102},[],{"trials":8023,"activeCount":102},[8024],{"nctId":8025,"briefTitle":8026,"status":140,"phases":8027,"primaryCompletion":8028,"completion":4225,"start":6603,"enrollment":3339,"conditions":8029,"interventions":8030},"NCT02751359","Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers",[90,91],"2017-07",[135],[8031],"Cannabidiol",{"trials":8033,"activeCount":102},[],{"trials":8035,"activeCount":102},[],{"trials":8037,"activeCount":102},[8038],{"nctId":8039,"briefTitle":8040,"status":8041,"phases":8042,"conditions":8043,"interventions":8045},"NCT02556008","Cannabidiol for Pediatric Epilepsy (Compassionate Use)","NO_LONGER_AVAILABLE",[],[8044],"Refractory Childhood Epilepsy",[8016],{"intervention":8047,"totalTrials":253,"cells":8048},"Oral Probiotics",{"EARLY_PHASE1":8049,"PHASE1":8051,"PHASE2":8053,"PHASE3":8055,"PHASE4":8057,"NA":8059},{"trials":8050,"activeCount":102},[],{"trials":8052,"activeCount":102},[],{"trials":8054,"activeCount":102},[],{"trials":8056,"activeCount":102},[],{"trials":8058,"activeCount":102},[],{"trials":8060,"activeCount":102},[8061],{"nctId":8062,"briefTitle":8063,"status":267,"phases":8064,"primaryCompletion":5274,"completion":5274,"start":5815,"enrollment":102,"conditions":8065,"interventions":8067},"NCT00378300","The Effects of Probiotics in Atopic Dermatitis",[94],[8066],"Atopic Dermatitis",[8047],{"intervention":8069,"totalTrials":253,"cells":8070},"Cognitive behavioral therapy for anxiety plus benzodiazepine taper",{"EARLY_PHASE1":8071,"PHASE1":8073,"PHASE2":8075,"PHASE3":8077,"PHASE4":8079,"NA":8081},{"trials":8072,"activeCount":102},[],{"trials":8074,"activeCount":102},[],{"trials":8076,"activeCount":102},[],{"trials":8078,"activeCount":102},[],{"trials":8080,"activeCount":102},[],{"trials":8082,"activeCount":102},[8083],{"nctId":8084,"briefTitle":8085,"status":140,"phases":8086,"primaryCompletion":67,"completion":67,"start":8087,"enrollment":8088,"conditions":8089,"interventions":8091},"NCT05573906","Benzodiazepine Taper With Cognitive Behavioral Therapy in Patients Using Prescription Opioids",[94],"2023-04-13",42,[8090],"Anxiety Disorders",[8069,8092],"Health education control plus benzodiazepine taper",{"intervention":8092,"totalTrials":253,"cells":8094},{"EARLY_PHASE1":8095,"PHASE1":8097,"PHASE2":8099,"PHASE3":8101,"PHASE4":8103,"NA":8105},{"trials":8096,"activeCount":102},[],{"trials":8098,"activeCount":102},[],{"trials":8100,"activeCount":102},[],{"trials":8102,"activeCount":102},[],{"trials":8104,"activeCount":102},[],{"trials":8106,"activeCount":102},[8107],{"nctId":8084,"briefTitle":8085,"status":140,"phases":8108,"primaryCompletion":67,"completion":67,"start":8087,"enrollment":8088,"conditions":8109,"interventions":8110},[94],[8090],[8069,8092],{"intervention":8112,"totalTrials":253,"cells":8113},"Amisulpride 50 MG",{"EARLY_PHASE1":8114,"PHASE1":8116,"PHASE2":8118,"PHASE3":8120,"PHASE4":8122,"NA":8124},{"trials":8115,"activeCount":102},[],{"trials":8117,"activeCount":102},[],{"trials":8119,"activeCount":102},[],{"trials":8121,"activeCount":102},[],{"trials":8123,"activeCount":102},[],{"trials":8125,"activeCount":102},[8126],{"nctId":8127,"briefTitle":8128,"status":267,"phases":8129,"primaryCompletion":2309,"completion":312,"start":8130,"enrollment":102,"conditions":8131,"interventions":8133},"NCT05956600","An Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Amisulpride in Treating Patients With Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive Symptoms",[94],"2023-11",[8132],"Schizophrenia, Treatment-Resistant",[8112],{"intervention":8135,"totalTrials":253,"cells":8136},"Standard care",{"EARLY_PHASE1":8137,"PHASE1":8139,"PHASE2":8141,"PHASE3":8143,"PHASE4":8145,"NA":8147},{"trials":8138,"activeCount":102},[],{"trials":8140,"activeCount":102},[],{"trials":8142,"activeCount":102},[],{"trials":8144,"activeCount":102},[],{"trials":8146,"activeCount":102},[],{"trials":8148,"activeCount":102},[8149],{"nctId":8150,"briefTitle":8151,"status":140,"phases":8152,"primaryCompletion":2847,"completion":2847,"start":2744,"enrollment":8153,"conditions":8154,"interventions":8156},"NCT00644150","Effectiveness of HIV\u002FSexually Transmitted Infection Training for Physicians in China",[94],1373,[24,6413,8155],"Chlamydia",[8135],{"intervention":8158,"totalTrials":253,"cells":8159},"emtricitabine\u002Ftenofovir",{"EARLY_PHASE1":8160,"PHASE1":8162,"PHASE2":8164,"PHASE3":8166,"PHASE4":8168,"NA":8170},{"trials":8161,"activeCount":102},[],{"trials":8163,"activeCount":102},[],{"trials":8165,"activeCount":102},[],{"trials":8167,"activeCount":102},[],{"trials":8169,"activeCount":102},[],{"trials":8171,"activeCount":102},[8172],{"nctId":8173,"briefTitle":8174,"status":140,"phases":8175,"primaryCompletion":8176,"completion":8177,"start":8178,"enrollment":8179,"conditions":8180,"interventions":8182},"NCT03902418","Evaluation of Pre-Exposure Prophylaxis (PrEP) in Pregnant and Breastfeeding Women",[],"2024-06-30","2024-09-30","2019-07-01",1195,[8181],"HIV-I Infection",[8158],{"intervention":8184,"totalTrials":253,"cells":8185},"Antiretrovirals",{"EARLY_PHASE1":8186,"PHASE1":8188,"PHASE2":8190,"PHASE3":8192,"PHASE4":8194,"NA":8196},{"trials":8187,"activeCount":102},[],{"trials":8189,"activeCount":102},[],{"trials":8191,"activeCount":102},[],{"trials":8193,"activeCount":102},[],{"trials":8195,"activeCount":102},[],{"trials":8197,"activeCount":102},[8198],{"nctId":8199,"briefTitle":8200,"status":140,"phases":8201,"primaryCompletion":8202,"completion":8203,"start":6880,"enrollment":8204,"conditions":8205,"interventions":8207},"NCT03205696","Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection",[],"2021-07-20","2023-11-30",101,[8206],"Human Immunodeficiency Virus",[8184],{"intervention":8209,"totalTrials":253,"cells":8210},"[F-18]FDDNP-PET",{"EARLY_PHASE1":8211,"PHASE1":8213,"PHASE2":8215,"PHASE3":8217,"PHASE4":8219,"NA":8221},{"trials":8212,"activeCount":102},[],{"trials":8214,"activeCount":102},[],{"trials":8216,"activeCount":102},[],{"trials":8218,"activeCount":102},[],{"trials":8220,"activeCount":102},[],{"trials":8222,"activeCount":102},[8223],{"nctId":8224,"briefTitle":8225,"status":267,"phases":8226,"primaryCompletion":8227,"completion":8227,"start":8228,"enrollment":102,"conditions":8229,"interventions":8232},"NCT04311281","FDDNP Protocol for Visualizing Brain Proteinopathies to Assist in the Diagnosis of Persons With Suspected CTE and AD",[],"2021-05-03","2021-05",[8230,8231],"Suspected Chronic Traumatic Encephalopathy (CTE) or Traumatic Encephalopathy Syndrome (TES)","Suspected Alzheimer's Disease (AD)",[8209],{"intervention":8234,"totalTrials":253,"cells":8235},"Statseal",{"EARLY_PHASE1":8236,"PHASE1":8238,"PHASE2":8240,"PHASE3":8242,"PHASE4":8244,"NA":8246},{"trials":8237,"activeCount":102},[],{"trials":8239,"activeCount":102},[],{"trials":8241,"activeCount":102},[],{"trials":8243,"activeCount":102},[],{"trials":8245,"activeCount":102},[],{"trials":8247,"activeCount":102},[8248],{"nctId":8249,"briefTitle":8250,"status":267,"phases":8251,"primaryCompletion":67,"completion":67,"start":5690,"enrollment":102,"conditions":8252,"interventions":8256},"NCT05468957","Comparing Perclose to Statseal in Conjunction With Perclose in Femoral 6 French Arteriotomy Closure",[94],[8253,8254,588,8255],"Arterial Occlusion","Cardiovascular Diseases","Hematoma",[8234],{"intervention":8258,"totalTrials":253,"cells":8259},"Increlex",{"EARLY_PHASE1":8260,"PHASE1":8262,"PHASE2":8264,"PHASE3":8266,"PHASE4":8268,"NA":8270},{"trials":8261,"activeCount":102},[],{"trials":8263,"activeCount":102},[],{"trials":8265,"activeCount":102},[],{"trials":8267,"activeCount":102},[],{"trials":8269,"activeCount":102},[],{"trials":8271,"activeCount":102},[8272],{"nctId":8273,"briefTitle":8274,"status":267,"phases":8275,"primaryCompletion":2562,"start":4455,"enrollment":102,"conditions":8276,"interventions":8279},"NCT01314508","Increlex Treatment of Children With Chronic Liver Disease and Short Stature",[94],[8277,8278],"Growth Failure","Chronic Liver Disease",[8258],{"intervention":561,"totalTrials":253,"cells":8281},{"EARLY_PHASE1":8282,"PHASE1":8284,"PHASE2":8286,"PHASE3":8288,"PHASE4":8290,"NA":8292},{"trials":8283,"activeCount":102},[],{"trials":8285,"activeCount":102},[],{"trials":8287,"activeCount":102},[],{"trials":8289,"activeCount":102},[],{"trials":8291,"activeCount":102},[],{"trials":8293,"activeCount":102},[8294],{"nctId":551,"briefTitle":552,"status":553,"phases":8295,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8296,"interventions":8297},[94],[559],[561,519],{"intervention":8299,"totalTrials":253,"cells":8300},"Iloprost",{"EARLY_PHASE1":8301,"PHASE1":8303,"PHASE2":8305,"PHASE3":8307,"PHASE4":8309,"NA":8311},{"trials":8302,"activeCount":102},[],{"trials":8304,"activeCount":102},[],{"trials":8306,"activeCount":102},[],{"trials":8308,"activeCount":102},[],{"trials":8310,"activeCount":102},[],{"trials":8312,"activeCount":102},[8313],{"nctId":8314,"briefTitle":8315,"status":108,"phases":8316,"primaryCompletion":3336,"completion":3336,"start":4455,"enrollment":2463,"conditions":8317,"interventions":8319},"NCT01319045","Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease",[94],[3859,5161,8318],"Eisenmenger's Syndrome",[8299],{"intervention":8321,"totalTrials":253,"cells":8322},"Pegylated interferon alfa and ribavirin",{"EARLY_PHASE1":8323,"PHASE1":8325,"PHASE2":8327,"PHASE3":8329,"PHASE4":8331,"NA":8333},{"trials":8324,"activeCount":102},[],{"trials":8326,"activeCount":102},[],{"trials":8328,"activeCount":102},[],{"trials":8330,"activeCount":102},[],{"trials":8332,"activeCount":102},[],{"trials":8334,"activeCount":102},[8335],{"nctId":8336,"briefTitle":8337,"status":140,"phases":8338,"primaryCompletion":4865,"completion":4865,"start":6987,"enrollment":8339,"conditions":8340,"interventions":8342},"NCT00747539","Brain Deficits in HIV\u002FHCV Coinfected People Before and After Anti-HCV Therapy",[],330,[21,4228,8341],"Infections",[8321],{"intervention":8344,"totalTrials":253,"cells":8345},"Nesiritide",{"EARLY_PHASE1":8346,"PHASE1":8348,"PHASE2":8350,"PHASE3":8352,"PHASE4":8354,"NA":8356},{"trials":8347,"activeCount":102},[],{"trials":8349,"activeCount":102},[],{"trials":8351,"activeCount":102},[],{"trials":8353,"activeCount":102},[],{"trials":8355,"activeCount":102},[],{"trials":8357,"activeCount":102},[8358],{"nctId":8359,"briefTitle":8360,"status":140,"phases":8361,"primaryCompletion":2509,"completion":2509,"start":4130,"enrollment":34,"conditions":8362,"interventions":8364},"NCT00709163","Nesiritide - Dilated Cardiomyopathy",[94],[8363],"Dilated Cardiomyopathy",[8344,8365],"5% Dextrose",{"intervention":8365,"totalTrials":253,"cells":8367},{"EARLY_PHASE1":8368,"PHASE1":8370,"PHASE2":8372,"PHASE3":8374,"PHASE4":8376,"NA":8378},{"trials":8369,"activeCount":102},[],{"trials":8371,"activeCount":102},[],{"trials":8373,"activeCount":102},[],{"trials":8375,"activeCount":102},[],{"trials":8377,"activeCount":102},[],{"trials":8379,"activeCount":102},[8380],{"nctId":8359,"briefTitle":8360,"status":140,"phases":8381,"primaryCompletion":2509,"completion":2509,"start":4130,"enrollment":34,"conditions":8382,"interventions":8383},[94],[8363],[8344,8365],{"intervention":8385,"totalTrials":253,"cells":8386},"Sevelamer Carbonate",{"EARLY_PHASE1":8387,"PHASE1":8389,"PHASE2":8391,"PHASE3":8393,"PHASE4":8395,"NA":8397},{"trials":8388,"activeCount":102},[],{"trials":8390,"activeCount":102},[],{"trials":8392,"activeCount":102},[],{"trials":8394,"activeCount":102},[],{"trials":8396,"activeCount":102},[],{"trials":8398,"activeCount":102},[8399],{"nctId":8400,"briefTitle":8401,"status":140,"phases":8402,"primaryCompletion":4865,"completion":4865,"start":2658,"enrollment":3339,"conditions":8403,"interventions":8405},"NCT00999037","FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease",[94],[8404],"Secondary Hyperparathyroidism",[8385],{"intervention":8407,"totalTrials":253,"cells":8408},"Broccoli sprout extract",{"EARLY_PHASE1":8409,"PHASE1":8411,"PHASE2":8413,"PHASE3":8415,"PHASE4":8417,"NA":8419},{"trials":8410,"activeCount":102},[],{"trials":8412,"activeCount":102},[],{"trials":8414,"activeCount":102},[],{"trials":8416,"activeCount":102},[],{"trials":8418,"activeCount":102},[],{"trials":8420,"activeCount":102},[8421],{"nctId":8422,"briefTitle":8423,"status":140,"phases":8424,"primaryCompletion":6221,"completion":6221,"start":8425,"enrollment":2501,"conditions":8426,"interventions":8428},"NCT00882115","Broccoli Sprout Extract Effects on Allergic Inflammation in the Nose",[94],"2009-07-10",[8427],"Allergic Airway Disease",[8407],{"intervention":8430,"totalTrials":253,"cells":8431},"Cenegermin Ophthalmic Solution [Oxervate]",{"EARLY_PHASE1":8432,"PHASE1":8434,"PHASE2":8436,"PHASE3":8438,"PHASE4":8440,"NA":8442},{"trials":8433,"activeCount":102},[],{"trials":8435,"activeCount":102},[],{"trials":8437,"activeCount":102},[],{"trials":8439,"activeCount":102},[],{"trials":8441,"activeCount":102},[],{"trials":8443,"activeCount":102},[8444],{"nctId":8445,"briefTitle":8446,"status":140,"phases":8447,"primaryCompletion":8448,"completion":8448,"start":8449,"enrollment":6988,"conditions":8450,"interventions":8452},"NCT04627571","Corneal Nerves After Treatment With Cenegermin",[],"2025-03-25","2022-05-23",[8451],"Neurotrophic Keratitis",[8430],{"intervention":8454,"totalTrials":253,"cells":8455},"Neurologist Initiated Treatment",{"EARLY_PHASE1":8456,"PHASE1":8458,"PHASE2":8460,"PHASE3":8462,"PHASE4":8464,"NA":8466},{"trials":8457,"activeCount":102},[],{"trials":8459,"activeCount":102},[],{"trials":8461,"activeCount":102},[],{"trials":8463,"activeCount":102},[],{"trials":8465,"activeCount":102},[],{"trials":8467,"activeCount":102},[8468],{"nctId":8469,"briefTitle":8470,"status":267,"phases":8471,"primaryCompletion":767,"completion":767,"start":8472,"enrollment":102,"conditions":8473,"interventions":8476},"NCT05704439","Cardiovascular Risk Reduction in Epilepsy",[94],"2024-01",[5345,8474,8475],"Hypertension","Hyperlipidemia (E.G., Hypercholesterolemia)",[8454],{"intervention":8478,"totalTrials":253,"cells":8479},"buprenorphine and low-dose naloxone",{"EARLY_PHASE1":8480,"PHASE1":8482,"PHASE2":8484,"PHASE3":8486,"PHASE4":8488,"NA":8490},{"trials":8481,"activeCount":102},[],{"trials":8483,"activeCount":102},[],{"trials":8485,"activeCount":102},[],{"trials":8487,"activeCount":102},[],{"trials":8489,"activeCount":102},[],{"trials":8491,"activeCount":102},[8492],{"nctId":8493,"briefTitle":8494,"status":140,"phases":8495,"primaryCompletion":2426,"completion":2426,"start":2589,"enrollment":618,"conditions":8496,"interventions":8497},"NCT00679458","Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine",[94],[135],[8478,8498],"buprenorphine alone",{"intervention":8498,"totalTrials":253,"cells":8500},{"EARLY_PHASE1":8501,"PHASE1":8503,"PHASE2":8505,"PHASE3":8507,"PHASE4":8509,"NA":8511},{"trials":8502,"activeCount":102},[],{"trials":8504,"activeCount":102},[],{"trials":8506,"activeCount":102},[],{"trials":8508,"activeCount":102},[],{"trials":8510,"activeCount":102},[],{"trials":8512,"activeCount":102},[8513],{"nctId":8493,"briefTitle":8494,"status":140,"phases":8514,"primaryCompletion":2426,"completion":2426,"start":2589,"enrollment":618,"conditions":8515,"interventions":8516},[94],[135],[8478,8498],{"intervention":8518,"totalTrials":253,"cells":8519},"Fenfluramine",{"EARLY_PHASE1":8520,"PHASE1":8522,"PHASE2":8524,"PHASE3":8526,"PHASE4":8528,"NA":8530},{"trials":8521,"activeCount":102},[],{"trials":8523,"activeCount":102},[],{"trials":8525,"activeCount":102},[],{"trials":8527,"activeCount":102},[],{"trials":8529,"activeCount":102},[],{"trials":8531,"activeCount":102},[8532],{"nctId":8533,"briefTitle":8534,"status":8535,"phases":8536,"conditions":8537,"interventions":8539},"NCT04437004","Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)","APPROVED_FOR_MARKETING",[],[8538],"Dravet Syndrome",[8518],{"intervention":622,"totalTrials":253,"cells":8541},{"EARLY_PHASE1":8542,"PHASE1":8544,"PHASE2":8546,"PHASE3":8548,"PHASE4":8550,"NA":8552},{"trials":8543,"activeCount":102},[],{"trials":8545,"activeCount":102},[],{"trials":8547,"activeCount":102},[],{"trials":8549,"activeCount":102},[],{"trials":8551,"activeCount":102},[],{"trials":8553,"activeCount":102},[8554],{"nctId":614,"briefTitle":615,"status":553,"phases":8555,"primaryCompletion":617,"completion":617,"start":538,"enrollment":618,"conditions":8556,"interventions":8557},[94],[620],[622,623,624,595,625,626,627],{"intervention":623,"totalTrials":253,"cells":8559},{"EARLY_PHASE1":8560,"PHASE1":8562,"PHASE2":8564,"PHASE3":8566,"PHASE4":8568,"NA":8570},{"trials":8561,"activeCount":102},[],{"trials":8563,"activeCount":102},[],{"trials":8565,"activeCount":102},[],{"trials":8567,"activeCount":102},[],{"trials":8569,"activeCount":102},[],{"trials":8571,"activeCount":102},[8572],{"nctId":614,"briefTitle":615,"status":553,"phases":8573,"primaryCompletion":617,"completion":617,"start":538,"enrollment":618,"conditions":8574,"interventions":8575},[94],[620],[622,623,624,595,625,626,627],{"intervention":624,"totalTrials":253,"cells":8577},{"EARLY_PHASE1":8578,"PHASE1":8580,"PHASE2":8582,"PHASE3":8584,"PHASE4":8586,"NA":8588},{"trials":8579,"activeCount":102},[],{"trials":8581,"activeCount":102},[],{"trials":8583,"activeCount":102},[],{"trials":8585,"activeCount":102},[],{"trials":8587,"activeCount":102},[],{"trials":8589,"activeCount":102},[8590],{"nctId":614,"briefTitle":615,"status":553,"phases":8591,"primaryCompletion":617,"completion":617,"start":538,"enrollment":618,"conditions":8592,"interventions":8593},[94],[620],[622,623,624,595,625,626,627],{"intervention":626,"totalTrials":253,"cells":8595},{"EARLY_PHASE1":8596,"PHASE1":8598,"PHASE2":8600,"PHASE3":8602,"PHASE4":8604,"NA":8606},{"trials":8597,"activeCount":102},[],{"trials":8599,"activeCount":102},[],{"trials":8601,"activeCount":102},[],{"trials":8603,"activeCount":102},[],{"trials":8605,"activeCount":102},[],{"trials":8607,"activeCount":102},[8608],{"nctId":614,"briefTitle":615,"status":553,"phases":8609,"primaryCompletion":617,"completion":617,"start":538,"enrollment":618,"conditions":8610,"interventions":8611},[94],[620],[622,623,624,595,625,626,627],{"intervention":627,"totalTrials":253,"cells":8613},{"EARLY_PHASE1":8614,"PHASE1":8616,"PHASE2":8618,"PHASE3":8620,"PHASE4":8622,"NA":8624},{"trials":8615,"activeCount":102},[],{"trials":8617,"activeCount":102},[],{"trials":8619,"activeCount":102},[],{"trials":8621,"activeCount":102},[],{"trials":8623,"activeCount":102},[],{"trials":8625,"activeCount":102},[8626],{"nctId":614,"briefTitle":615,"status":553,"phases":8627,"primaryCompletion":617,"completion":617,"start":538,"enrollment":618,"conditions":8628,"interventions":8629},[94],[620],[622,623,624,595,625,626,627],{"intervention":8631,"totalTrials":253,"cells":8632},"Digoxin",{"EARLY_PHASE1":8633,"PHASE1":8635,"PHASE2":8637,"PHASE3":8639,"PHASE4":8641,"NA":8643},{"trials":8634,"activeCount":102},[],{"trials":8636,"activeCount":102},[],{"trials":8638,"activeCount":102},[],{"trials":8640,"activeCount":102},[],{"trials":8642,"activeCount":102},[],{"trials":8644,"activeCount":102},[8645],{"nctId":8646,"briefTitle":8647,"status":140,"phases":8648,"primaryCompletion":806,"completion":806,"start":2164,"enrollment":1032,"conditions":8649,"interventions":8651},"NCT02277249","Transvaginal Versus Transabdominal Digoxin Prior to Second-trimester Abortion",[94],[8650],"Abortion, Induced",[8631,8631],{"intervention":8653,"totalTrials":253,"cells":8654},"Remicade",{"EARLY_PHASE1":8655,"PHASE1":8657,"PHASE2":8659,"PHASE3":8661,"PHASE4":8663,"NA":8665},{"trials":8656,"activeCount":102},[],{"trials":8658,"activeCount":102},[],{"trials":8660,"activeCount":102},[],{"trials":8662,"activeCount":102},[],{"trials":8664,"activeCount":102},[],{"trials":8666,"activeCount":102},[8667],{"nctId":8668,"briefTitle":8669,"status":140,"phases":8670,"primaryCompletion":8671,"completion":8671,"start":6383,"enrollment":34,"conditions":8672,"interventions":8673},"NCT00948610","Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy",[94],"2011-04",[3005],[8653],{"intervention":8675,"totalTrials":253,"cells":8676},"Nicotine Replacement Therapy",{"EARLY_PHASE1":8677,"PHASE1":8679,"PHASE2":8681,"PHASE3":8683,"PHASE4":8685,"NA":8687},{"trials":8678,"activeCount":102},[],{"trials":8680,"activeCount":102},[],{"trials":8682,"activeCount":102},[],{"trials":8684,"activeCount":102},[],{"trials":8686,"activeCount":102},[],{"trials":8688,"activeCount":102},[8689],{"nctId":8690,"briefTitle":8691,"status":553,"phases":8692,"primaryCompletion":671,"completion":671,"start":8671,"enrollment":790,"conditions":8693,"interventions":8695},"NCT01705951","Effect of Resistance Training on Tobacco-Related Cardiovascular Disease Risk",[94],[5427,8694],"Cardiovascular Disease Risk",[8675],{"intervention":8697,"totalTrials":253,"cells":8698},"Remodulin",{"EARLY_PHASE1":8699,"PHASE1":8701,"PHASE2":8703,"PHASE3":8705,"PHASE4":8707,"NA":8709},{"trials":8700,"activeCount":102},[],{"trials":8702,"activeCount":102},[],{"trials":8704,"activeCount":102},[],{"trials":8706,"activeCount":102},[],{"trials":8708,"activeCount":102},[],{"trials":8710,"activeCount":102},[8711],{"nctId":8712,"briefTitle":8713,"status":267,"phases":8714,"primaryCompletion":7784,"completion":7784,"start":3361,"enrollment":102,"conditions":8715,"interventions":8716},"NCT01980979","Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension",[94],[5161],[8697],{"intervention":8718,"totalTrials":253,"cells":8719},"Optional NRT",{"EARLY_PHASE1":8720,"PHASE1":8722,"PHASE2":8724,"PHASE3":8726,"PHASE4":8728,"NA":8730},{"trials":8721,"activeCount":102},[],{"trials":8723,"activeCount":102},[],{"trials":8725,"activeCount":102},[],{"trials":8727,"activeCount":102},[],{"trials":8729,"activeCount":102},[],{"trials":8731,"activeCount":102},[8732],{"nctId":8733,"briefTitle":8734,"status":140,"phases":8735,"primaryCompletion":2658,"completion":2658,"start":8736,"enrollment":144,"conditions":8737,"interventions":8738},"NCT00631020","Youth Smoking Cessation: Therapy +\u002F- \"The Patch\"",[94],"2007-12",[5427],[8718],{"intervention":8740,"totalTrials":253,"cells":8741},"Bosentan",{"EARLY_PHASE1":8742,"PHASE1":8744,"PHASE2":8746,"PHASE3":8748,"PHASE4":8750,"NA":8752},{"trials":8743,"activeCount":102},[],{"trials":8745,"activeCount":102},[],{"trials":8747,"activeCount":102},[],{"trials":8749,"activeCount":102},[],{"trials":8751,"activeCount":102},[],{"trials":8753,"activeCount":102},[8754],{"nctId":8755,"briefTitle":8756,"status":140,"phases":8757,"primaryCompletion":3089,"completion":3089,"start":2425,"enrollment":735,"conditions":8758,"interventions":8759},"NCT00989911","Endothelin Blockade in Patients With Single Ventricle Physiology",[94],[5161],[8740],{"intervention":7914,"totalTrials":253,"cells":8761},{"EARLY_PHASE1":8762,"PHASE1":8764,"PHASE2":8766,"PHASE3":8768,"PHASE4":8770,"NA":8772},{"trials":8763,"activeCount":102},[],{"trials":8765,"activeCount":102},[],{"trials":8767,"activeCount":102},[],{"trials":8769,"activeCount":102},[],{"trials":8771,"activeCount":102},[],{"trials":8773,"activeCount":102},[8774],{"nctId":7907,"briefTitle":7908,"status":267,"phases":8775,"primaryCompletion":2649,"start":6987,"enrollment":102,"conditions":8776,"interventions":8777},[94],[7911,7912],[7914,7873]]